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The regulated expression of cell surface receptors is essential for cellular homeostasis and 
defective in disease states. Receptor regulation is particularly important as receptor 
internalization limits the duration and intensity of substrate signaling. Interferon-γ (IFN-γ), a 
critical antiviral cytokine, transduces its signal through the interferon-γ receptor (IFNGR), a 
single-pass heterodimeric receptor composed of IFNGR1 and IFNGR2. While the IFN-γ signal 
transduction pathway is well studied, the cell surface regulation of the IFNGR is less well 
characterized.  
To gain a better understanding of the ligand-independent regulation of cell surface IFNGR, I 
performed a CRISPR/Cas9 genome-wide genetic screen to identify genes critical for IFNGR 
regulation. Loss of CHIC2 or STUB1, also known as CHIP, increased IFNGR1 cell surface 
expression and their role in receptor regulation was further characterized. CHIC2 is a poorly 
studied, cysteine-rich protein, while the cytosolic E3 ligase, STUB1 is well-recognized for its 
role in the ubiquitination, internalization and lysosome-mediated degradation of cell surface 
proteins. To determine if CHIC2 also plays a more generalized role in cell surface protein 
regulation, I performed ‘plasma membrane profiling’, an unbiased, quantitative proteomic 
approach to compare the cell surface protein abundance in wildtype vs CHIC2 knockout cells. 
CHIC2 deficiency increased cell surface expression of 61 proteins in THP-1 cells, 43% of 
which were also STUB1 regulated, suggesting a critical role for CHIC2 in receptor regulation. 
In the absence of CHIC2, less cell surface IFNGR1 was internalized and the increased cell 
surface IFNGR1 expression potentiated IFN-γ-mediated signaling, confirming CHIC2’s 
functional importance.  
Chromosomal translocation of CHIC2 is associated with hematological malignancies, but its 
endogenous function is unknown. I showed that palmitoylation of CHIC2 is essential for 
function as CHIC2’s membrane insertion is required for interacting with STUB1 and regulation 
of the IFNGR.  STUB1 is likely recruited to IFNGR1 through an exposed hydrophobic region 
that binds Hsp70, an interaction facilitated by CHIC2. Furthermore, CHIC2 is 
monoubiquitinated by STUB1 and internalized from the plasma membrane in a STUB1-
dependent manner. CHIC2’s ubiquitination is essential for its internalization and likely affects 
IFNGR1 internalization, though the exact details of this interaction remain unclear. I therefore 
propose a model whereby membrane-associated CHIC2 recruits the soluble STUB1 E3 ligase 
to the plasma membrane, allowing STUB1 to associate with, ubiquitinate and internalize 
IFNGR1, and other receptor substrates. CHIC2 therefore plays a novel and essential role in the 
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Chapter 1: Introduction 
 
 
The main subject of my PhD is the use of genome-wide, forward genetic screens to uncover 
novel insights into the regulation of the interferon-γ receptor (IFNGR). I identify a role for the 
poorly characterized CHIC2 protein, which together with the STUB1 E3 ligase is essential for 
the regulation of the IFNGR and additional cell surface receptors. I biochemically characterize 
the role of CHIC2 on IFNGR1 regulation and internalization to help gain insight into plasma 
membrane quality control.  
In the introduction, I will therefore briefly introduce cytokine receptors. I then describe 
peripheral membrane protein quality control (QC) as a means of regulating endoplasmic 
reticulum (ER) and plasma membrane (PM) substrates, focusing more specifically on PM QC 
and regulation of these substrates by the STUB1 ubiquitin E3 ligase. I discuss the role of 
ubiquitin in the turnover of cell surface receptors, some of which are highlighted in a later 
chapter. The regulated turnover of the IFNGR is the major focus of my thesis. I will conclude 
with a brief overview of genome-wide CRISPR/Cas9 forward genetic screens.   
1.1 Cytokine Receptors  
Cytokines (e.g. chemokines, interferons (IFN) and interleukins (IL)) are signaling polypeptides 
that promote and regulate the immune response. Interferons (IFNs) are anti-viral cytokines, 
essential for both innate and adaptive immune responses, tumor surveillance and defense, and 
modulation of immune cell function (de Weerd and Nguyen 2012), and were first described by 
Isaacs and Lindenmann in 1957 (Isaacs & Lindenmann, 1957) for their ability to interfere with 
viral replication. There are three classes of IFN: type I (of which there are more than 15 
subtypes, e.g. IFN-α, IFN-β, etc.), type II (IFN-γ) or type III (IFN-λ). The classical virus-




produced by natural killer (NK) cells in early defense and autocrine signaling, and by activated 
CD4 helper T cells to stimulate Th1 cell-mediated immunity.  
The IFNs bind to multi-chain cell-surface receptor complexes to initiate signal transduction 
pathways. These complexes are comprised of at least two different subunits known as class II 
helical cytokine receptors (hCRs). As hCRs lack intrinsic kinase activity, they must therefore 
rely on constitutively associated Janus kinases (JAKs) to initiate downstream signaling 
pathways to the nucleus to regulate gene transcription, through the phosphorylation and 
activation of cytoplasmic signal transducer and activator of transcription (STAT) proteins. The 
JAK/STAT pathway is utilized by many cytokine receptors, growth receptors, and G-protein 
coupled receptors and has been studied extensively. First, I will give a brief overview of 
cytokine receptors (Figure 1.1, adapted from Winthrop 2017). I will then describe the 
regulation of the poorly understood IFNGR as a focus of my thesis, and well-studied IFNAR.  
 
1.1.1 Type I versus type II cytokine receptors  
 
Type I cytokines commonly have a four α-helical bundle structure and their receptors share 
similar structural features (Leonard 2003). There are five classes of type I cytokines: those that 
use (i) the common cytokine receptor γ chain (γc) and related cytokines (IL-2, IL-4, IL-7, IL-
9, IL-13, IL-15, IL-21), involved in lymphocyte proliferation and homeostasis; (ii) the common 
 chain (c) (IL-3, IL-5); (iii) gp130 (IL-6 and IL-11) involved in T-cell differentiation and 
inflammation; (iv) homodimeric receptors including growth hormone (GH), prolactin, 
erythropoietin and leptin receptor, some of which are involved in erythropoiesis and platelet 
production; (v) tyrosine kinase receptors such as macrophage colony-stimulating factor (M-




Type I cytokine receptors are type I membrane glycoproteins that share conserved similarity in 
their extracellular domain, including a common amino acid motif (WSXWS) in the 
extracellular portion adjacent to the cell membrane, four cysteines involved in intrachain 
disulfide bonds and fibronectin type III modules (Taniguchi 1995). In addition, type I receptor 
cytoplasmic domains have conserved box 1/box 2 regions (box 1 is a proline-rich region 
involved in the interaction of receptors and JAK kinases), and most lack intrinsic tyrosine 
kinase activity, except for group (v) (Leonard 2003). An additional important feature is that 
one or two receptor subunits can be shared by several different cytokines, thereby allowing for 
cytokine redundancy (cross-talk).  
Type II cytokines commonly share a six α-helical structure, and are organized as monomers or 
homodimers (Renauld 2003). Type II cytokine receptors are type I transmembrane 
glycoproteins that share sequence homology in their extracellular domains, possess two 
fibronectin type III domains, but in contrast to type I cytokine receptors, they lack a WSXWS 
motif (Renauld 2003). They are typically heterodimers with a high and low affinity component: 
e.g. IFN (type I and II) receptors, involved in innate antiviral defense (Figure 1.1), and IL-10, 
IL-19, IL-20, IL-22, IL-24, IL-26, IL-28 and IL-29 receptors (Leonard 2003).  
1.1.2 Interferon (IFN) receptors (IFNR) – signaling and internalization 
The regulated expression of cell surface receptors is an essential feature of cellular homeostasis 
and is defective in many disease states (Newport et al. 1996). Receptor internalization can limit 
the duration and intensity of signaling and must therefore be tightly regulated. In addition, 
signaling can continue from endosomes after receptor endocytosis. In this section, I will 






Figure 1.1 Overview of cytokine receptors and their role in cellular homeostasis. Ligand binding 
of a type I or a type II cytokine activates a type I or type II cytokine receptor and initiates intracellular 
signal transduction via the JAK/STAT pathway. Adapted from (Winthrop 2017). GM-CSF, 
granulocyte-macrophage colony-stimulating factor. ECM, extracellular matrix. PM, plasma membrane.  
 
1.1.2.1 The IFN-γ receptor (IFNGR) 
IFN-γ production is limited to immune cells and it signals as an anti-parallel homodimer 
(Walter et al. 1995). This critical anti-viral protein transduces its signal through the IFN-γ 
receptor (IFNGR), a membrane bound, single-pass heterodimeric receptor composed of distinct 
subunits: two chains of the high-affinity interferon-γ receptor 1 (IFNGR1) and two chains of 
the low-affinity interferon-γ receptor 2 (IFNGR2) (Figure 1.2) (Pestka et al. 2004). Both 
components are required for maximal activity of IFN-γ.  
Ligand binding of IFN-γ promotes receptor subunit dimerization, and subsequent 
phosphorylation of JAK1 and JAK2, which are constitutively bound to IFNGR1 and IFNGR2, 




IFNGR1 which serves as the STAT1 docking site, and is phosphorylated at Y701, resulting in 
the formation of STAT1-STAT1 homodimers that translocate to the nucleus and bind γ-
interferon-activation sites (GAS) to initiate transcription of interferon-stimulated genes (ISGs) 
(Decker et al. 1997; Platanias, 2005). Gene transcription occurs rapidly – within 15-30 min 
of IFN-γ treatment (Figure 1.2) (Kerr and Stark 1991; Bach et al. 1997).  
 
 
Figure 1.2 Signaling pathways for IFNGR and IFNAR. Ligand binding of IFN-γ induces 
dimerization of IFNGR1 and IFNGR2, and subsequent phosphorylation of JAK1 and JAK2 thereby 
recruiting STAT1 to associate with IFNGR1. A phosphorylated STAT1-STAT1 homodimer 
translocates to the nucleus and binds γ-interferon-activated sites (GAS) to initiate transcription of 
interferon-stimulated genes (ISGs). Ligand binding of IFN-α/β induces dimerization of IFNAR1 and 
IFNAR2, and subsequent phosphorylation of TYK2 and JAK1 thereby recruiting STAT1 and STAT2, 
which translocate to the nucleus with IRF-9 to initiate transcription of ISREs. GAS, γ-interferon-
activation sites; IRF-9, interferon regulatory factor 9; ISRE, interferon-stimulated response element; 




1.1.2.2 The IFN-α/β receptor (IFNAR) 
The human type I IFN system is made up of 17 different ligands (including 13 IFN-α subtypes) 
that bind the IFN-α/β receptor (IFNAR) with different affinities. These type I IFNs transduce 
their signal through the IFNAR, a membrane bound, single-pass heterodimeric receptor 
comprised of IFN-α/β receptor 1 (IFNAR1) and IFN-α/β receptor 2 (IFNAR2) (Figure 1.2).  
Ligand binding of type I IFN induces dimerization of the two subunits, and subsequent 
phosphorylation of tyrosine kinases (TYR) tyrosine kinase 2 (TYK2) and Janus kinase 1 
(JAK1), constitutively bound to IFNAR1 and IFNAR2, respectively (Figure 1.2) (Yeh and 
Pellegrini 1999). IFNAR1’s pre-association with TYK2 (Yan et al. 1996), stabilizes IFNAR1 
cell surface expression levels (Marijanovic et al. 2006).  
 
1.1.3 Endocytosis of IFN receptors  
IFNAR is better studied than IFNGR. Understanding the regulation of IFNGR is crucial 
because it functions as a critical signaling receptor. Clathrin-mediated endocytosis (CME) and 
clathrin-independent endocytosis (CIE, e.g. lipid microdomains and caveolae, which are 
cholesterol- and sphingolipid-enriched membrane domains) are the main endocytic pathways 
for these transmembrane receptors. Receptors are recruited to clathrin coated pits (CCPs) via 
direct binding to the AP-2 complex, of which there are two AP-2 binding motifs: a tyrosine 
based YXXϕ motif (Y-tyrosine and ϕ for an amino acid with a bulky hydrophobic side chain), 
and a dileucine (LL) motif, commonly found in immune receptors. Rapid endocytosis and 
lysosomal degradation is a major pathway to regulate cell surface receptors like IFNAR1 
(Kumar et al. 2003).  
The finding that IFNAR and IFNGR were associated with microdomains (Takaoka et al. 2000) 
suggests that the uptake of IFNRs also occurs through a raft-mediated process (Subramaniam 




IFNGR to a recycling compartment regardless of whether substrate (IFN-γ) is bound to 
IFNGR1, and found that IFNGR1 is endocytosed by both CME and CIE (Marchetti et al. 2006). 
They showed that IFN-γ bound receptor complexes are associated with lipid microdomains at 
the plasma membrane, indicating that IFNGR internalization and signaling are not coupled to 
each other (i.e. internalization does not increase upon ligand binding) (Marchetti et al. 2006). 
 
1.1.3.1 Internalization and subsequent degradation of IFNAR  
Although the two IFNAR subunits are not thought to be pre-associated at the cell surface, they 
are both required for full type I IFN dependent STAT activation and development of an 
effective anti-viral state (Hwang et al. 1995). Unlike IFN-γ, IFN-α initiates the clathrin-
dependent internalization of IFNAR1 and relies on an exposed endocytic motif (YXXϕ) 
recognized by the AP-2 endocytic machinery complex (Kumar et al. 2007); TYK2 masks this 
endocytic motif in unstimulated conditions (Kumar et al. 2008). In addition, treatment with 
IFN-α downregulates IFNAR1 cell surface levels (Constantinescu et al. 1994). IFNAR1 is 
ubiquitinated and degraded by the SKP1–CUL1–F-box β-transducin repeat-containing protein, 
SCFβTrCP, a Cullin-based E3 ubiquitin ligase (Kumar et al. 2003). This ubiquitination plays a 
role in the post-internalization trafficking of IFNAR1-containing vesicles toward late-
endosomal and lysosomal intracellular compartments (Kumar et al. 2003; Kumar et al. 2004).  
 
1.1.3.2 Internalization and subsequent degradation of IFNGR 
CME of IFNGR1 is mediated by two putative AP-2 binding sites: a leucine-isoleucine doublet 
at residues 270-271 and a tyrosine-based motif YVSL at 287-290 (Claudinon et al. 2007). 
Initial studies showed IFN-γ and IFNGR1 associated in CCPs (Filgueira et al. 1989; Sadir et 




levels inhibits IFN-γ signaling (Bernabei et al. 2001; Regis et al. 2006). IFNGR2 is the limiting 
factor for IFN-γ responsiveness, is required for signal transduction, and is present at the cell 
surface at lower concentrations, whilst IFNGR1 is typically in excess (Bach et al. 1997; 
Bernabei et al. 2001). However, the surface immunofluorescence staining pattern of IFNGR2 
suggested that, following ligand stimulation, the majority of IFNGR2 remains at the cell 
surface (Larkin et al. 2000). In a recent study, ligand stimulation did not alter IFNGR1 
expression or stability, and therefore does not alter receptor degradation (Londino et al. 2017).  
Little is known about the molecular mechanisms controlling receptor stability and turnover of 
the IFNGR. Li and colleagues showed that K3 and K5, Kaposi’s sarcoma-associated 
herpesvirus (KSHV) ubiquitin ligases, induced ubiquitination of IFNGR1 (Li et al. 2007). 
These proteins downregulate surface expression of IFNGR by increasing their rates of 
endocytosis, which leads to the suppression of cell-mediated immunity, through a reduction in 
host cell responsiveness to IFN-γ (Li et al. 2007). A recent study claims that IFNGR1 is 
degraded by the proteasome (Londino et al. 2017). However, it was unclear where this occurred 
and they note that other modes of IFNGR1 degradation can occur, including lysosomal-
mediated degradation. Endogenous ubiquitination of IFNGR1 has not been reported, and the 
E3 ubiquitin ligases involved in IFNGR1 ubiquitination remained to be identified (see Chapter 
3), making further work necessary in this area.  
 
1.2 Peripheral Protein Quality Control  
1.2.1 Plasma membrane (PM) quality control (QC)  
The regulation and quality control of protein folding in the early secretory pathway is well 
studied but peripheral membrane QC i.e. in the late secretory pathway, including the plasma 




the cell surface and in endosomes). Hence, it is important to understand how this system might 
function, in order to put my work on IFNGR into perspective. The PM is of great importance 
as it represents the interface between the extracellular environment and the interior workings 
of the cell, and is the first point of contact for a wide variety of signaling networks that play 
essential roles in cellular regulation including proliferation, development, migration and 
maintenance of the extracellular space (Babst 2014). To preserve cellular homeostasis, native 
conformations of PM proteins must be preserved. If damaged, misfolded or aggregation-prone 
cytotoxic polypeptides accumulate on the cell surface, disruption of critical PM functions, 
protein aggregation and disease could ensue, leading to the targeted destruction of the cell by 
the immune surveillance system.  
Membrane proteins exported from the ER are regulated by the peripheral QC system in the late 
secretory pathway, endocytic pathway, and at the PM (Okiyoneda et al. 2010). Conformational 
surveillance mechanisms of mature polypeptides involve refolding of unfolded polypeptides 
by chaperone intermediates and/or the proteolytic degradation of damaged molecules via the 
ubiquitin proteasome system (UPS), autophagosomes or lysosomal/vacuolar proteolysis 
(Apaja and Lukacs 2014).  
 
1.2.2 PM QC – S. cerevisiae as a model system  
Initial evidence for the existence of a PM QC system was provided by studies in yeast. The 
yeast multidrug transporter Pdr5 (Egner et al., 1995) is ubiquitinated prior to endocytosis, 
trafficked to the vacuole and proteolytically degraded (Egner and Kuchler 1996). Hein and 
colleagues provide further evidence for QC by investigating induced degradation of the 
stressed uracil transporter (Fur4p) due to E3 ligase, Rsp5, the yeast homologue of (human) 
Nedd-4 (Hein et al. 1995). In another study, upon shifting yeast to a restrictive temperature, 




be targeted for rapid endocytic removal from the PM and degradation in the vacuole (Jenness 
et al. 1997). A comparable study on temperature-sensitive Pma1 (a PM H+ ATPase) described 
the same effect (Gong and Chang 2001), and involved ubiquitination and recruitment of epsin 
family proteins, which form part of the yeast internalization machinery (Liu and Chang 2006). 
This work was an important start in understanding key mechanisms that regulate protein 
checkpoints and ensure cell survival, and lays the foundation for the necessary expansion into 
mammalian cells. However, it is of interest to note that yeast do not express a ubiquitin ligase 
homologous to mammalian STUB1. Ubr1 and San1 have been identified to function similarly 
to STUB1 in cytoplasmic QC (Heck et al. 2010), but all studies of peripheral QC in yeast 
identified Rsp5 as the major ubiquitin ligase responsible for the degradation of damaged plasma 
membrane proteins.  
 
1.2.3 PM QC in mammalian cells  
Whilst evidence of PM QC originated more than a decade ago, the mechanism of PM QC in 
mammalian cells has only recently been reported. Two well-cited studies examined the rapid 
turnover of unfolded plasma membrane proteins (Apaja et al. 2010; Okiyoneda et al. 2010). 
Apaja and colleagues used a proteomics-based approach with the chimeric temperature-
sensitive substrate, CD4tl-λC, and identified roles for heat shock protein (Hsc/p70), Hsp90, 
and E3 ubiquitin ligase, CHIP, also known as STUB1 (STIP1 Homology and U-Box 
Containing Protein 1) in its ubiquitin-mediated endocytosis (Apaja et al. 2010). STUB1 
catalyzes the ubiquitination of misfolded substrates, and is thus required for subsequent 
endocytosis and lysosomal trafficking events (see section 1.5).  
Peripheral protein QC eliminates unfolded CFTR from the cell surface, thereby preserving 
cellular homeostasis by degrading damaged PM proteins that have escaped ER QC. ΔF508-




the PM at 26°C but is metabolically unstable at 37°C and ubiquitin-tagged for endocytosis 
(Okiyoneda et al. 2010). An siRNA screen identified Hsp70/90, STUB1, gp78 and Hrd1 as 
implicated in the regulation and ubiquitin-mediated endocytosis of rΔF508CFTR, and KD of 
STUB1 showed a delayed degradation of rΔF508CFTR (Okiyoneda et al. 2010). In both of 
these aforementioned studies, chaperones recognized unfolded cytoplasmic regions of PM 
proteins and in turn, these chaperones recruited STUB1 to promote the clearance of these 
proteins. A similar degradation route exists for mutant dopamine D4.4 receptor (DRD4) and 
vasopression V2 receptor (V2R) in their removal from the PM (Apaja and Lukacs 2014). 
Hence, these studies provided insight into the multiple substrate recognition capabilities of the 
peripheral QC system.   
 
1.2.4 Degradative PM QC 
Transmembrane receptors destined for degradation can be internalized by the endocytic 
pathway (see section 1.4). This process requires a number of critical steps. First, the 
recognition of nonnative proteins and recruitment of ubiquitination machinery takes place, 
which leads to the internalization, and endosomal sorting of ubiquitinated cargo into budding 
intraluminal vesicles (ILV) by the endosomal sorting complexes required for transport 
(ESCRT) and the formation of multivesicular bodies (MVB) (see section 1.4.2). The final step 
is the fusion of MVBs with lysosomes/vacuolar compartments leading to the recycling of 
certain amino acids from cleaved polypeptides (Henne et al. 2011; MacGurn et al. 2012).  
The overall ‘quality’ of PM proteins is determined by multiple sequential QC mechanisms, and 
not just by the ability to recognize misfolding of proteins at the PM (like it would at the ER 
membrane) (MacGurn 2014; Okiyoneda et al. 2011). Many receptors are post-translationally 
modified via ubiquitin. Ubiquitin acts as a signal for the internalization, sorting and degradation 




activity. There is a lack of knowledge about how IFNGR is regulated and in Chapter 3, I report 
the finding of E3 ubiquitin ligase, STUB1, involved in the regulated turnover of this receptor.  
 
1.3 Ubiquitination of cell surface receptors  
Ubiquitination can be manipulated for the regulated disposal of native and non-native PM 
proteins in mammalian cells (Rotin and Staub 2010), and has been shown to play an important 
role in the modulation of immune responses (Liu et al. 2005). Ubiquitin’s role in the 
endocytosis of transmembrane receptors, and the regulation of cytokine receptors, via an 
adaptor protein (CHIC2) becomes a central focus of my thesis. Monoubiquitination is a critical 
feature of CHIC2, which I discuss in Chapter 5. I will therefore describe ubiquitin-mediated 
endocytosis, as this is the probable mechanism for the turnover of IFNGR1.  
 
1.3.1 Ubiquitin as a sorting signal  
Ubiquitin is a small, highly conserved, 76 amino acid polypeptide. Ubiquitin is covalently 
attached to lysine residues of other proteins, and this post-translational modification is critical 
for a range of cellular functions including receptor mediated endocytosis, cell cycle 
progression, transcriptional regulation and apoptosis (Hershko and Ciechanover 1998; 
Komander and Rape 2012).   
 
1.3.2 Types of E3 ligases  
Three major families of E3 ubiquitin ligases have been characterized by their unique E2-
binding domains – HECT, RING or U-Box domain (Ardley and Robinson 2005). Most of the 
specificity and regulation of ubiquitination occurs at the level of E3 ligases, of which more 




E3 ubiquitin ligases. RING/U-box ligases possess no intrinsic catalytic activity and act as 
scaffolds to recruit E2 enzymes (Joazeiro and Weissman 2000). Importantly, U-box E3 ligases 
have been implicated in the degradation of damaged proteins (Hatakeyama et al. 2001; Jiang 
et al. 2001). A well-studied example is STUB1, which identifies its substrates through 
chaperone (heat shock protein (hsp)) intermediates (Hatakeyama et al. 2001, 2004), and 
becomes a focus of my thesis (see section 1.5). In contrast, HECT (Homologous to E6-
associated protein (AP) C Terminus) E3 ligases have a catalytic cysteine residue that forms a 
ligase-ubiquitin intermediate before transferring ubiquitin onto the substrate (Metzger et al. 
2012).   
 
1.3.3 Ubiquitin linkages and their functions  
Substrate proteins can be modified with ubiquitin in the form of monoubiquitin, multi-
monoubiquitin, or polyubiquitin chains (Kirisako et al. 2006; Hicke 2001). All seven lysine 
(K) residues (K-6, 11, 27, 29, 33, 48, 63) within a ubiquitin molecule can be used for chain 
formation. Polyubiquitination of K48-linked chains predominantly function as a target signal 
for cytosolic degradation by the 26S proteasome (Pickart and Fushman 2004).The function of 
K63-linked chains has many fates, ranging from DNA damage (Spence et al. 1995) to cell 
signaling (Chen 2005), and endocytosis of plasma membrane receptors (Duncan et al. 2006; 
Geetha et al. 2005).  
Monoubiquitination has been shown to regulate diverse cellular processes such as endocytosis 
(Haglund et al. 2003; Hicke, 2001), protein sorting (Raiborg et al. 2003), intracellular signaling 
(Sun and Chen 2004), histone regulation and budding of retroviruses from the plasma 
membrane (Hicke 2001). Studies in yeast show that monoubiquitination of a single lysine 
residue on GPCR was sufficient for endocytosis (Terrell et al. 1998), whilst modification with 




Haguenauer-Tsapis 1997). In addition, Hicke reports that lysines in cytoplasmic tails of yeast 
proteins were found to be crucial for rapid internalization, and mutations in genes encoding the 
cellular ubiquitination machinery severely inhibited internalization (Hicke and Dunn 2003). In 
mammalian cells, receptors and their endocytic adaptors are often ubiquitinated in response to 
extracellular stimuli. Other examples demonstrating the importance of this modification 
include the ligand stimulated ubiquitination on cytoplasmic tails of the ζ subunit of the T-cell 
receptor, which appears to be monoubiquitinated (Cenciarelli et al. 1987), and receptors such 
as GHR and PDGFR, which are modified with multiple ubiquitin molecules (Mori et. al. 1992; 
Strous et al. 1996). These observations demonstrated that ubiquitination of plasma membrane 
cargo is required for internalization (Hicke and Dunn 2003).  
 
1.4 Endocytic regulation of cell surface receptors   
A major mechanism used to regulate the strength and duration of the IFN response is through 
the regulation of receptor levels, allowing for cytokine-specific sensitivity of the target cell (de 
Weerd and Nguyen 2012). Recent studies on endocytosis and endosomal sorting of signaling 
receptors as investigated by Lamaze have enabled us to better understand the biological activity 
of IFNRs (Blouin and Lamaze 2013). However, more work is required to understand how 
membrane and endosome dynamics can control the signaling outputs of the IFNGR (Blouin 
and Lamaze 2013). In this thesis, I investigate the regulated turnover of IFNGR1. 
Ubiquitin is well recognized to play a role in internalization (Cendrowski et al. 2016), and 
ubiquitin-modified proteins are recognized by ubiquitin binding domain (UBD) containing 
proteins for ESCRT mediated lysosomal degradation, as studied extensively (Duncan et al. 
2006; Hewitt et al. 2002; Lehner et al. 2011). Receptors are often polyubiquitinated to form 




role in the regulation of transmembrane signaling receptors. Constitutive endocytosis may be 
ligand independent (e.g. for the LDL or transferrin receptors) or through ligand-induced 
endocytosis, as seen for most receptor tyrosine kinases (RTKs) such as EGFR (via AP-2) or 
GPCRs (via β-arrestins).  
 
1.4.1 Endocytosis  
Endocytosis is the process by which extracellular molecules, cell surface components and 
fluids are internalized through the invagination of the plasma membrane. The endosome 
represents an important extension of the PM for the control of receptor signaling and this 
process depends on various signaling adaptors. This pathway is critical for the tight regulation 
of signaling, sorting of various cargo and degradation of many cellular components. 
 
1.4.2 The endocytic system  
The endocytic system is comprised of various membrane vesicles that are destined for complex 
sorting events. Ubiquitination of a receptor is a crucial marker for sorting into early endosomes 
(EE) and for onward trafficking to degradation pathways. The first sorting station in the 
endocytic system is the EE, which derives from the primary endocytic vesicles that fuse with 
each other and adopts either a tubular structure or a vacuolar structure (Huotari and Helenius 
2011). The vacuolar structure is the precursor to the late endosome (LE). Endocytic sorting 
converges at the EE marked by the GTPase, Rab5 and early endosome antigen 1 (EEA1) or 
adaptor protein containing a pleckstrin-homology (PH) domain, phosphotyrosine binding 
(PTB) domain, and leucine zipper motif 1 (APPL1). Recycling of various receptors and their 
ligands can be regulated by Rab4 and/or Rab11 for recycling back to the plasma membrane 




Rab7 transition, along with changes in luminal pH (Luzio et al. 2007; Rink et al. 2005) in 
preparation for lysosomal fusion and degradation of endosomal contents such as formation of 
intraluminal vesicles (ILVs). ILVs undergo a process of maturation into multivesicular 
endosomes (MVEs), also known as multivesicular bodies (MVBs), which are transition 
molecules between the EE and LE (Gruenberg 2001). This process ends in fusion with the 
lysosome and delivery of the contents for degradation (Luzio et al. 2007).  
 
1.4.3 Endocytic regulation of cell surface receptors  
Receptor mediated endocytosis is usually a mechanism for ligand/receptor recycling and/or 
signal attenuation, without contributing further to signaling (Yancoski et al. 2012). Sorting of 
cell surface proteins into the endo-lysosomal system is mediated by signals present within the 
cytosolic domains of those proteins, coupled to the molecular machinery that recognizes those 
signals and delivers proteins to their intended destinations (Yancoski et al. 2012).  Multiple 
sorting steps and a strict selection process transport cargo into the degradation pathway.  
PM proteins can be selectively regulated by ligand-mediated receptor downregulation or as a 
way to remove damaged proteins from the cell surface (e.g. CFTR). RTK ubiquitination has 
been widely studied – ligand induced ubiquitination of RTKs leads to rapid ubiquitination of 
several RTKs at the PM by the family of Cbl (Cas-Br-M ectopic retroviral transforming 
sequence) RING-type E3 ubiquitin ligase (Joazeiro et al. 1999; Levkowitz et al. 1999; Thien 
and Langdon 2001). A well-recognized example is the ligand-induced internalization and 
subsequent ubiquitination of EGFR. Other RTK’s that undergo ligand-stimulated 
ubiquitination by the Cbl family include hepatocyte growth factor (HGF), vascular endothelial 
growth factor (VEGFR-1) (Duval et al. 2003; Kobayashi et al. 2004) and platelet-derived 
growth factor (PDGF) receptors (Haglund & Dikic 2012; Lennartsson et al. 2006; Mori et al. 




Ubiquitinated receptors are rapidly endocytosed and delivered to the lysosome for degradation 
in an ESCRT-dependent manner. Cell surface proteins are predominantly degraded in the MVB 
pathway (Babst 2014). Notably, STUB1 modifies PM proteins preferentially with K63-linked 
polyubiquitin chains (Apaja and Lukacs 2014), which is the preferred ubiquitin tag for the 
MVB pathway (Lauwers et al. 2009). However, STUB1 adds K48-linked polyubiquitin chains 
to cytoplasmic substrates (Cyr et al. 2002; Zhang et al. 2005), indicating that STUB1 mediated 
ubiquitin is not solely K63-chain specific, as STUB1’s cytoplasmic-target substrates are 
ubiquitinated in a K48-dependent manner.  
 
1.5 STUB1 as a critical ubiquitin ligase for peripheral membrane protein QC 
STUB1 is a highly conserved protein responsible for regulating many physiological processes 
(McDonough and Patterson 2003). STUB1 was originally identified as a cytosolic co-
chaperone (Ballinger et al. 1999) and was later shown to function as a U-box ubiquitin E3 
ligase for Hsc70-Hsp70 (heat shock protein 70 family) client proteins (Connell et al. 2001; 
Meacham et al. 2001). I introduce STUB1 and cite studies pertaining to STUB1’s role in 
peripheral membrane QC since a CRISPR/Cas9 genetic screen identified STUB1 as regulating 
IFNGR1 (Chapter 3).  
 
1.5.1 STIP1 Homology and U-Box Containing Protein 1 (STUB1) 
STUB1, also known as carboxy-terminus of Hsc70 interacting protein (CHIP), encodes a 34.5-
kD protein of 303 amino acids (Figure 1.3). STUB1 contains three N-terminal tandem 
tetratricopeptide (TPR) repeats and a C-terminal U-box domain, separated by a central charged 
coil-coil region (Ballinger et al. 1999; Shi et al. 2013). The TPR repeats (residues 26-131) are 




interaction with chaperones (Hsc70-Hsp70 and Hsp90) (Figure 1.3) which work to actively 
refold misfolded or aberrant proteins, or promote their degradation. STUB1’s interaction with 
chaperones results in the ubiquitination and degradation of chaperone-bound substrates. 
STUB1’s E3 ligase activity is mediated by a U-box domain (Figure 1.3) which has a similar 
structure to RING-finger domains but is stabilized by hydrogen bonds instead of zinc binding 
(Aravind and Koonin 2000). STUB1’s central charged region is essential for STUB1’s function 
and dimerization (Nikolay et al. 2003).  
 
 
Figure 1.3 Schematic showing relative positions of different STUB1 domains. STUB1 consists of 
303 amino acids. Three tandem tetratricopeptide (TPR) repeats (aa 26-127, purple), a central charged 
coil-coil region (aa 127-226) and a C-terminal U-box domain (aa 226-303). The TPR domain interacts 




STUB1 is a well-studied, cytosolic chaperone-dependent E3 ligase recruited to the plasma 
membrane via chaperones at a low affinity – the C-terminal tails of chaperones determine the 
specificity and affinity of the STUB1-substrate association, which is rather low (Zhang et al. 
2005). Weak interactions suggest dynamic and transient collaboration between STUB1 and 
chaperones (Kopp et al. 2017). However, STUB1’s functional redundancy as a QC ubiquitin 
ligase was noted – a study demonstrated that STUB1 did not play an exclusive role in regulating 
the glucocorticoid receptor (GR) since degradation of GR still took place in its absence 





1.5.2 Quality control of CFTR by STUB1   
A few key studies have uncovered the regulation of CFTR, both in the ER, and from the PM 
(see section 1.2.3). The cystic fibrosis transmembrane conductance regulator (CFTR) is a 
protein kinase A (PKA) regulated PM chloride channel, expressed on respiratory epithelium 
and mutations in CFTR cause cystic fibrosis. WT CFTR is invaginated in CCPs (from the PM) 
and can enter several different routes including an initial sorting step marked by EE marker, 
Rab5, followed by either Rab11-dependent recycling to the cell surface, or Rab7-regulated 
delivery to LE (Gentzsch et al. 2004; Lukacs et al. 1997).  
 
Receptor Function/Degradation Route Reference 
CFTR (cystic fibrosis 
transmembrane 
conductance regulator) 
Ion Transport;   
endocytic lysosomal degradation 
proteasomal degradation (ERAD) 
(Okiyoneda et al., 2010 
 
Meacham et al., 2001) 
IL-4Rα (interleukin-4 
receptor subunit alpha) 
proteasomal degradation  (Wei et al. 2014) 
GHR (growth hormone 
receptor) 
lysosomal degradation;   
proteasomal degradation via 
SCFβTrCP 
(Slotman et al. 2012) 
INSR (insulin receptor) 
 
endocytic lysosomal degradation   (Tawo et al. 2017) 
Glucocorticoid receptor 
 
proteasomal degradation (Wang and DeFranco 
2005) 
Toll-like receptor 4/9  proteasomal degradation;  
K48-linked and K63-linked 
polyubiquitination 
(Yang et al. 2011) 
Met receptor  proteasomal degradation (Jang et al. 2011) 





(Zhang et al. 2011;  
Fan et al. 2005) 
        





Matsumura and colleagues report that most nascent CFTR is retained in the ER, as was shown 
by co-localization of STUB1 with CFTR and Hsc70 in the ER, and degraded by the UPS via 
endoplasmic-reticulum-associated degradation (ERAD) (Meacham et al. 2001). Their finding 
suggested that STUB1 and Hsc70 function in the ER to regulate the fate of immature CFTR, 
and that STUB1’s U-box domain is required to facilitate CFTR ubiquitination. Later, an 
inactive STUB1 was found to allow a small population of ΔF508-CFTR to fold, escape the ER 
and accumulate as a mature-glycosylated protein (Grove et al. 2009). 
 
1.5.3 STUB1 regulates EGFR 
EGFR was one of the first receptors found to be ubiquitinated (in a ligand-dependent manner) 
and has become a model for studying the endocytic regulation of cell surface receptors 
(Haglund et al. 2003). STUB1 acts as a tumor suppressor in pancreatic cancer cells and 
ubiquitinates EGFR for proteasome-mediated degradation, thereby inhibiting the activation of 
EGFR downstream pathways – downregulated STUB1 expression was shown to increase 
oncogenic EGFR signaling (Wang et al. 2014). A similar role for STUB1-mediated degradation 
of EFGR was identified in lung adenocarcinoma (Chung et al. 2016). Moreover, ErbB2/Her2 
(upregulated in some types of breast cancer) is resistant to c-Cbl degradation; instead, STUB1 
ubiquitinates Her2, thereby decreasing its endogenous expression (Xu et al. 2002). As protein 
degradation is required for cellular homeostasis, STUB1’s ability to degrade disease proteins 
like ErbB2 prove that STUB1 could be a therapeutic target.  
 
1.5.4 STUB1 regulates GHR  
Growth hormone receptor (GHR), a type I cytokine receptor, is important for growth and 
metabolism. GHR ubiquitination is not required, but GHR depends on SCFβTrCP for endocytosis 




lysosomes, Slotman and colleagues examined the role of STUB1 in the K63-linked 
polyubiquitination of GHR, and identified both STUB1 and Ubc13 as interacting with GHR 
(preceding the endocytosis of GHR) (Slotman et al. 2012). They propose a model whereby 
STUB1-Ubc13 activity occurs after SCFβTrCP ubiquitin ligase activation and before GHR 
selection into CCPs. Moreover, this same group performed competition experiments to 
investigate whether SCFβTrCP and STUB1 bind independently or cooperatively to the same 
region of GHR – their study shows that the GHR substrate can bind two E3s, independently 
(Slotman et al. 2012).  
 
 
1.5.5 Regulation of the Insulin Receptor by STUB1  
The Hoppe lab recently report that STUB1 limits insulin receptor (INSR) degradation from the 
PM (Tawo et al. 2017). They observed that siRNA depletion of STUB1 led to increased levels 
of the INSR, and affected longevity of D. melanogaster and C.elegans. Depletion of STUB1 
also showed activated protein kinase B (AKT) signaling and stabilized INSR in D. 
melanogaster, and activated AKT signaling (by increased p-AKT kinase) in HEK293T, whilst 
protein levels of AKT were unchanged (Tawo et al. 2017).  
Furthermore, in vitro studies showed that INSR is mono-ubiquitinated, rather than poly-
ubiquitinated, and STUB1 ubiquitinated the INSR but not the insulin-like growth factor 
receptor 1 (IGFR1), conveying the substrate-specific role of STUB1 in INSR degradation. 
Moreover, treatment with the lysosomal inhibitor, Bafilomycin (BafA1), or a dynamin inhibitor 
that blocks endocytosis, increased total INSR expression in 293T cells suggesting that the 
INSR is turned over in an endosomal-lysosomal manner (Tawo et al. 2017). They provide 
evidence from in vivo studies in worms to suggest that STUB1’s role in the degradation of 




ubiquitinate the INSR in vitro, in the absence of its partner chaperones, allowing for the specific 
and direct recognition of the receptor by STUB1, devoid of a chaperone-dependent mechanism, 
suggesting STUB1 can recognize its substrates in the absence of partner chaperones.  
 
1.5.6 STUB1 as a regulator of cytokine receptors  
STUB1 substrates have been studied in the context of immune signaling and cancer progression 
(Paul and Ghosh 2014). Toll-like receptors initiate a cascade of downstream signaling events, 
which leads to the activation of pro-inflammatory immune cells and are important for innate 
and adaptive immunity (Kawai and Akira 2010). In an siRNA screen, Yang and colleagues 
identified STUB1 as a regulator of lipopolysaccharide (LPS)-mediated TLR4/9 signaling, and 
showed that STUB1 could directly bind Hsc70/PKCζ/Src via its TPR domain (Yang et al. 
2011). Furthermore, they report that STUB1 mediates K63-linked polyubiquitination on 
tyrosine kinase Src (Yang et al. 2011). Another study by Wang et al. mirrored Yang’s findings 
of an enhancing activity of STUB1 towards TLR4 signaling by showing that CARMA1 is a 
novel STUB1 target that is ubiquitinated through K27-linked polyubiquitination (Wang et al. 
2013). These studies are significant as they identify adaptor proteins ubiquitinated by STUB1 
as opposed to direct ubiquitination of cell surface receptors.  
Furthermore, cytokines IL-4 and IL-13 act through IL-4Rα and regulate airway inflammation 
(Perkins et al. 2006). A study by Wei et al. found that STUB1 ubiquitinates IL-4Rα and that 
the TPR domain interacts with a chaperone intermediate. Wei and coworkers also reported that 
STUB1 knockout mice showed an increase in inflammatory cells in bronchioles, sustained IL-
4Rα-STAT6 signaling, and that patient samples with asthma or COPD showed increased levels 
of STUB1 (Wei et al. 2014). The role of IL-4Rα in lung inflammation demonstrates the 




Therefore, STUB1 is responsible for the PM QC of a multitude of cell surface receptors. A 
chaperone intermediate is usually required for the STUB1-substrate interaction (via the TPR 
domain), and STUB1’s ligase activity subsequently ubiquitinates these PM substrates for 
onward degradation.  
 
1.6 CRISPR/Cas9 Genetic Screens 
1.6.1 Genetic Screens  
Forward genetic screens are powerful tools to identify the genetic components of a phenotype 
of interest. The advent of cost-effective DNA sequencing allows for the rapid interrogation of 
whole genomes. These technologies, together with bioinformatics, proteomics and systems 
biology, enable the identification of genes involved in previously uncharacterized cellular 
pathways. Genetic screens have been performed in model systems of bacteria, yeast, fruit flies 
and nematodes due to easy genetic manipulation. The principle underlying genetic screens are 
to: (i) identify a process of interest, (ii) predict the phenotype the mutant will possess, (iii) 
identify/select mutants with that phenotype, and (iv) identify the affected genes (Forsburg 
2001).  
1.6.2 Genome-wide CRISPR/Cas9 forward genetic screens  
The advent of bacterial clustered regularly interspaced short palindromic repeats 
(CRISPR)/Cas9 (CRISPR-associated protein 9) as a gene editing technology has transformed 
genetic manipulations. CRISPR/Cas9 has two components: a sgRNA that recruits Cas9 to the 
precise nucleotides it is predicted to cut, and the Cas9 nuclease which produces double strand 
breaks to the DNA. CRISPR/Cas9 allows the creation of bi-allelic inactivation of a target gene 
due to a high efficiency of double-stranded breaks (DSBs) at multiple loci, and is an efficient, 




With this approach, genome wide knock-out forward genetic screens can be performed in 
almost any cell type by using a library of small guide RNAs (sgRNAs) to target the Cas9 
nuclease to all annotated genes (Koike-Yusa et al. 2013; Morgens et al. 2017; Shalem et al. 
2014; Wang et al. 2014).   
CRISPR screens are limited in that the design of the sgRNA library can cause off-target 
mutations that are observed at greater frequencies than intended for the particular mutation, 
and may therefore perturb the function of normal genes and cause genomic instability (Zhang, 
et al. 2015). In order to decrease the number of off-target effects, it is good practice to use 
multiple gRNAs per gene, since each may have different off-target effects (Fu et al. 2013; 
Morgens et al. 2017).  
 
1.7 Aims of this thesis    
The IFNGR1 is of critical importance for the innate and adaptive immune response. Since the 
cell surface regulation of IFNGR is not well understood, I wanted to characterize the regulation 
of IFNGR using genome-wide genetic approaches. The aim of my thesis was to perform a 
CRISPR/Cas9 forward genetic screen to identify the genes responsible for the ligand-
independent regulation of IFNGR. I then used an unbiased proteomic approach to determine 
whether CHIC2 and STUB1 play a more general role in the regulation of other cell surface 
(immune) receptors. I subsequently focus on the characterization of CHIC2, a palmitoylated, 
membrane-associated protein, which works with the cytosolic E3 ubiquitin ligase, STUB1, to 
regulate a number of cell surface receptors, and explore the role of monoubiquitinated CHIC2 
as an internalization signal from the plasma membrane. Finally, I studied the ligand-
independent internalization and turnover of IFNGR1, and determined whether loss of CHIC2 









Phosphate-buffered saline (PBS): 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM 
KH2PO4, pH 7.4 
Tris-buffered saline (TBS): 10 mM Tris, 150 mM NaCl, pH 7.4 
1% Digitonin / TBS: 1% Digitonin (Calbiochem) in 10 mM Tris, 150 mM NaCl, pH 7.4 
1% Triton X-100 / TBS: 1% Triton X-100 in 10 mM Tris, 150 mM NaCl, pH 7.4 
Luria-Bertani (LB) medium: 1% (w/v) Bacto-tryptone, 0.5% (w/v) Bacto-yeast extract, 1% 
(w/v) NaCl, 0.1% (w/v) glucose 
SOC medium: 2% tryptone, 0.5% w/v yeast abstract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4 and 20 mM glucose 
6X SDS Loading Buffer: 60% glycerol, 300 mM Tris pH 6.8, 6% (w/v) SDS, 9% (w/v) DTT, 
0.03% (w/v) bromophenol blue 
 
2.1.2 Enzymes, Reagents and Inhibitors 
Enzymes for manipulation of DNA and proteins were purchased from New England Biolabs 
(NEB). Reagents and inhibitors were purchased from Sigma unless stated otherwise. 
 
2.1.3 Antibodies 
Primary antibodies were used as follows: mAb W6/32 (recognizes conformational MHC-I), in-
lab production from hybridoma), mouse α-IFNAR1 (AA3, a kind gift from M. Weekes, CIMR), 




Aldrich, AC-74, A5316), mouse α-CHIC1/2 (Santa Cruz Biotechnology, B-11, sc-515175), 
rabbit α-STUB1 (Abcam, ab2917), PE (Phycoerythrin) α-human CD119 IFN-γRα chain 
(IFNGR1) (BioLegend, GIR-94, #308704), mouse α-IFNGR1 (BD Biosciences, GIR-94, 
#558935), rabbit α-IFNGR1 (ProteinTech, #10808-1-AP), rat α-HA (Sigma, 3F10, 
#11867423001), mouse α-FLAG (Sigma, M2), rabbit α-calreticulin (Cell Signaling 
Technology (CST)), mouse α-p97/VCP (Abcam), mouse α-ubiquitin (Vu-1) (LifeSensors 
Technologies, #VU101), rat α-RFP (Chromotek, 5F8), rabbit α-pSTAT1 (Tyr701) (CST, 
D4A7), rabbit α-STAT1 (CST, 9172), rabbit α-IRF-1 (CST, D5E4).  
 
Secondary antibodies:  
Western blotting: HRP (horse radish peroxidase)-conjugated goat α-mouse, goat α-rabbit, and 
goat α-rat antibodies were obtained (Jackson ImmunoResearch).   
HRP-conjugated Protein A (Invitrogen) and Mouse Trueblot ULTRA (eBioscience).  
Immunofluorescence / flow cytometry: Alexa-Fluor 488 (AF488)-conjugated goat α-mouse, 
AF546 goat α-rat, AF647 goat α-mouse, AF647 donkey α-sheep (all from Invitrogen).  
 
2.2 Molecular biology 
2.2.1 Polymerase Chain Reaction (PCR)  
 
Oligonucleotide primers were purchased from Sigma-Aldrich and typically used to amplify 10 
ng of plasmid DNA in a total volume of 50 µl using Phusion DNA polymerase (NEB).  
Standard conditions were: 
10 μl  5x Phusion-HF Buffer (NEB)  
10 ng   DNA template  
1 μl   10mM dNTP mix  




0.25 μl  Primer 2 (100 μM)  
0.5 μl   Phusion polymerase  
to 50 μl  ddH20 
Typical cycling parameters were:  
95˚C   30 s  
95˚C   10 s 
55-68˚C  20 s   x 30 cycles 
72˚C   20s per kb  
72˚C   5 min 
 
2.2.2 Constructs  
 
The lentiviral expression vector pHRSIN was a generous gift from Y.Ikeda. STUB1 cDNA 
plasmids in pCDNA.3 were a gift from J. Christianson (University of Oxford).  
 
2.2.3 DNA Cloning 
 
2.2.3.1 Gibson assembly  
 
Recombinant DNA plasmids were constructed using standard ligation or the Gibson assembly 
method (Gibson et al. 2009). Plasmid vectors were digested for 4 h with restriction enzymes at 
the appropriate temperature, typically 37°C, and then run out on an agarose gel. Bands were 
excised and purified using the QIAquick gel extraction kit (Qiagen). PCR was used to amplify 
inserts with 20-30 bp overhangs with the desired vector. PCR products were also run out on an 
agarose gel and purified using the QIAquick gel extraction kit. The DNA concentration of 
inserts and vectors were measured using a NanoDrop spectrophotometer. Typically, 50 ng of 
vector and a 2-3 fold molar excess of inserts were mixed with and equal volume of 2x Gibson 
Assembly Maser Mix (NEB) and incubated for 1 h at 50°C. Two microliters of the mix was 




containing ampicillin and incubated overnight at 37°C. Individual colonies were picked into 4 
ml LB medium containing ampicillin and cultured at 37°C for 16 h with shaking.  
 
The E. coli were pelleted by centrifugation and plasmid DNA was isolated using the QIAprep 
Spin miniprep kit (Qiagen). A sample of the plasmid DNA from each colony was digested and 
resolved on an agarose gel to ensure the insert was the correct size. Constructs were verified 
by Sanger sequencing (SourceBioscience). 
 
2.2.3.2 DNA ligation cloning  
 
Plasmid vectors were digested for 4 h with restriction enzymes, run out on a gel and the desired 
bands were purified using the QIAquick gel extraction kit. Inserts were cut from plasmid DNA 
or amplified by PCR. PCR products were digested with restriction enzymes for at least 6 h, run 
out on a gel and purified using the QIAquick gel extraction kit. The DNA concentration of 
digested vectors and inserts was measured using a NanoDrop spectrophotometer. The vector 
and insert were mixed in a 1:4 molar ratio with T4 DNA Ligase (NEB) and incubated at room 
temperature for 1 h. Two microliters of the ligation mix were used to transform DH5α E. coli 
(Bioline) which were spread on selective agar plates and incubated overnight at 37°C. 
Individual colonies were selected into 3ml of LB medium containing ampicillin or kanamycin 
and cultured at 37°C for 16 h with shaking. Plasmid DNA was then isolated using the QIAprep 
spin miniprep kit. Constructs were verified by Sanger sequencing (SourceBioscience). 
 
2.2.3.3 sgRNA cloning  
 
For CRISPR-mediated gene disruption, gRNAs were cloned as recommended by the Zhang 
laboratory (Ran et al. 2013). Oligonucleotides were ordered from Sigma-Aldrich, annealed, 
and cloned into the lentiviral gRNA expression vector pKLV-U6gRNA(BbSI)-





2.2.4 RNA extraction   
 
Total cellular RNA was prepared using a RNeasy Plus Minikit (Qiagen) according to 
manufacturer’s protocol. Briefly, cells were lysed in a 12-well plate using 350 μl of RLT buffer 
supplemented with β-mercaptoethanol. 350 μl 70% ethanol was added and samples were 
loaded onto RNeasy spin columns. After spin-through (1 min, 13,000 rpm), columns were 
washed once with RW1 buffer, twice with RPE buffer and eluted in 50 μl RNase-free water. 
RNA samples were stored at -80°C.  
2.2.5 Quantitative Real Time Polymerase Chain Reaction (RT-PCR) 
RNA was prepared from THP-1 cells as described above. Genomic RNA was quantified by 
real-time qRT-PCR (Applied Biosciences 7500 Fast Real-Time PCR System) using an IRF1 
probe and normalized against cellular GAPDH.  
IRF1 qPCR forward primer 
5’-GGGAAGATAGCCGAAGACCT-3’  
 
IRF1 qPCR reverse primer  
5’-CCTCGAGGGCTGTCAATCT-3’ 
 
GAPDH qPCR forward primer  
5’-GAAATCCCATCACCATCTTCCAGG-3’ 
 
GAPDH qPCR reverse primer  
5’-GAGCCCCAGCCTTCTCCATG 
 
2.3 Constructs  
2.3.1 Lentiviral vectors 
 
The pHRSIN lentiviral system was used for the expression of exogenous genes (Demaison et 
al. 2002). These vectors contain the cis-acting HIV1 viral elements, the long terminal repeats 
(LTRs), the ψ packaging signal, the rev response element (RRE) and the central polypurine 




of the gene of interest, followed by the woodchuck hepatitis virus post-transcriptional 
regulatory element (WPRE) to increase the stability of the transcribed mRNA. A downstream 
promoter drives the expression either a fluorescent protein or a selectable marker.  
 
2.3.2 Lentiviral expression of exogenous genes  
 
The lentiviral vectors pHRSIN-pSFFV-MCS(+)-pPGK-PuromycinR and pHRSIN-pSFFV 
MCS(+)-pPGK-HygromycinR were used for exogenous expression of CHIC2 or STUB1, with 
the gene of interest cloned in place of MCS using BamHI and NotI. CHIC2 coding sequence 
was ordered as a gBlock (IDT) and assembled using the Gibson Assembly. CHIC2 mutants 
were cloned by PCR from the wt-CHIC2 construct and assembled using the Gibson Assembly. 
CHIC2 was later cloned with an N terminal 3xHA or mScarlet tag using BamHI and NotI. 
STUB1 cDNA was a gift from J. Christianson (Nuffield Department of Medicine, University 
of Oxford). STUB1 was also cloned into pHRSIN.SFFV-FLAG-MCS-pGK HygromycinR 
using BamHI and NotI. The nuclease Cas9 was cloned from the lenti-Blast vector (Addgene 
#49535, kindly deposited by Feng Zhang) into pHRSIN using BamHI and NotI. 
 
2.4 Cell Culture   
2.4.1 Tissue Culture 
THP-1, HeLa, WM-852 and MD-MBA-231 cells were maintained in RPMI 1640 
supplemented with 10% fetal calf serum and penicillin/streptomycin. HEK293T (293T) cells 
were grown in DMEM plus 10% fetal calf serum and penicillin/streptomycin.  
Where indicated, cells were treated with interferon-γ (IFN-γ, Peprotech, 300-02) at 200 U/ml 
for the indicated time periods. Bafilomycin A1 (BafA1) (Enzo Life Sciences) at 25 nM for 16 
h. Raltegravir (RTV) (Cayman Chemical, 16071) was used at 1nM during lentiviral 




2.4.2 Lentivirus Production 
Lentivirus was generated by triple transfection of 293T cells with the pHRSIN lentiviral vector 
plus the packaging vectors pCMVΔR8.91 and pMD.G. For a standard transfection in a 6-well 
plate, 293T cells seeded at 60-80% confluency were transfected with 2 µg total DNA 
(comprising 1 µg pHRSIN vector, 0.7 µg pCMVΔR8.91, and 0.3 µg pMD.G) using TransIT-
293 (Mirus) as recommended by the manufacturer. After 48 h the virus-containing supernatant 
was harvested, filtered through a 0.45 µm filter (Elkay Laboratory Products) and then applied 
to target cells which were then centrifuged at 1800 rpm for 45 min. Transgene expression was 
assessed from 48 h post-transduction. 
 
2.5 Biochemistry 
2.5.1 Cell lysis  
For α-CHIC2 and α-IFNGR1 immunoblots, cells were lysed in 1% SDS plus 1:100 Benzonase 
(Sigma-Aldrich) in TBS for 30 min at room temperature. The lysates were then heated to 65°C 
in SDS sample buffer for 10 min. 
For all other immunoblots and immunoprecipitations (IP), cells were lysed in 1% digitonin or 
NP-40 plus 10 mM iodoacetate (IAA), 0.5 mM phenylmethylsulfonyl fluoride (PMSF) and 
Roche complete protease inhibitor, as well as 10 mM N-ethylmaleimide for IPs probed for 
ubiquitination, for 45 min on ice. Lysates were spun at 13000 xg for 10 min to remove insoluble 
material. The supernatant was then processed for immunoblot or immunoprecipitation. The 
postnuclear supernatants were heated to 65°C in SDS sample buffer for 10 minutes, separated 





2.5.2 Immunoprecipitation  
Post-nuclear supernatants were made up to 1 ml with 0.5% digitonin or NP-40 and then 
precleared with IgG Sepharose for 1 h on a rotator at 4°C. 3xHA-CHIC2 was 
immunoprecipitated using EZview Red α-HA (Merck, E6779) for 2-3 h on a rotator at 4°C. 
FLAG-STUB1 was immunoprecipitated using EZview Red α-FLAG M2 (Merck, F2426) 
overnight on a rotator at 4°C. Endogenous IFNGR1 was immunoprecipitated using rabbit α-
IFNGR1 and protein A-sepharose for 3 h at 4°C on a rotator. 
After one wash with 0.5% digitonin or NP-40 and at least four washes with 0.1% digitonin or 
NP-40, samples were eluted by heating in 2% SDS at 65°C for 10 min and processed as above.  
 
 
2.5.3 SDS-PAGE  
Lysates and immunoprecipitates were separated by SDS-PAGE. Tris-glycine acrylamide gels 
were made using the following recipe: 
Resolving gel    Stacking gel 
0.375 mM Tris-HCl pH 8.8  0.125 mM Tris-HCl pH 6.8 
0.1% SDS    0.1% SDS 
0.1% APS    0.1% APS 
6-12% acrylamide   1.8% acrylamide 
 
2.5.4 Immunoblotting 
Polyvinylidene fluoride (PVDF) membranes (Millipore) were incubated in methanol before 
soaking in transfer buffer. Proteins separated by SDS-PAGE were transferred onto PVDF 
membrane at 110V for 90 min using a Bio-Rad Transfer Cell. Membranes were blocked with 
5% milk in PBS-T (PBS plus 0.2% Tween-20) for 1 h at room temperature and probed with 




membranes were probed with horseradish peroxidase (HRP) secondary antibody (Jackson) in 
5% milk in PBS-T for 1 h at room temperature. Membranes were washed at least four times 
for 5 min with PBS-T before visualizing reactive bands with ECL, West Pico or West Dura 
(Thermo Fisher Scientific).  
To visualize ubiquitinated CHIC2 with the α-ubiquitin Vu-1 antibody, after protein transfer 
onto a PVDF membrane, the PVDF membrane was treated with 0.5% glutaraldehyde/PBS for 
20 min, washed twice with PBS and then blocked in 5% milk in 0.1% Tween-20 in PBS.  
 
2.6 Cell Biology 
2.6.1 Immunofluorescence microscopy  
HeLa cells were grown overnight on glass coverslips and seeded approximately 24 h prior to 
staining. Cells were either stained with a cell surface marker (W6/32) for 30 min at 4°C in the 
dark, the coverslips washed in PBS, fixed with 4% PFA (10 min  at room temperature), 
permeabilized with 0.5% Saponin and then blocked for 30 min -1 h with 3% BSA dissolved in 
PBS + 0.1% Tween-20 (PBS-T). 0.01% Saponin was used in all subsequent washes and 
staining steps to ensure that the membranes remained open. Primary antibody was then applied 
for 1 h, the coverslips washed in PBS-T, and the fluorophore-conjugated secondary antibody 
applied for 45 min. Coverslips were mounted in ProLong® Gold Antifade Reagent with 4′, 6-
diamidino-2-phenylindole (DAPI) (Invitrogen). Slides were visualized at room temperature 
with a Zeiss LSM880 confocal microscope (x63 oil immersion objective lens) and images were 






2.6.2 Flow cytometry 
 
Cells were harvested, washed with PBS, and incubated with primary antibody for 30 min at 
4⁰ C, washed once with PBS, and then incubated with fluorophore-conjugated secondary 
antibody for 30 min at 4⁰ C. Live samples were analyzed on a FACSCalibur (BD) or a 
LSRFortessa (BD). Flow cytometry data was analyzed using FlowJo software. 
 
2.6.3 Fluorescence-activated cell sorting (FACS) 
 
Cells were harvested, washed with PBS, and incubated with primary antibody for 30 min at 
4⁰ C, washed once with PBS, and then incubated with fluorophore-conjugated secondary 
antibody for 30 min at 4⁰ C. Cells were resuspended in sort solution (PBS containing 10 mM 
HEPES and 2% FCS) and filtered through a 50 μm filter. Samples were sorted on an Influx 
machine (BD). 
 
2.6.4 Internalization Assays   
 
Cells were seeded in fresh media the day prior, cells harvested and washed with ice-cold PBS, 
and incubated with α-IFNGR1 antibody for 30 min on ice, washed twice to remove unbound 
antibody, a baseline sample was removed and cells were incubated at 37°C for the designated 
time point, and diluted directly into ice cold-PBS. Samples were kept on ice to stop further 
endocytosis, washed once in ice-cold PBS, and the remaining surface-bound IFNGR1 was 
stained with a secondary antibody conjugated to AlexaFlour-647 for 20 min at 4°C.  
 
2.7 CRISPR/Cas9 knockout screens 
2.7.1 sgRNA library  
For the genome-wide CRISPR knockout screens in Chapter 5, the Bassik gRNA library was 




2.7.2 sgRNA library lentivirus  
Lentivirus was produced using the standard protocol (section 2.4.2) in 14 cm plates of HEK 
293T cells by the triple transfection of the gRNA library plasmid pool and the packaging 
vectors pCMVΔR8.91 and pMD.G in a ratio of 10:7:3. The viral supernatant was harvested 48 
h post-transfection, filtered through a 45 μm filter and immediately frozen in aliquots of 5 ml 
and 1 ml to be stored at -80oC. 
To determine the viral titer of the gRNA library viral supernatant, a 1ml aliquot of the frozen 
supernatant was thawed and a range of volumes were added to wells containing 1 million cells 
to be used in the screen. Plates were spun at 1800 rpm for 1 h. The transduction efficiency was 
determined 48 h post transduction. For the Bassik library transduction efficiency was measured 
by assessing the percentage of cells expressing the mCherry and BFP markers respectively. 
The volume of viral supernatant required to achieve a multiplicity of infection (M.O.I.) of 
approximately 0.3 was noted for use in forward genetic screens. 
 
2.7.3 Cell-surface fluorescence based CRISPR/Cas9 screens  
For the CRISPR screens with the Bassik library in Figure 3.3 and Figure 3.6, 1 x 108 THP-1 
cells were transduced at an M.O.I of 0.27 or 0.35, respectively.  
The cell line chosen to use in a CRISPR screen was transduced with pHRSIN-PSFFV-Cas9 
PPGK-BlasticidinR. Transduced cells were selected with blasticidin treatment. To confirm 
Cas9 activity in the screen cell line, the Cas9-expressing cells were transduced the pKLV vector 
encoding a β-2-microglobulin (β2m)-targeting gRNA. Transduced cells were selected with 
puromycin. MHC-I surface expression was assessed five days post-transduction by flow 
cytometry. β2M knockout results in the loss of MHC-I surface expression. The β2m gRNA 
typically results in about 90% population with low MHC-I surface expression, although there 




For THP-1 cells, transductions were performed in 6-well plates with 2x106 cells per well. All 
plates were spun for 1 h at 1800 rpm. Transduced cells were selected with 1 μg/ml puromycin 
24 h post-transduction. The puromycin concentration was increased to 2 μg/ml 48 h post-
transduction. Puromycin treatment was maintained until the first FACS selection as 
recommended by the Zhang laboratory (Shalem et al. 2014).  
A first FACS selection was performed on day 8 post-transduction to select gene knockouts 
with altered expression of the fluorescent reporter. Typically, 1x108 cells were stained and 
processed by the FACS machine to select the top 0.5% reporter-expressing ‘low’ or ‘high’ 
cells. Selected cells were pelleted and genomic DNA extracted immediately after sorting, using 
the Quick-gDNA MicroPrep kit (Zymo Research). The selected cells were expanded in culture, 
typically for eight days, before a second FACS selection was performed to purify the 
population of mutants. The cells selected in the second sort were expanded in culture until 
5x106 cells could be harvested for genomic DNA extraction using the Gentra Puregene kit 
(Qiagen). 
 
2.7.4 DNA preparation and sequencing  
To amplify the gRNA sequences from extracted genomic DNA, two PCR steps were 
performed. The first PCR amplified the gRNAs using 50 separate 100 μl reactions with 4 μg 
genomic DNA in each reaction using Q5 High-Fidelity DNA Polymerase (NEB). Primer 
sequences in Appendix 4. For each sample, the PCR products were pooled. A tenth was taken 
and purified by QIAquick PCR Purification (Qiagen). A second PCR was performed to attach 
Illumina adaptors to barcode the samples. This was done with a single 100 μl reaction for each 
sample using 1ng of product from PCR 1. Amplification was carried out using 12, 16 or 20 
cycles. The products from PCR 2 were purified using Ampure XP beads (Agencourt). The 




(Agilent) was selected for sequencing. Samples from IFNAR1low and IFNGR1low screens were 
sequenced on the Illumina HiSeq platform; samples from the IFNGR1high screen was sequenced 
on the Illumina MiniSeq platform. 
 
2.7.5 CRISPR Screen Data Analysis  
Illumina HiSeq data as analyzed through a custom analysis pipeline developed by Richard 
Timms (CIMR, University of Cambridge) (Timms et al. 2016). Using the fastx toolkit 
(http://hannonlab.cshl.edu/fastx_toolkit/) the raw cram files were converted into fastq files. 
The 3’ end of the resulting reads were trimmed to the leave the gRNA sequences, and then 
mapped to an index of the gRNA sequences in the relevant gRNA library using Bowtie 2 
(Langmead et al. 2009). The resulting gRNA counts were analyzed using the RSA algorithm 
using the default settings (König et al. 2007).   
 
2.8 Proteomics 
2.8.1 Plasma membrane pulldown 
THP-1 cells expressing either Cas9 alone (Clone 22) or Cas9 C22 plus one of two verified 
guide RNAs against CHIC2 or STUB1 were cultured to ~80% confluence (3x14cm dishes 
each). Cells were pelleted and washed in PBS before biotinylation of the cell surface. Cells 
were biotinylated in the culture dish with 10mL PBS pH6.7, 100uM Aminooxy-biotin, 100nM 
Sodium(Meta)periodate and 10nM aniline for 30 min at 4°C in the dark. After quenching with 
1mM glycerol and further washes with PBS, cells were lysed by resuspension in 1% Triton in 
TBS pH8 with protease inhibitors (cOmplete EDTA-free, Roche) and incubated for 30mins at 
4°C with end-over-end agitation. Unlysed nuclei were removed by centrifugation (13’000g 
10mins). Supernatants were applied to 50µL of High-Capacity Streptavidin-agarose resin 




beads were applied to 500µL fritted microcolumns (Snap-Cap, Thermo Fisher Scientific) and 
washed as follows using a vacuum manifold. 20x400µL Lysis buffer, 20x400µL 0.5% SDS in 
PBS, 10x400µL 6M urea in 50mM TEAB buffer (pH8). Beads were then resuspended in 400µL 
urea wash buffer containing 10mM TCEP and 10mM Iodoacetamide (IAA) and incubated for 
30 minutes in the dark at room temperature to effect reduction and alkylation of cysteines. This 
was followed by a further 10x400µL washes with urea wash buffer and 5x400µL washes with 
50mM TEAB. Beads were then recovered into Eppendorf tubes (Protein LoBind, Eppendorf) 
spun briefly and supernatant removed before resuspending in 50µL of 50mM TEAB containing 
0.5µg trypsin (Proteomics Grade, Thermo Fisher). Samples were incubated at 37°C for 8 hours 
in a Thermo mixer C equipped with a heated lid at 1200rpm. Subsequently samples were 
recovered from streptavidin beads and the beads washed once with 50µL 50mM TEAB. 
Samples were then dried in a vacuum centrifuge and resuspended in 20µL 50mM TEAB.  
 
2.8.2 TMT Labelling  
To each tube 0.2ug of a unique TMT label for each sample was added in 8.5µL acetonitrile and 
incubated for 1 h at room temperature. Labels were as follows. Control: 126, 127N, 127C. 
sgRNA CHIC2: 128N, 128C, 129N. sgRNA STUB1: 129N, 130N, 130C. TMT reactions were 
quenched by addition of 3µL of 200mM ammonium formate, pooled and dried in a vacuum 
centrifuge. The sample was then resuspended in 800µL 0.1% TFA and acidified to ~pH2 with 
formic acids before performing a C18-SPE cleanup using a Sep-Pak cartridge (Waters) 
attached to a vacuum manifold. C18 Eluate was dried in a vacuum centrifuge and resuspended 






2.8.3 High pH Reversed Phase Fractionation  
Sample was injected onto an Ultimate 3000 RSLC UHPLC system (Thermo Fisher Scientific) 
equipped with a 2.1 i.d x25cm, 1.7µm particle Kinetix Evo C18 column (Phenomenex). Mobile 
phase consisted of A: 3% ACN, B:ACN and C: 200mM ammonium formate pH 10. Isocratic 
conditions were 90% A/10%C and C was maintained at 10% throughout the gradient elution. 
Separations were carried out at 45°. After loading at 200µL/min for 5 mis and ramping the flow 
rate to 400µL/min over 5min the gradient elution proceed as follows: 0-19% B over 10 minutes 
(curve 3), 19-34%B over 14.25mins (curve 5), 34-50%B over 8.75mins (curve 5), followed by 
a 10 min wash at 90% B. UV absorbance was monitored at 280nm and 15s fractions were 
collected into 96 well microplates using the integrated fraction collector. Peptide containing 
fractions were then orthogonally recombined into 12 fractions and dried in a vacuum centrifuge 
and resuspended in 10µL 5% DMSO 0.5% TFA for analysis.  
 
2.8.4 LC-MS Analysis  
All samples were injected onto an Ultimate 3000 RSLC nano UHPLC equipped with a 300µm 
i.d. x 5mm Acclaim PepMap µ-Precolumn (Thermo Fisher Scientific) and a 75µm i.d. x75cm 
2.1µm particle Acclaim PepMap RSLC analytical column. Loading solvent was 0.1% TFA, 
analytical solvent A: 0.1% FA and B: ACN+0.1% FA. All separations are carried out at 55 
degrees. Samples were loaded at 10µL/min for 5 mins in loading solvent before beginning the 
analytical gradient. For High pH RP fractions a gradient of 3-5.6% B over 4 mins, 5.6 – 32%B 
over 162mins, followed by a 5 minute wash at 80%B and a 5 minute wash at 90%B and 
equilibration at 3%B for 5mins. For IP samples a linear gradient from 3-5.6%B over 8 min and 
5.6-32%B over 72min, followed by a 5 min wash at 80%B and a 5 min wash at 90%B and 





2.8.5 Data Processing  
All Raw files were searched by Mascot within Proteome Discoverer 2.1 (Thermo Fisher 
Scientific) against the Swissprot Human database and a database of common contaminants. For 
TMT labelled samples the search parameters were as follows. Enzyme: Trypsin. MS1 tol: 
10ppm. MS2 tol: 0.6Da. Fixed modifications: Carbamidomethyl Cysteine, TMT peptide N 
termini and Lysine. Variable modification oxidised methionine. MS3 reporter ion tol: 20ppm, 
most confident centroid. Mascot Percolator was used to calculate PSM FDR.  
Search results were further processed and filtered as follows: Peptides below a percolator FDR 
of 0.01% and proteins below the 0.01% protein FDR (calculated from a built-in decoy database 
search) were rejected.  Protein groups were then generated using the strict parsimony principle. 
Peptides both unique and razor with a co-isolation threshold of 50 and an average s/n threshold 
of 10 were used for quantification and a normalization of these values on the total peptide 
amount in each channel was applied. Instances where a protein was identified but not quantified 
in all channels were rejected form further analysis. Manual interpretation of the data did not 
reveal any protein conspicuously absent from any sample set. Remaining protein abundances 
were output to Excel and imported to R, a computer programming language (R Core Team, 
2017), where a custom script was used to apply the moderated t-test LIMMA (p-value) 
including Benjamini-Hochberg correction for multiple hypotheses (Q-value) (Huber et al. 
2015; Schwämmle et al. 2013). In this way, Q-values for each comparison of each protein were 




Chapter 3: A series of genome-wide 
CRISPR/Cas9 knockout screens to 





This project commenced out of my interest in attaining a deeper understanding of the peripheral 
quality control of cell surface receptors. The regulation of cell surface receptors is vital for 
cellular homeostasis as they make up major components of signal transduction from the plasma 
membrane. This regulated function can protect the host against infection and cancer, whereas 
excessive signaling could result in toxicity (Ivashkiv and Donlin 2014) and even death.  
The Lehner laboratory has had a long-term interest in identifying novel genes and mapping 
cellular pathways involved in virus-host interactions, and has used CRISPR/Cas9 forward 
genetic screens and proteomic approaches to interrogate these systems. CRISPR/Cas9 is a 
popular gene-editing technique that allows scientists to edit and silence genomes of a large 
variety of cells and organisms, has been used in high-throughput screens (Koike-Yusa et al. 
2013; Tim Wang et al. 2014; Shalem et al. 2014; Zhou et al. 2014; Morgens et al. 2017), and 
has recently been used to study cellular signaling mechanisms (Sharma and Petsalaki 2018). 
Our lab has developed and utilized this screening technique to successfully identify a critical 
role for a novel E3 ligase in HMGCR regulation (Menzies et al. 2018), to study ERAD of 
MHC-I molecules (Timms et al. 2016), and to identify the HUSH complex (Tchasovnikarova 
et al. 2015). Accordingly, I thought a CRISPR/Cas9 genome-wide knockout screen could be a 




surface receptors. The lab’s expertise, along with my first year PhD experience, equipped me 
with a strong skillset to carry out a successful CRISPR/Cas9 genome-wide knockout screen.  
Prof Serge Y. Fuchs, who was on sabbatical in the Lehner lab, works on identifying the 
abnormalities in ‘eliminative signaling’ of cytokine receptors that are critical for the 
development of cancers (e.g. IFNAR) and responses to infections and autoimmune pathways. 
The interferon-α receptor (IFNAR) has antiviral and anti-tumorigenic functions, and the 
immunomodulatory effects of type I interferon (IFN) are used in the treatment of some cancers, 
chronic viral infections and multiple sclerosis (Clerico et al. 2007; Fuchs 2013). IFNAR is 
important in mediating type I IFN responses in hematopoiesis and innate and acquired 
immunity to infection and cancer. Hence, we discussed a potential collaboration on screening 
IFNAR (looking into melanomas and the underpinnings of repressed IFNAR expression). The 
rationale for the first screen performed in this chapter also grew out of my interest in screening 
therapeutic targets.  
Although many studies have focused on IFN binding at the plasma membrane, fewer studies 
have addressed the endocytosis and intracellular trafficking of IFN receptors following ligand 
binding and receptor dimerization. Given the similarity between IFNAR and the related 
interferon-γ receptor (IFNGR), I was also interested in screening IFNGR1 as the peripheral 
quality control of this receptor is poorly understood. IFNGR1 is the ligand-binding subunit 
necessary for IFN-γ binding and receptor internalization. IFNGR2 is required for signal 
transduction but does not bind IFN-γ (Bach et al. 1997). IFN-γ, produced by activated T cells 
and natural killer cells, is involved in the regulation of specific immune responses, immune 
surveillance and tumor suppression (Billiau 1996; Bach et al. 1997). As IFNGR is less well 
studied than IFNAR, I was interested in understanding more about the regulation and stability 




mechanisms for the downregulation of cell surface IFNGR1 could lead to the identification of 
new molecular targets for therapeutics.  
I wanted to address the following aims through CRISPR/Cas9 genome-wide knockout screens:  
1. To identify genes required for the cell surface expression of IFNAR1 (i.e. select 
mutant IFNAR1low cells that are defective in trafficking IFNAR1 to the cell surface) 
2. To identify genes required for the cell surface expression of IFNGR1 (i.e. select 
mutant IFNGR1low cells that are defective in trafficking IFNGR1 to the cell surface) 
3. To identify genes required for the ligand-independent turnover of IFNGR1 (i.e. 
select mutant IFNGR1high cells that are defective in internalizing/downregulating 
IFNGR1 from the cell surface) 
I therefore set up screens for the following cell surface receptors: (i) IFNAR, (ii) IFNGR, and 
(iii) poliovirus receptor (PVR), the latter of which I will not discuss in my thesis. Prior to 
performing the screens, it was important for me to identify appropriate and readily available 
reagents for the screens (identifying suitable cell lines, searching for commercially available 
antibodies). During the screens, I used fluorescence-activated cell sorting (FACS) to select 
mutant cells of interest on the basis of a change in cell surface phenotype by antibody staining. 
While screens were performed on all the three receptors, I will only briefly discuss the more 
well-studied IFNAR. For the remainder of my thesis, I will focus on the more interesting, less 









3.2 Results (I)  
3.2.1 Creating a stably expressing THP-1 Cas9 cell line  
Throughout my PhD project, THP-1 monocytic suspension cells were used for all studies 
(unless indicated otherwise). In order to carry out the CRISPR/Cas9 screens, I needed to create 
a stably expressing THP-1 Cas9 cell line, so that the single guide RNA (sgRNA) targeting the 
gene I wanted to knockout could recruit the Cas9 nuclease and make the genetic deletion. I 
transduced WT THP-1 cells with a lentiviral construct encoding the Cas9 nuclease (Figure 
3.1A). Cells were selected on blasticidin and single cell cloned. To identify a Cas9 active clone, 
a sgRNA encoding β2-microglobulin (β2M) (Figure 3.1B) was transduced into THP-1 Cas9 
clones and cells were puromycin selected (two clones are shown, Figure 3.1C). Knockout of 
the β2M gene can be detected by a reduction in cell surface MHC-I. Cell surface MHC-I 
expression was tested five days post-transduction by flow cytometry resulting in ~ 90% down-
regulation of MHC-I, as expected (blue to red line, Figure 3.1C), proving that Cas9 was active 








Figure 3.1 Creating and isolating a stably expressing THP-1 Cas9 clone. (A) A schematic of the 
lentiviral construct encoding Cas9. Expression is driven by the powerful spleen focus-forming virus 
(SFFV) promoter. Encodes a resistance gene for blasticidin (BlastR) driven by the phosphoglycerate 
kinase (PGK) promoter. (LTR, long-terminal repeat; WPRE, Woodchuck hepatitis virus 
posttranscriptional regulatory element). (B) A schematic of the lentiviral construct encoding the sgRNA 
in green (in this case, β2-microglobulin). Encodes a resistance gene for puromycin (PuroR) with a 2A 
linker to blue fluorescent protein (BFP) to detect expression of the sgRNA driven by the human U6 
(hU6) promoter. (C) Twenty-two THP-1 Cas9 clones were tested for Cas9 activity of which two clones 
are shown. Cells were transduced with construct in (B), puromycin selected, and stained for cell surface 
MHC-I with W6/32 mAb, followed by fluorochrome-conjugated secondary antibody (AF647) five days 
post-transduction. WT THP-1 unstained (gray), Cas9 clone stained (blue), Cas9 clone + sgβ2m (red). 
 
 
3.2.2 Establishing the screening window for IFNAR1 in THP-1 cells  
In order to carry out a cell surface antibody screen, I needed to establish the screening window 
sufficient to sort for an IFNAR1low phenotype. Prior to doing so, I was made aware that a 
previous PhD student in the lab had an issue with false positives as hits in a screen due to a 




The Fc receptor is a protein of the immunoglobulin (IgG) superfamily that binds antibody and 
plays an important regulatory function in the immune system. The Fc receptor is expressed at 
the surface of monocytes, macrophages, dendritic cells, natural killer cells, and B cells. As 
THP-1 is a monocytic cell line and therefore expresses Fc receptor, I wanted to block 
nonspecific binding of my primary antibody (IFNAR1, and later, IFNGR1). Therefore, I pre-
incubated THP-1 cells with human IgG for 10 minutes at 4°C (this was done for every cell 
surface staining experiment I discuss in my thesis, inclusive of the large-scale sorts).   
The IFNAR1 consists of 557 amino acids including an extracellular domain, a transmembrane 
domain and a cytosolic (luminal) domain (Figure 3.2A). IFNAR1 cell surface expression was 
tested by flow cytometry by staining WT THP-1 cells with human IgG (to block the Fc 
receptor), followed by incubation with either of two primary monoclonal antibodies specific to 
different extracellular domains of human IFNAR1 (AA3 or GB8) (Figure 3.2B). AA3 
recognizes the second subdomain of IFNAR1, and GB8 recognizes the third subdomain 
(between amino acids 278-293) (Figure 3.2A). Both antibodies were good candidates, but 
neither were commercially available, so I used the one that was more available in the lab.  
Twenty-two Cas9 clones were screened for an IFNAR1 screening window, of which four are 
shown (Figure 3.2C). Although clone 15 may have been a more suitable candidate as it 
displayed slightly higher cell surface IFNAR1, clone 22 (C22) grew better, whilst clone 15’s 
growth was compromised. In selecting a clone for the screen, I also wanted to choose a clone 
whose cell surface phenotype did not cover a broad range, like clone 4, so as to keep the peak 






Figure 3.2 Establishing the IFNAR1 cell surface screening window in THP-1 cells. (A) Schematic 
depicting domains of IFNAR1. Signal peptide, aa 1-28. Extracellular domain, aa 29-437 (blue), 
transmembrane domain (TM), aa 437-457 (gray) and cytosolic domain, aa 457-557 (green). aa, amino 
acids. (B) Two antibodies against IFNAR1 were used for cell surface expression of IFNAR1. WT THP-
1 unstained (gray), WT THP-1 secondary antibody only (blue), WT THP-1 cells stained (red). (C) Four 
THP-1 Cas9 expressing clones were tested for optimal cell surface IFNAR1 expression. WT THP-1 
unstained (gray), THP-1 Cas9 parent (red), THP-1 Cas9 clone (shaded blue).    
 
At this point, a Senior Research Associate in the lab, Dr. Dick van den Boomen, brought 
another important point to my attention. Ensuring optimal viability of THP-1 cells after the 
FACS sort is crucial as cell death could greatly affect the screen results (i.e. not all potential 
hits would be identified if the cells died after a sort). To help optimize my protocol, cells were 
sorted into PBS and 10mM HEPES, instead of into the standard sheath fluid (BD FACS Flow), 
which contains a preservative that could harm the cells. Sorted THP-1 cells were subsequently 
seeded in a 1:1 fresh RPMI and conditioned RPMI media (which contains some secreted 




3.2.3 A genome-wide CRISPR knockout screen identifies genes essential for cell surface 
trafficking of IFNAR1 
The first screen I carried out was the IFNAR1low screen aimed at enriching mutant cells that 
might have a defect in forward trafficking of IFNAR1 to the cell surface (aim I). I hypothesized 
that the screen would identify hits in the early secretory pathway or endosomal genes (i.e. 
considering the possibility in which IFNAR1 was (i) stuck in the ER or Golgi, and therefore 
unable to reach the surface; or (ii) makes it to the surface, is internalized in endosomes and 
unable to recycle back to the surface).  
All CRISPR/Cas9 screens in this chapter were carried out in the same manner (described in 
section 2.7.3), albeit the two screens were transduced with different lentivirus at slightly 
different multiplicity of infection (M.O.I.) and different sorting gates applied for ‘low’ or ‘high’ 
screens. The genome-wide CRISPR knockout screens were performed using the Bassik Human 
CRISPR Knockout Library (a kind gift from M. Bassik, now publicly available on Addgene) 
(Morgens et al. 2017). This library is one of the newer CRISPR libraries containing 218,041 
sgRNAs targeting 20,570 genes. Each gene is targeted by 10 sgRNAs and the library includes 
non-targeting controls (Morgens et al. 2017). Prior to carrying out the screens, lentivirus was 
produced by transfecting HEK293T cells with the pooled sgRNA plasmids and standard 
lentivirus packaging vectors (as described in section 2.7.2). The viral supernatant was titrated 
onto Cas9 C22 to determine the volume of supernatant required to infect roughly 30% of the 
cells.  
To perform a IFNAR1low or IFNGR1low/high genome-wide CRISPR knockout screen, 108 THP-
1 Cas9 C22 cells were transduced with the Bassik sgRNA library (day 0) at a M.O.I of 0.27, 
meaning that there were 121 cells/guide (123x-fold coverage) for the IFNAR1low screen 
(Figure 3.3A), or at an M.O.I of 0.35, meaning that there were 159 cells/guide (160x-fold 




24 hours post-transduction, with selection maintained until the first sort (day 8) (Figure 3.3A 
and 3.6). Mutant IFNAR1low or IFNGR1low/high cells were enriched using two sequential rounds 
of FACS (Figure 3.3B and 3.6). On both sorting days (days 8 and 20), approximately 108 cells 
(C22) were labelled with human IgG to block the Fc receptor, incubated with primary antibody 
for 30 minutes at 4°C (AA3), washed, stained with a fluorochrome conjugated secondary 
antibody (AF-647) for 30 minutes at 4°C, and 0.5% of ‘low’ or ‘high’ cells were FACS sorted.  
Genomic DNA was extracted from the selected IFNAR1low population and from the library of 
unselected mutagenized cells grown for the same amount of time (Figure 3.3A and 3.6) and 
samples were prepared for sequencing. The first PCR amplified the gRNA sequences using 
primers that bind to the integrated lentiviral construct, whilst the second PCR attached Illumina 
adaptors for deep sequencing using the HiSeq platform (IFNAR1low and IFNGR1high screens ) 
or MiniSeq platform (IFNGR1high screen). The sgRNA abundance was quantified in the 
selected mutant cells and an unsorted mutant library by deep sequencing. The RSA algorithm 
was used to identify candidate genes (König et al. 2007).   
For the IFNAR1low screen, the first sort resulted in about a 1.5% enrichment for mutant 
IFNAR1low cells, while a highly enriched population of nearly 60% IFNAR1low cells was 
obtained after the second sort (Figure 3.3C). The RSA algorithm was used to identify 
candidate genes (Figure 3.3D) (König et al. 2007).   
Experience from the Lehner laboratory suggested that any gene with a significance value (-
logP) above 5 is likely to validate. The raw data that the RSA algorithm produces also provides 
a read-out of the number of active guides per gene, in addition to a score, which can be any 
number above 0. For example, a score above 1 means that the guide is active. Scores close to 
3 denote that that guide is very active. I took this into account and chose to validate some genes 




(Figure 3.3D). It was reassuring that the screen identified IFNAR1 as the critical positive 
control and as the top hit, proving that the screen was technically successful. The hits can be 
grouped into the following categories.  
Stabilizer of IFNAR1 
Tyrosine kinase 2 (TYK2), a member of the JAK family of kinases, is constitutively associated 
with IFNAR1, and phosphorylates IFNAR1 upon ligand binding of a type I IFN. As mentioned 
in section 1.1.2.2, in unstimulated conditions, IFNAR1-associated TKY2 masks an endocytic 
motif (YXXϕ) in IFNAR1’s intracellular domain. Indeed, human cells lacking TYK2 exhibit 
low levels of IFNAR1 (Gauzzi et al. 1997). In addition, the Pellegrini group report that in the 
absence of TYK2, mature IFNAR1 is weakly expressed at the plasma membrane, is 
internalized, accumulates in endocytic organelles overlapping with that of recycling transferrin 
receptors and rapidly degraded (Ragimbeau et al. 2003). This study provides evidence that JAK 
proteins are critical regulators of cytokine receptor trafficking and emphasizes that preformed 
receptor-JAK complexes are favorable. In unstimulated cells, TYK2 exerts a positive effect on 
IFNAR1 cell surface expression, by anchoring it to the plasma membrane, whereas in 
stimulated cells, TYK2 contributes catalytically to the degradation of internalized IFNAR1 









Figure 3.3 CRISPR/Cas9 forward genetic screen identifies members of the translocation complex 
as required for forward transport of IFNAR1 to the cell surface. (A) Timeline of the CRISPR 
screen. (B) Schematic representation of the CRISPR genetic screen. I predicted that knockout of genes 
essential for IFNAR1 trafficking/cell surface expression would allow me to enrich for cells that were 
deficient in cell surface IFNAR1. THP-1 Cas9 C22 was mutagenized and IFNAR1low cells selected by 
two rounds of FACS, followed by Illumina sequencing. (C) Isolating mutant cells unable to traffic 
IFNAR1 to the cell surface. (D) Bubble plot illustrating the hits from the screen identified using the 
RSA algorithm (König et al. 2007). 
 
Protein translocation into the ER via Super Elongation complex (SEC) 
The conserved heterotrimeric SEC61 complex and the dimeric SEC62/SEC63 complex play 
a major role in translocating nascent polypeptides into the ER (Rapoport 2007). The SEC61 
complex is the central component of the protein translocation machinery of the ER membrane. 
SEC61β is one of the components of the SEC61 complex (the others being SEC61α and 
SEC61γ). SEC62 targets and positions the newly synthesized chain into the SEC61 translocon 
complex, causing channel opening for polypeptide translocation into the ER lumen. The screen 
identified SEC62 and SEC61β, but not other components of the complex, such as SEC61α, 
SEC61γ, SEC63 and SRP (which recognizes the transmembrane sequence of a growing 
polypeptide chain) suggesting that the screen was not saturating. The identification of these 
hits implies that IFNAR1 maturation and forward trafficking from the ER membrane was 
affected.  
RNA Splicing 
Splicing factor, muscleblind like splicing regulator 1 (MBNL1), plays an important role in 







Phospho-mannomutase 2 (PMM2) is cytosolic enzyme that catalyzes the conversion of 
mannose-6-phosphate (M6P) to mannose-1-phosphate, a precursor for the synthesis of N-
glycans. Its absence could indicate that the lack of glycosylation, a post-translational 
modification, could impede forward trafficking of IFNAR1 to the cell surface. In addition, most 
proteins destined for lysosomes contain a M6P tag and are sorted into vesicles coated with 
another protein complex based on clathrin (Braulke and Bonifacino 2009). The M6P tag is a 
marker that targets lysosomal hydrolyases to the lysosome (Braulke and Bonifacino 2009). It 
was somewhat surprising that additional glycosylation enzymes were not identified. Mutations 
in PMM2 cause congenital disorders of glycosylation (C. Thiel et al. 2006).  
Other  
DHRSX is a poorly characterized protein that has been reported to play a role in non-classical 
secretion and promotes starvation-induced autophagy (G. Zhang et al. 2014).   
 
3.2.4 CRISPR-mediated gene disruption of several genes impairs forward trafficking of 
cell surface IFNAR1  
The results from the CRISPR/Cas9 screen indicate that the loss of IFNAR1, TYK2, MBNL1, 
SEC61β and SEC62 are likely to cause a defect in cell surface trafficking of IFNAR1. CRISPR-
mediated gene disruption was used to validate a role for each of these genes. I generated 
knockout cell populations by transducing C22 with a candidate-gene targeting sgRNA (denoted 





First, I sought out to confirm that depletion of IFNAR1 would cause a near complete loss of 
cell surface IFNAR1 using four independent sgRNAs. Cell surface IFNAR1 expression was 
tested eight days post transduction by flow cytometry. In each population, I observed a decrease 
in cell surface IFNAR1 as compared to the sgRNA control population (red line to dark blue 
shaded, Figure 3.4A). The shaded blue population overlaid with the secondary only staining 
(light blue line, Figure 3.4A). I did not confirm loss of IFNAR by immunoblot as we did not 
have a blotting antibody and I was wary of continuing this project due to the low number of 
hits.  
Next, I sought out to validate whether the loss of TYK2 contributed to a decrease in cell surface 
IFNAR1 (Figure 3.4B), following the aforementioned protocol. Four respective guides against 
TYK2 produced a partial loss of IFNAR1 from the cell surface (e.g. 3.7-fold decrease for 
sgRNA #2), confirming that TYK2 is also essential for stabilization of IFNAR1 at the cell 
surface, as reported by Pellegrini and colleagues (Ragimbeau et al. 2003). 
I then went on to examine whether depletion of translocation machinery components produced 
a similar cell surface phenotype. For SEC61β, only guide #3 proved to be slightly active in 
comparison to other sgRNAs (since this is such an important gene, I could have analyzed the 
cells earlier, e.g. on day 4/5 because the knockout may have been lethal) (Figure 3.4B). For 
SEC62, all guides were active, although they did not have as profound of an effect as expected 
(Figure 3.4B). I could also have tested the samples on an earlier day.  
Finally, I also validated the role of MBNL1 for the loss of total cell surface IFNAR1 using 
three independent sgRNAs, and guides #1 and #3 validated (Figure 3.4B). The inability of 






Figure 3.4 Validation of candidate genes identified in the IFNAR1low genome-wide CRISPR 
knockout screen. (A-B) THP-1 Cas9 clone 22 (C22) was transduced with a candidate gene-targeting 
sgRNA or control sgRNA (β2m). Transduced cells were selected with puromycin. IFNAR1 expression was 
measured by flow cytometry eight days post-transduction. WT THP-1 unstained (gray), C22 secondary 




3.2.5 Summary  
The IFNAR1low screen was successful in its identification of positive controls, however, none 
of the genes were especially novel, and whilst the resulting population had a significant 
enrichment, the hits obtained after the second sort were not as comprehensive as expected 
(Figure 3.3D).  
 
 
3.2.6 Discussion  
CRISPR/Cas9 IFNAR1low screen: pitfalls and optimization  
The screen was successful in identifying IFNAR1, TYK2, SEC61β, SEC62, MBNL1, PMM2 
and DHRSX as essential for the forward trafficking of IFNAR1. In retrospect, a limiting 
reagent in this screen was the AA3 antibody; the screen may have been more successful if a 
better cell surface IFNAR1 antibody was available. The GB8 antibody displayed very similar 
cell surface staining to AA3 (Figure 3.2B), so using GB8 probably would not have made a 
significant difference.  
If I were to repeat the screen, I could have used a larger window to select the ‘low’ cells since 
the main population (red) sits quite close to the secondary only stained sample (light blue) 
(Figure 3.4A). This means that the window to sort for ‘low’ cells may have actually been very 
small, despite a high enrichment after the second sort. Alternatively, I could have 
overexpressed an epitope-tagged IFNAR1 to induce greater cell surface expression of IFNAR1 
and not depend on the endogenous antibody, but that may have altered the results since the aim 
was to perform the screen on endogenous steady-state levels. Furthermore, THP-1 cells are far 
more sensitive to FACS sorting in comparison to HeLa cells, in terms of viability. As I was 
concerned about the viability, perhaps I could have used a different cell line that more readily 




cell surface IFNAR chains (approximately 250,000 chains per cell) (Constantinescu et al. 
1995). Mutantlow cells need to both survive and maintain normal growth characteristics to 
survive until the next round of sorting, and some cells could have died after the first sort. In 
terms of validation, the phenotype for SEC61β and SEC62 should have been determined on 
day 5 as opposed to day 8. Typically, I waited until day 7 or day 8 (day 8 was the day of the 
first sort during the screen) for knockouts to emerge and would FACS stain the cells on this 
day, and a few later days. An alternative reason as to why some sgRNAs did not generate 
knockouts in Figure 3.4A could be due to off-target effects.  
 
 
3.3 Results (II)  
3.3.1 Background on IFNGR1 
Previously, the Kaposi’s sarcoma-associated herpesvirus (KSHV) encoded E3 ubiquitin ligases 
K3 and K5 were reported to degrade IFNGR1 (Li et al. 2007). Since the regulation of cell 
surface IFNGR1 is poorly understood, I used CRISPR/Cas9 genome-wide knockout screens to 
screen for IFNGR1low and IFNGR1high cells exactly as described for IFNAR (see section 3.2.3). 
3.3.2 Establishing the screening window for IFNGR1 in THP-1 cells 
IFNGR1 is a N-glycosylated single-pass transmembrane protein consisting of 489 amino acids 
(aa) and contains a 17 aa signal peptide, 228 aa extracellular domain, 23 aa transmembrane 
domain and 221 aa intracellular (cytosolic) domain (Figure 3.5A). IFNGR1’s predicted MWT 
is 54-kD but by SDS-PAGE runs around 90-kD (between 75 and 100-kD, dependent on cell 
type and percentage of SDS-PAGE gel). IFNGR1 is ubiquitously expressed on most cell types, 
binds IFN-γ and initiates a signal transduction pathway (Bach et al. 1997).  
While establishing the antibody readout for the IFNAR1low screen in the previous section, I 




range with this antibody-labelling screen. I screened the aforementioned THP-1 Cas9 clones 
with a phycoerythrin (PE)-conjugated α-IFNGR1 antibody to establish IFNGR1 expression. 
Four clones seemed suitable (Figure 3.5B), and because I was already carrying out the 
IFNAR1low screen in C22, I performed both IFNGR1 screens in C22 as well. Because this 
antibody was PE-conjugated and the Bassik sgRNA library contains a mCherry reporter, I 
obtained and tested an unconjugated α-IFNGR1 antibody that recognizes the extracellular 
domain of human IFNGR1. Antibody staining showed an optimal window to screen in either 
direction as indicated by the arrows in red (Figure 3.5C).  
To confirm specificity of the antibody to IFNGR1, I designed three separate sgRNAs against 
IFNGR1 and transduced C22 with sgRNA targeting IFNGR1. Cells were puromycin selected 
as before (Figure 3.5D). Cell surface IFNGR1 expression was tested eight days post-
transduction by flow cytometry (red to blue histogram, Figure 3.5D). CRISPR-mediated gene 
disruption confirmed that these knockout cell populations were IFNGR1 specific (Figure 





Figure 3.5 Establishing the cell surface screening window for IFNGR1 in WT THP-1 cells. (A) 
Schematic of IFNGR1. Signal peptide, aa 1-18. Extracellular domain, as 19-246. Transmembrane (TM) 
domain, aa 246-266. Cytosolic domain, aa 266-489. aa, amino acids. (B) THP-1 Cas9 expressing clones 
were tested for cell surface IFNGR1 expression using a PE-conjugated α-IFNGR1 antibody. WT THP-
1 unstained (gray), Cas9 parent population (red), Cas9 clone (blue shaded). (C) C22 was stained for 
cell surface IFNGR1 with an unconjugated α-IFNGR1 antibody. WT unstained (gray), C22 secondary 
only staining (light blue) and C22 stained (red). (D) CRISPR-mediated gene disruption of IFNGR1 in 
C22. Cells was transduced with different IFNGR1 sgRNAs and analyzed by flow cytometry eight days 
post transduction. WT THP-1 unstained (gray), C22 + sg2m (red), C22 + IFNGR1 sgRNA (blue).  
 
 
3.3.3 A CRISPR/Cas9 screen for IFNGR1low expression identifies known components of 
the IFNGR1 signaling pathway 
As Cas9 activity was already confirmed in C22 from the IFNAR1 screen, one library was 
maintained for both IFNGR1 screens, and cells were sorted for both a ‘low’ and ‘high’ 




IFNGR1 cell surface differences in the two mutant populations after two sequential rounds of 
FACS sorting are outlined in Figure 3.6B. For the ‘low’ screen, I hypothesized that knockout 
of genes essential for IFNGR1 trafficking/cell surface expression would allow me to enrich for 
cells that were deficient in cell surface IFNGR1.   
 
Figure 3.6 Timeline and schematic of the IFNGR1 CRISPR/Cas9 screens. (A) Timeline of the 
CRISPR/Cas9 IFNGR1low and IFNGR1high screens. (B) Schematic representation of either the 
IFNGR1low or IFNGR1high screen. THP-1 Cas9 C22 cells were mutagenized, puromycin selected, stained 
for cell surface IFNGR1 and FACS sorted twice, followed by Illumina sequencing.  
 
The IFNGR1low and IFNGR1high genome-wide CRISPR knockout screens were performed as 
before (see section 3.2.3). The first sort resulted in about 3% enrichment for mutant IFNGR1low 
cells, while the second sort resulted in a highly enriched population of nearly 83% (Figure 




HiSeq, and the RSA algorithm was used to identify candidate genes (Figure 3.7B) (König et 
al. 2007).  
 
Figure 3.7 CRISPR/Cas9 forward genetic screen identifies members of the SRP complex as 
required for forward transport of cell surface IFNGR1. (A) Isolating mutant cells unable to traffic 
IFNGR1 to the cell surface. (B) Bubble plot illustrating the hits from the screen identified using the 





The IFNGR1low screen identified many candidate genes and was successful at identifying 
IFNGR1 as a positive control. The loss of IFNGR1 was validated prior to carrying out the 
screen and although it was used as a positive control in subsequent validation experiments, I 
have not included it in Figure 3.8. The hits can be grouped into the following functional 
categories. A major group of candidate genes identified are involved in transcription and 
translation (green/purple). Hits in brown are part of the SRP complex mediating the target of 
secretory proteins to the ER. Hits in yellow are involved in mitotic progression. 
Protein Synthesis, Processing, and Gene Expression  
The largest group of genes identified are involved in transcription and translation including 
NARS, HARS, VARS, EEF1A1, AARS, FARSA.  
Co-translational Targeting of Secretory Proteins to the ER 
This screen identified multiple components of the signal recognition particle (SRP) complex 
including SRP72, SRP68, SRP19 and SRPR but no other members of the SRP complex, 
suggesting that the screen was not saturating. These genes, along with other members of the 
SRP complex, play a role in delivering nascent polypeptides from SRP to the translocon in the 
ER membrane, so they can mature, continue along the secretory pathway and traffic to the 
surface. A majority of proteins destined for the secretory pathway are delivered by the SRP, a 
conserved protein targeting machine (Akopian et al. 2013). The SRP complex is a 
ribonucleoprotein complex that mediates the targeting of secretory proteins to the endoplasmic 
reticulum (ER). This complex consists of a 7S RNA and 6 protein subunits: SRP9, SRP14, 





3.3.4 The SRP complex is involved in the forward trafficking of IFNGR1  
I sought to validate a role for SRP72 and SRP68 via CRISPR-mediated gene disruption using 
three independent sgRNAs for each gene. Knockout populations were made by transducing 
C22 as before.  
Initially, I tested the phenotype by flow cytometry seven days post transduction (based on my 
experience with validating hits from other CRISPR screens). In each case, I observed a small 
population of cells that expressed less cell surface IFNGR1, but the remainder of the population 
overlaid with the control population (blue to red line, Figure 3.8A). I excluded the possibility 
of a poor lentiviral transduction efficiency, because the sgRNA is under BFP and all gated cells 
were BFP+ (Figure 3.1B). Given that this complex is crucial in mediating insertion of 
polypeptides into the ER for onward processing and trafficking to the cell surface, I recreated 
a population of knockout cells and examined the phenotype two days earlier, as loss of these 
genes seemed likely to have a greater cell surface reduction than initially observed. I chose the 
sgRNA that gave the best phenotype for SRP72 and SRP68 (from Figure 3.8A) and tested 
them individually and ‘pooled’ to see if there would be an enhanced effect. The phenotype on 
day five showed a shift in the entire population compared to the phenotype previously obtained 
(Figure 3.8B). These observations show that the loss of two components of the SRP complex 
inhibit cell surface trafficking of IFNGR1, likely by preventing translocation into the ER.  
Although the IFNGR1low screen was successful, it also did not identify any novel genes. The 
candidate genes identified in Figure 3.7B were from DNA extracted from the first sort. Despite 
an enrichment of 83% mutantlow cells, the sort 2 samples (data not shown) only identified two 
hits: IFNGR1 (positive control, p-value of 40) and RNF128/GRAIL (p-value of 5.4), an E3 





Figure 3.8 Validation of candidate genes identified in the IFNGR1low genome-wide CRISPR 
knockout screen. (A-B) THP-1 Cas9 clone 22 (C22) was transduced with a candidate gene-targeting 
sgRNA (red) or control sgRNA (β2m, blue). Transduced cells were selected with puromycin. IFNGR1 
expression was measured by flow cytometry (A) seven or (B) five days post-transduction. WT THP-1 
unstained (gray), C22 + control sgRNA (blue), C22 + sgIndicated (red). 
 
The aim of the IFNGR1high screen was to identify genes required for the regulation of cell 
surface IFNGR1. I predicted that knockout of genes essential for IFNGR1 internalization, 




3.3.5 Known and novel regulators of IFNGR1 identified in IFNGR1high screen  
The IFNGR1high screen was carried out simultaneously with the IFNGR1low screen using the 
protocol detailed in section 3.2.3. Although there were not many high cells after the first sort 
(just over a 1% enrichment for mutant IFNGR1high cells), the second sort enriched nearly 16% 
in the final population (Figure 3.10A). Genomic DNA and samples were prepared and 
sequenced using the MiniSeq platform, and the RSA algorithm was used to identify candidate 
genes (Figure 3.10B) (König et al. 2007).  
This screen identified 13 candidate genes. It was reassuring that the screen identified STUB1 
as a regulator of IFNGR1 since it regulates a multitude of other cell surface receptors (Table 
1.1). CRISPR-mediated gene disruption was used to validate six of these genes, of which four 
had a clear phenotype (STUB1, CHMP5, CHIC2, AHR), whereas one gene only partially 
validated (GFI1) and one gene did not validate (FAM26D) (not shown). The candidate genes 






Figure 3.10 CRISPR/Cas9 forward genetic screen identifies STUB1 and CHIC2 as required for 
regulation of cell surface IFNGR1. (A) Isolating mutant cells unable to internalize cell surface 
IFNGR1. (B) Bubble plot illustrating the hits from the screen identified using the RSA algorithm (König 
et al. 2007). Bubble sizes correlate to significance (p-value). Genes with a p-value >10 are shown as 
large bubbles, genes with a p-value between 10 and 5 are shown as medium sized bubbles and those 
with a p-value <5 are shown as small bubbles (with the exception of TM2D1).    
Regulators of other receptors 
STIP1 Homology and U-Box Containing Protein 1, STUB1 (or CHIP), is a well-known co-




functions including targeting misfolded proteins towards both proteasomal and lysosomal 
degradation and modulating the activity of several chaperone complexes. STUB1 is known to 
regulate the peripheral quality control of cell surface receptors including CFTR, GHR, IL4R, 
and PD-L1 (Mezzadra et al. 2017).   
Charged Multivesicular Body Protein 5, CHMP5, is a component of the endosomal sorting 
complex required for transport III complex (ESCRT-III) involved in the degradation of cell 
surface receptors and formation of multivesicular bodies (MVBs) (Shim et al. 2006). The MVB 
pathway requires the function of all four ESCRT complexes. ESCRT-III proteins are 
responsible for dissociating from the invaginating endosomal membrane before the 
intraluminal vesicle (ILV) is released to lysosomes thereby allowing for the degradation of 
membrane proteins (Henne et al. 2011; Luzio et al. 2007; Mccullough et al. 2018).  
Poorly characterized gene products 
Cysteine-rich hydrophobic containing protein 2, CHIC2, is a poorly characterized protein 
reported to localize to the plasma membrane and vesicular structures (Cools et al. 2001). A 
translocation of CHIC2 (amino terminal 110 amino acids, exons 1-3) with ETV6/TEL 
(carboxyterminal 441 amino acids, exons 2-8), has been implicated in hematological 
malignancies such as acute myeloid leukemia (AML) (Cools et al. 1999; Kuchenbauer et al. 
2005). Due to this rearrangement in the fusion protein, a domain within ETV6 activates the 
kinase domain of PDGFRβ (Golub et al. 1994), ABL (Papadopoulos et al. 1995) and JAK2 
(Peeters et al. 1996). Another study examined patient samples with systemic mastocytosis, 
who have had a fusion rearrangement of the Fip1-like 1 (FIP1L1) and PDGFRα (FIP1L1- 
PDGFRα), containing a CHIC2 deletion (Pardanani et al. 2003; Fink et al. 2008). Since 




The screen also identified TM2D2, TM2D3 and TM2D1 that share structural similarity to the 
seven-transmembrane domain G-protein coupled receptor superfamily important for 
heterotrimeric G-protein activation. These proteins possess two C-terminal transmembrane 
domains. However, there are only a handful of studies on their putative function, and not much 
is known. TM2D2 and TM2D3 may play regulatory roles in cell death or proliferation signal 
cascades. TM2D3 has been reported to be associated with late-onset Alzheimer’s disease 
(Jakobsdottir et al. 2016). TM2D1 is important in heterotrimeric G-protein activation and was 
thought to control β-amyloid toxicity by coupling to G-protein (Kajkowski et al. 2001), but this 
effect was later shown not to be direct (Lee et al. 2010).   
 
Proteins involved in transcriptional activation or repression  
EYA4 is a tyrosine phosphatase that dephosphorylates histone H2AX that plays a major role in 
DNA repair, and acts as a marker to distinguish between apoptotic and repair responses to 
genotoxic stress, and may be important for eye development. This protein is also a supposed 
oncogene that mediates DNA repair, apoptosis, and innate immunity following DNA damage, 
cellular damage, and viral attack. EYA4 is reported to be a novel tumor suppressor in 
hepatocellular carcinoma (Gu et al. 2019) that disrupts aberrant activation of the NF-kB 
signaling pathway.  
GFI1 encodes a nuclear zinc finger protein that functions as a transcriptional repressor 
(Zweidler-Mckay et al. 1996) essential for hematopoiesis and oncogenesis. It functions as part 
of a complex along with other cofactors to control histone modifications that lead to silencing 
of the target gene promoters. It has also been implicated in non-transcriptional post-
translational modifications, such as in regulating key DNA damage signaling and repair 




L3MBTL3 is a chromatin interacting transcriptional repressor that recognizes methylated lysine 
residues on histone protein tails (repression of gene expression). Binding of L3MBTL3 to 
methylated SOX2 leads to the recruitment of the CRL4DCAF5 (CUL4) E3 ubiquitin ligase and 
sheds light on how the stability of a methylated non-histone protein is regulated (Zhang et al. 
2019). This protein is also a putative component of the Polycomb (PcG) repressor complex.   
 
Other receptors 
The Aryl Hydrocarbon Receptor, AHR, is a cytosolic transcription factor that regulates gene 
expression and plays a role in regulating metabolism enzymes, regulating immunity, stem cell 
maintenance and cellular differentiation. AhR is bound to co-chaperones in its resting state and 
is a ligand-activated transcriptional activator. In a recent study, AhR was reported to bind 
STUB1, suggesting a role for STUB1 in the regulation of the AhR complex (Morales and 
Perdew 2007). AhR’s putative functions include chemical and microbial defense, organ 
development, modulation of immunity and inflammation, reproduction, and NAD+-dependent 
energy metabolism. AhR activation appears to be important for immunological responses and 
inhibiting inflammation (Li et al. 2011) through upregulation of interleukin-22 (Monteleone et 
al. 2011).   
TAAR1 is a G-protein coupled receptor activated by trace amines (which exhibit 
neurotransmitter-like activity) present in very low levels in mammalian tissues; TAAR1 is 
mostly unresponsive to classical biogenic amines such as histamine and epinephrine. Its 
physiological role occurs in the modulation of central nervous system function and there is a 
potential pharmacological role of TAAR1 agonists in neurology (Rutigliano et al. 2018). 
Recently, TAAR1 was found on pancreatic-β cells and triggers beneficial anti-diabetic 





LACEI, also known as AFG1L, is a putative mitochondrial ATPase that plays a role in 
mitochondrial morphology and mitochondrial protein metabolism. It has been shown to interact 
with p53 and mediate its mitochondrial translocation and transcription independent-apoptosis 
(Cesnekova et al. 2016). FAM26D is an uncharacterized protein with a pore-forming subunit 
of a voltage-gated ion channel. 
3.3.6 Loss of STUB1, CHIC2, CHMP5 and AHR increase cell surface IFNGR1   
The screen identified STUB1, CHMP5, CHIC2 and AHR as required for cell surface IFNGR1 
internalization. I sought to validate a role for each of these genes by CRISPR-mediated gene 
disruption (Figure 3.11). Cell surface IFNGR1 expression was tested 10 days post transduction 
by flow cytometry (this time, a phenotype took slightly longer to develop). In each population, 
I observed an increase in cell surface IFNGR1 as compared to the sgRNA control population 
(shift from blue to red histogram, Figure 3.11).  
Four respective guides against the E3 ligase STUB1 increased cell surface IFNGR1 (2.5-fold 
increase for sgRNA #4) (blue to red histogram, Figure 3.11), confirming that STUB1 is 
essential for downregulation of IFNGR1 from the cell surface. CHIC2 is also required for 
IFNGR1 internalization, albeit sometimes displaying a smaller increase in cell surface IFNGR1 
than STUB1, but still a reproducible window (2.4-fold increase for sgRNA #3). Next, I 
validated the role of CHMP5 in mediating IFNGR1 stabilization and found an even greater 
increase in cell surface IFNGR1 (3.1-fold increase for sgRNA #1). Finally, I validated the role 
of AHR, of which each sgRNA produced a similar phenotype (2.2-fold increase for sgRNA 






Figure 3.11 Validation of candidate genes identified in the IFNGR1high genome-wide CRISPR 
knockout screen. THP-1 Cas9 Clone 22 (C22) was transduced with a candidate gene-targeting sgRNA 
or control sgRNA (β2m). Transduced cells were selected with puromycin. IFNGR1 expression was 
measured by flow cytometry 10 days post-transduction. WT THP-1 unstained (gray), C22 + control 
sgRNA (blue), C22 + sgIndicated (red).  
 
Prior to carrying out further studies, and to ensure that the phenotypes observed in Figure 3.11 




STUB1 and CHIC2 in an independent THP-1 Cas9 clone (Figure 3.12) (Cas9 activity 
previously confirmed, Figure 3.1C).  
 
Figure 3.12 Loss of STUB1 and CHIC2 also cause cell surface increase in a different THP-1 Cas9 
Clone. THP-1 Cas9 Clone 2 was transduced with a candidate gene-targeting sgRNA or control sgRNA 
(β2m). Transduced cells were selected with puromycin. IFNGR1 expression was measured by flow 
cytometry 10 days post-transduction. WT THP-1 unstained (gray), THP-1 Cas9 C2 + control sgRNA 
(blue), Cas9 C2 + sgIndicated (red).  
 
 
I then wanted to assess whether the requirement for CHIC2 and STUB1 was specific to THP-
1 cells, or whether CHIC2 and STUB1 were also required for IFNGR1 function in other cell 
types. I used CRISPR-mediated gene disruption to knockout IFNGR1, STUB1 and CHIC2 in 
HeLa, MDA-MB-231 (breast cancer) and WM-852 (melanoma) cell lines via lentiviral 
transduction and observed the same cell surface increases in all of these cell lines (Figure 
3.13). These data suggest that CHIC2 and STUB1 are likely to be required for the function of 





Figure 3.13 Loss of CHIC2 and STUB1 have a similar effect on cell surface IFNGR1 in various 
cell lines. HeLa-Cas9, MDA-MB-231-Cas9 and WM852-Cas9 knockout populations were transduced 
with a candidate gene-targeting sgRNA or control sgRNA (β2m). Cells were selected with puromycin. 
IFNGR1 expression was measured by flow cytometry. WT unstained (gray), cell line + control sgRNA 
(blue), cell line + sgIndicated (red).  
 
3.3.7 Summary  
The IFNGR1high screen successfully identified a number of genes involved in the cell surface 
regulation of IFNGR1. The identification of STUB1, CHMP5, and perhaps, CHIC2, support 
my hypothesis that the screen would detect genes that are involved in the downregulation and 
degradation of cell surface receptors from the plasma membrane. In this thesis, I focus on 




3.3.8 Generating knockout clones of IFNGR1 and STUB1 for subsequent studies 
To determine the effect of the loss of IFNGR1 and STUB1 on IFNGR1 regulation, I wanted to 
create stable reagents for further functional studies. IFNGR1 knockout clones were isolated by 
transient transduction of THP-1 Cas9 C22 with a sgRNA targeting IFNGR1 in the presence of 
integrase inhibitor, raltegravir (RTV), and single cell cloned by serial dilution. STUB1 
knockout clones were isolated by the same means. I used RTV during the transductions because 
I knew that the IFNGR1 and STUB1 cDNA I would later complement the knockout phenotype 
with were not codon optimized, so I needed to ensure that the guide was only transiently 
expressed.  
The resulting clones were assayed for cell surface IFNGR1 expression by flow cytometry 
(Figure 3.14A-B), before further validation by immunoblot (Figure 3.14C). Forty IFNGR1 
knockout clones were screened by flow cytometry to ensure a loss of cell surface IFNGR1 in 
comparison to the knockout parent population, of which five are shown (red to blue shaded 
histogram, Figure 3.14A). Immunoblot analysis confirmed complete loss of IFNGR1 in clones 
1 and 32 (Figure 3.14C). Whilst some IFNGR1 knockout clones had a residual band at around 
75-kD, a longer exposure with DURA did not reveal any bands for clones 1 and 32. Clone 32 
grew well and was used for further experiments.  
Thirty-five STUB1 knockout clones were screened for an increase in cell surface IFNGR1 
surface by flow cytometry, of which five are shown (all of which display greater cell surface 
IFNGR1 levels in comparison to the Cas9 stained population, blue to blue shaded histogram, 
Figure 3.14B). Immunoblot analysis confirmed the loss of STUB1 in all clones, but clone 13 
most convincingly displayed greater total levels of IFNGR1 (Figure 3.14C). Clone 13 also 





Figure 3.14 Loss of STUB1 causes an increase of cell surface and total IFNGR1. (A-B) THP-1 Cas9 
Clone 22 was transduced with a sgRNA targeting (A) IFNGR1 or (B) STUB1 in the presence of 1nM 
raltegravir (RTV). Transduced cells were analyzed for BFP two days post-transduction (enough of a 
window before the guide is lost), and were single cell cloned by dilution cloning. Cell surface IFNGR1 
expression was measured by flow cytometry once knockout clones emerged. WT THP-1 unstained 
(gray), Cas9 C22 (blue), C22 + sgIndicated knockout population (red), C22 +sgIndicated knockout 
clone (blue shaded). (C) Immunoblot analysis to screen IFNGR1 knockout clones for the loss of 
IFNGR1. Immunoblot analysis to screen STUB1 knockout cells for the loss of STUB1 and for an 
increase in total IFNGR1 expression.  
 
3.3.9 STUB1 knockout clone has increased cell surface IFNGR1 expression that is rescued 
by complementation with full-length STUB1 cDNA  
To confirm a role for STUB1 in the internalization of IFNGR1, I sought to restore homeostatic 




STUB1 cDNA or mutant cDNA (i) STUB1-ΔTPR, which loses chaperone binding activity, or 
(ii) STUB1-ΔU-box (RING-like domain), which loses ligase activity, for complementation was 
cloned by PCR from constructs kindly provided by J. Christianson (Figure 3.15A). Two point 
mutants, STUB1-K30A and STUB1-H260Q (Figure 3.15A), were later cloned into an epitope 
tagged-STUB1 construct by PCR from wt-STUB1 cDNA (see section 3.3.10).  
Lentivirus was used to exogenously re-express wt-STUB1, STUB1-ΔTPR and STUB1-ΔU-
box in STUB1 KO C13 and samples were analyzed on days 7, 10 and 14. In the resulting wt-
STUB1 cells, STUB1 was able to completely rescue cell surface expression of IFNGR1 to 
wild-type levels (red to green histogram), whereas the STUB1-ΔTPR (herein ΔTPR cells) and 
STUB1-ΔU-box cells (herein ΔU-box cells) failed to rescue the cell surface phenotype 
(apparent from the green and red histograms, day 14, Figure 3.15B). This result implies that 
the chaperone-binding domain and ligase domain are required for STUB1 function and for the 
regulation of IFNGR1.  
Immunoblot analysis of this experiment revealed stable expression of STUB1 (day 14) in wt-
STUB1 (lane 3) and ΔTPR cells (lane 5) (Figure 3.15C). A cleavage product appears in wt-
STUB1 cells (lane 3, Figure 3.15C). ΔTPR cells ran below 25-kD due to deletion of the TPR 
domain (amino acids 26-127), as expected (lane 5, Figure 3.15C). However, since this STUB1 
antibody recognizes STUB1’s C-terminus (amino acids 218-232), I was unable to detect a band 
for STUB1 in ΔU-box cells (lane 4, Figure 3.15C). To get around this issue, I could have 
obtained an antibody targeting the N-terminal domain or tagged the protein to allow for 





Figure 3.15 WT cell surface IFNGR1 expression is rescued upon complementation with full-
length STUB1 cDNA. (A) Schematic depicting domains of STUB1. Three tandem tetratricopeptide 
(TPR) repeats (aa 26-127, purple), a central charged coil-coil region (aa 127-226) and a C-terminal U-
box domain (aa 226-303). STUB1-K30A and STUB1-H260Q point mutants. K, lysine. A, alanine. H, 
histidine. Q, glutamine. aa, amino acids. (B) STUB1 KO clone 13 was transduced with wt-STUB1, 
STUB1-ΔTPR or STUB1-ΔU-box cDNA, hygromycin selected and analyzed 14 days post transduction. 
WT THP-1 unstained (gray), Cas9 C22 (blue), STUB1 KO C13 (red), STUB1 KO C13 + STUB1 
complementation (green shaded). (C) Immunoblot of WT THP-1 and STUB1 KO complemented cells 
reveals endogenous STUB1 expression (day 14).  
 
 
3.3.10 FLAG-tagged STUB1 exhibits the same cell surface phenotype and total IFNGR1 
expression as untagged full-length STUB1 cDNA  
Although other STUB1 antibodies were commercially available and I was able to detect 
endogenous STUB1 (albeit not in the STUB1-ΔU-box cells), I wanted to create stable cell lines 
for follow-up immunoprecipitation experiments. I used lentivirus to exogenously re-express 




rescued wild-type cell surface IFNGR1 in FLAG-STUB1wild-type cells (red to green histogram, 
Figure 3.16A), as the untagged protein (Figure 3.15B), whilst FLAG-STUB1-ΔTPR and-ΔU-
box cells were unable to rescue wild-type cell surface IFNGR1 (apparent by the green and red 
histogram, Figure 3.16A), suggesting that both of these domains are responsible for STUB1 
function and the regulation of IFNGR1. Immunoblot analysis revealed stable expression of 
STUB1 and FLAG in FLAG-STUB1wildtype and mutant cells (Figure 3.16B), as in Figure 
3.15C. Therefore, the N-terminal tag did not perturb STUB1 function.  
At first glance, the C-terminal FLAG tag appears to be somewhat functional by flow cytometry 
(second row, Figure 3.16A). However, the C-terminal tag interfered with protein expression – 
I was unable to detect exogenous STUB1 in the STUB1-ΔTPR-FLAG or STUB1-ΔU-box-
FLAG cells, or exogenous STUB1-FLAG via immunoblot in all three cell lines (Figure 
3.16B).  
Other groups commonly use STUB1-point mutants to inhibit or abolish STUB1 function (Wei 
et al. 2014; Kopp et al. 2017). STUB1-K30A has impaired binding to chaperones and STUB1-
H260Q is unable to bind its cognate E2, thus losing its E3 ligase activity (S Hatakeyama et al. 
2001; Xu et al. 2002). To study the effects of these mutants on IFNGR1 regulation, I used 
lentivirus to exogenously re-express FLAG-tagged STUB1 point mutants in STUB1 KO C13, 
alongside FLAG-STUB1, FLAG-ΔTPR and FLAG-ΔU-box complemented cells. FLAG-
STUB1-K30A displayed an intermediate cell surface IFNGR1 phenotype (purple histogram, 
Figure 3.16C), as compared to the ΔTPR mutant (green histogram, Figure 3.16C) which was 
unable to rescue wild-type cell surface IFNGR1 (apparent by the green and red histograms, 
Figure 3.16C), as before (Figure 3.16A). Therefore, the K30A point mutant moderately 
impairs STUB1 function and partially rescues cell surface IFNGR1, whilst the ΔTPR mutant 
was unable to rescue cell surface IFNGR1. This partial effect was also reported by Wei and 




surface IFNGR1 and overlapped with the ΔU-box mutant (apparent from the purple and green 
histograms, Figure 3.15C), as expected.  
Immunoblot analysis formally demonstrated that the loss of STUB1 was responsible for a 
significant increase in total IFNGR1 (lane 3, Figure 3.16D), which was rescued to wild-type 
levels in FLAG-STUB1wild-type cells (lane 4, Figure 3.16D). IFNGR1 expression in FLAG-
STUB1-ΔTPR, -H260Q and -ΔU-box remained high (lanes 5, 7, and 8, Figure 3.16D), 
suggesting that these mutants are unable to regulate IFNGR1, thereby leading to increased total 
IFNGR1 levels. However, the FLAG-STUB1-K30A point mutant (lane 6, Figure 3.16D) 
expressed intermediate IFNGR1 levels in line with the partial cell surface phenotype observed 
in Figure 3.15C, suggesting that the chaperone binding is impaired. Hence, this interaction is 
weaker in comparison to a the ΔTPR mutant, where this domain is completely absent.  
Overall, I have identified STUB1 as an important regulator of cell surface IFNGR1, and for 





Figure 3.16 Full length and mutant FLAG-STUB1 is fully functional and expressed in THP-1 
cells. (A) STUB1 knockout clone 13 transduced with FLAG-STUB1, FLAG-STUB1-ΔTPR or FLAG-
STUB1-ΔU-box cDNA and with two additional mutants in (C) FLAG-STUB1-K30A and FLAG-
STUB1-H260Q. Cells were hygromycin selected and analyzed by flow cytometry seven days post 
transduction. WT THP-1 unstained (gray), Cas9 C22 (blue), STUB1 KO C13 (red), KO C13 + FLAG-
wt or mutant-STUB1 (green shaded), C13 KO + FLAG-STUB1-point mutant (purple). (B) Immunoblot 
analysis of STUB1 expression in STUB1 KO C13 complemented with N-or C-terminal FLAG-tagged 
STUB1 in THP-1 lysates (day 7). (D) Immunoblot analysis of IFNGR1 and FLAG-STUB1 expression 




3.4 Discussion  
In this chapter, I successfully used CRISPR’s unbiased forward genetic approach to identify 
genes involved in the regulation of cell surface IFNAR and IFNGR. The CRISPR/Cas9 
IFNGR1high screen was the most intriguing because it identified STUB1 and CHIC2 as 
candidate genes involved in the cell surface regulation of IFNGR1. For the remainder of my 
studies, I chose to focus on STUB1 (as it is well recognized in the ubiquitination, internalization 
and subsequent lysosome-mediated degradation of multiple cell surface receptors, Table 1.1), 
and more importantly on CHIC2 (a poorly characterized membrane-associated protein), which 
I will go on to describe in detail in Chapter 5. 
 
The CRISPR/Cas9 IFNAR1low and IFNGR1low genetic screens were technically successful in 
their identification of positive controls and other relevant hits in the early secretory pathway, 
albeit fewer in number than expected. Reflecting on our knowledge of CRISPR screens a few 
years later, and the numerous screens performed by members of the Lehner lab, not all screens 
were completely saturating, and further modifications could have been made.  
 
CRISPR/Cas9 Screen Design and Optimization  
Despite a modest enrichment after sort 2, the IFNGR1high screen forms the basis for the 
remainder of my PhD. My experience with the screens in this chapter indicated that sequencing 
sort 1 samples directly from the sort for DNA extraction may have carried more weight, as 
genes that are lethal will not always make it to the second sort. As the Lehner lab continued 
screening efforts, we realized that a second sort is not necessarily essential. A first sort around 
days 7-10, and deeper sequencing could provide us with a good representation of genes 
involved in the mechanisms we are trying to study. The candidate genes in Figure 3.10B come 




value of 5.5), possibly due to a meager enrichment of 1.5%. In retrospect, I think more hits 
could have been revealed if the sort 1 samples were sent for deeper sequencing on Illumina’s 
HiSeq as opposed to sequencing on the MiniSeq in the laboratory. Other candidate genes 
identified could have been genes involved in the ESCRT pathway such as EPS15, HRS, 
ESCRT-I (TSG101, VPS37, VPS28), ESCRT-II (CHMP 2-4), or E2s or additional E3 ligases. 
These hits may not have been identified in sort 2 because they could have been lethal, so the 
mutant cells would have died well before the second sort on day 20, but a deeper sequencing 
in sort 1 may have revealed more hits. Lastly, I could have validated a role for TM2D2, TM2D3 
and TM2D1 in regulating IFNGR1, but I did not want to base my project on completely 
uncharacterized proteins.  
 
CRISPR/Cas9 Screens 
Genome-wide CRISPR/Cas9 screens are powerful tools to uncover new genes and mechanisms 
for disease. In an age where genome-wide CRISPR screens are relatively quick and generate a 
lot of new data, the process of selecting hits for validation and follow-up can sometimes be 
elusive. In the past, CRISPR screens were limited by the sgRNA library due to sgRNA design 
and off-target effects. The Bassik library contains 10 sgRNAs per gene and places more 
importance on sgRNA efficacy (Morgens et al. 2017) in comparison with older libraries that 
contain less sgRNAs (e.g. 6 per gene). If there is a larger number of sgRNAs per gene, even 
those that have a couple of ineffective sgRNAs are more likely to be identified. The Bassik 
library was designed using algorithms that emphasize sgRNA efficacy but exclude sgRNAs 
with high off-target predictions (Morgens et al. 2017). This library contains non-targeting 
controls, safe-targeting guides that allow for proper control of toxicity from on-target DNA 
damage, and truncated guides that reduce off-target effects and preserve on-target activity 




process and it is probable that sgRNA library design will become more effective as we continue 
to gain a better understanding of CRISPR-mediated gene disruption. Furthermore, the Lehner 
lab has designed smaller, more targeted libraries as useful tools to identify E2s and E3s 
(ubiquitome library). The creation of this tool will continue to enhance the way we approach 
key research questions.  
 
3.5 Summary 
A CRISPR/Cas9 IFNGR1high screen identified a role for both CHIC2 and STUB1 in the 
regulation of IFNGR1. STUB1 is a critical E3 ubiquitin ligase responsible for peripheral 
membrane protein quality control. As no function has been ascribed to CHIC2, I performed 
further functional studies on this protein. The remainder of my thesis will focus on establishing 
the role of CHIC2 as a regulator of IFNGR1, and other immune cell surface receptors (Chapter 
4). I will then go on to biochemically characterize which domains of CHIC2 are functionally 
important, whether/how CHIC2 interacts with STUB1 and/or IFNGR1 in Chapter 5, and I will 
examine the functional consequence of CHIC2 on IFNGR1 signaling and internalization from 
the cell surface in Chapter 6. STUB1 and its role in the regulation of IFNGR1 internalization 








Chapter 4: Plasma membrane proteome 
profiling reveals a role for CHIC2 in 




4.1 Introduction  
The plasma membrane represents a crucial interface between the extracellular and intracellular 
compartments, and expresses essential receptors and transporters that are responsible for 
initiating signaling transduction. Cytokine binding to cognate receptors activates signal 
transduction pathways which play critical roles in regulating immune responses (e.g. 
JAK/STAT pathway, Ras-mitogen-activated protein kinase (MAPK) pathway, 
phosphatidylinositol 3-kinase (PI3K) pathway and others) (Taniguchi 1995; Leonard 2003; 
Fujii 2007). The interferon (IFN) receptors signal via the well-studied JAK/STAT pathway; 
negative regulators include SOCS proteins, which bind to cytoplasmic domains of cytokine 
receptors and/or JAK kinases (Fujii 2007).  
I will briefly highlight similarities and differences between the receptors identified and 
discussed in this chapter (see section 1.1.2, Figure 1.1). Type I cytokine receptors share similar 
structural features (Leonard, 2003) and include the IL-2R, IL-4R, IL-13R, IL-15R, IL-21, IL-
6, and homodimeric receptors including growth hormone (GH), prolactin, erythropoietin, and 
leptin receptors. These are type I transmembrane glycoproteins and some share related 
extracellular and cytoplasmic domains but lack tyrosine kinase activity (Taniguchi 1995). In 
contrast, type II cytokine receptors are type I spanning transmembrane glycoproteins that also 
lack tyrosine kinase activity, consist of two or more subunits, and are typically heterodimers 




At this stage of my project, I had successfully performed a forward genetic screen which 
identified CHIC2 and STUB1 as regulators of cell surface IFNGR1. As STUB1 is well 
recognized for its role in the ubiquitination, internalization and subsequent lysosome-mediated 
degradation of multiple cell surface receptors, I was interested to see whether an unbiased 
proteomic approach might provide supporting evidence that CHIC2 is responsible for 
regulating multiple immune cell surface receptors (i.e. other cytokine receptors). I turned to 
Plasma Membrane Proteome Profiling (PMP), a proteomic technique optimized by the Lehner 
laboratory (Weekes et al. 2010, 2012), to determine whether CHIC2 was specific for the 
IFNGR or, like STUB1, regulated additional cell surface receptors.  
PMP is an unbiased proteomic technique that combines the selective enrichment of sialylated 
plasma membrane proteins through aminooxy-biotinylation labelling with quantitative mass 
spectrometry (Hör et al. 2009; Weekes et al. 2010, 2012, 2013; Matheson et al. 2015). The 
Lehner laboratory has employed PMP extensively to identify candidate cell surface proteins 
regulated by Human Cytomegalovirus (HCMV) infection (Weekes et al. 2014) and HIV 
infection (Matheson et al. 2015), or Kaposi’s Sarcoma Associated Herpes Virus (KSHV) 
proteins (Timms et al. 2013).  
To gain a more complete understanding of cell surface receptors whose expression is dependent 
on CHIC2, or STUB1, I used PMP to compare the relative abundance of plasma membrane 
proteins in the presence or absence of these proteins. In this chapter, I ascertained whether the 
requirement for CHIC2 was specific for the downregulation of IFNGR1, or whether CHIC2 




4.2 Results  
4.2.1 CHIC2 is required for the regulation of multiple immune cell surface receptors     
To gain a comprehensive, unbiased overview of plasma membrane proteins regulated by 
CHIC2, I used PMP to measure expression levels of cell surface proteins in THP-1 cells 
expressing either Cas9 (Cas9 Clone 22, C22) or C22 cells expressing a sgRNA targeting either 
CHIC2 or STUB1. Cells were cell surface labelled with amino-oxybiotin, followed by 
streptavidin pulldown, as described in section 2.8 (Figure 4.1) and plasma membrane protein 
expression was quantified by mass spectrometry, kindly performed by Dr. James Williamson 
(Figure 4.1). Comparison of the plasma membrane proteome of (i) THP-1 Cas9 C22 versus 
THP-1 Cas9 C22 CHIC2 knockout cells, and (ii) THP-1 Cas9 C22 versus THP-1 Cas9 C22 
STUB1 knockout cells identified proteins whose cell surface expression is upregulated in each 
dataset, including some type I and type II cytokine receptors (Figure 4.2). Reassuringly, 
upregulation of IFNGR1 (type II cytokine receptor) was identified as a positive control in both 
datasets (Figure 4.2).  
 





Figure 4.2 Quantitative plasma membrane profiling identifies a role for CHIC2 in regulating 
many cell surface receptors. Scatterplots display pairwise comparisons between (i) parental THP-1 
Cas9 clone and CHIC2 knockout cells, or (ii) parental THP-1 Cas9 clone and STUB1 knockout cells 
(populations, not knockout clones). Fold change (x-axis) is shown as log2, and Q-value (y-axis) is shown 
as log2. Q-values determined using LIMMA with Benjamini–Hochberg adjustment for multiple testing. 
*Note: Only immune receptors are highlighted here. See Table 4.1 for a shared list of proteins, and 





This unbiased, comprehensive analysis revealed 26 proteins as significantly upregulated (>1.5-
fold) at the plasma membrane in both a CHIC2 knockout cell and in a STUB1 knockout cell, 
from the 1,419 plasma membrane proteins quantified (Figure 4.3). These upregulated shared 
proteins are highlighted further (Table 4.1), and include type I cytokine receptors such as 
interleukin-13 receptor subunit α 1 (IL-13αR1), interleukin receptor-6 subunit α (IL-6α), 
interleukin-21 receptor (IL-21R) and leptin receptor (LEPR), and type II cytokine receptors 
such as IFNAR2, IFNGR2, IFNGR1 (positive control), and interleukin receptor-10 subunit  
(IL-10R) (Table 4.1). 
 
Figure 4.3 Venn diagram comparing the cell surface changes in the CHIC2 knockout population 
versus the STUB1 knockout population as compared to the THP-1 Cas9 parental cell line. 
Analysis revealed 26 shared proteins that were upregulated (>1.5-fold) in the PMP dataset. 35 proteins 
were identified as upregulated in CHIC2 knockout cells, but not upregulated in the STUB1 knockout 
population. Conversely, 25 proteins were identified as upregulated in STUB1 knockout cells, but were 
not upregulated in the CHIC2 knockout population. Shared hits highlighted in Table 4.1. See Appendix 












P78552 Interleukin-13 receptor subunit alpha-1 IL13RA1 12 3.6 6.6 
P08887 Interleukin-6 receptor subunit alpha IL6R 12 2.6 4.5 
Q9HBE5 Interleukin-21 receptor IL21R 5 2.4 3.2 
P48551-2 Isoform 2 of Interferon alpha/beta 
receptor 2 
IFNAR2 2 2.4 5.3 
P38484 Interferon gamma receptor 2 IFNGR2 1 2.4 5.5 
Q8WTV0 Scavenger receptor class B member 1 SCARB1 13 2.2 2.1 
P58335 Anthrax toxin receptor 2 ANTXR2 13 2.1 2.3 
Q9NUJ7 PI-PLC X domain-containing protein 1 PLCXD1 3 2.0 3.5 
A6NL88 Protein shisa-7 SHISA7 1 2.0 1.6 
P0DMQ5 Putative transmembrane protein 
INAFM2 
INAFM2 3 1.9 2.1 
P23458 Tyrosine-protein kinase JAK1 JAK1 39 1.9 2.2 
Q12891 Hyaluronidase-2 HYAL2 3 1.9 2.2 
Q08334 Interleukin-10 receptor subunit beta IL10RB 7 1.9 2.2 
Q9HBX9 Relaxin receptor 1 RXFP1 7 1.9 2.2 
O14595 Carboxy-terminal domain RNA 
polymerase II polypeptide A small 
phosphatase 2 
CTDSP2 3 1.9 1.9 
Q96PD2 Discoidin, CUB and LCCL domain-
containing protein 2 
DCBLD2 17 1.8 2.4 
Q16827 Receptor-type tyrosine-protein 
phosphatase O 
PTPRO 5 1.8 2.0 
P51511 Matrix metalloproteinase-15 MMP15 6 1.8 2.4 
H0YC04 V-type proton ATPase subunit B, brain 
isoform (Fragment) 
ATP6V1B2 1 1.7 2.1 
P15260 Interferon gamma receptor 1 IFNGR1 9 1.7 2.9 
P43003 Excitatory amino acid transporter 1 SLC1A3 7 1.7 2.7 
Q96RV3 Pecanex-like protein 1 PCNX1 6 1.6 1.8 
Q13444 Disintegrin and metalloproteinase 
domain-containing protein 15 
ADAM15 17 1.5 1.7 
Q9NPF0 CD320 antigen CD320 3 1.5 4.3 
Q6UWB1 Interleukin-27 receptor subunit alpha IL27RA 13 1.5 2.2 
 
Table 4.1 Selected plasma membrane proteins significantly upregulated by >1.5-fold in both a 
CHIC2 knockout cell and a STUB1 knockout cell. THP-1 cells expressing either Cas9 alone (Clone 
22) or Cas9 Clone 22 plus a sgRNA targeting either CHIC2 or STUB1 were cultured in triplicate (3x 
14cm dishes each). Cells were biotinylated at the cell surface (labelled with sodium meta-periodate and 
amino-oxybiotin), lysed in Triton and pulled down with streptavidin beads. Immunoprecipitates were 
processed as in Figure 4.1 and analyzed by mass spectrometry. Proteins are ranked based on 
significance and fold-change is indicated for each sgRNA expressing population, in comparison to the 
THP-1 Cas9 C22 control population. Number of unique peptides shown. See Appendix 1 for the 







Some additional proteins that were upregulated in the CHIC2 dataset, but not in the STUB1 
dataset include NGFR, CD209 (DC-SIGN) expressed on dendritic cells and involved in innate 
immunity, and IL-31Rα, a type I cytokine receptor that shares homology to gp130, expressed 
on monocytes (could be THP-1 specific).  
As enrichment in PMP may include cell surface-associated proteins, another interesting cell 
surface protein-associated protein upregulated at the cell surface was JAK1. JAK1’s 
identification could be attributed to the fact that it is constitutively bound to tyrosine kinase 
receptor subunits including IFNGR1, IL-21R, IL-6R, IFNAR2 and IL-10R (Table 4.1). This 
is particularly relevant as increased cell surface IFNGR1 due to a CHIC2 knockout enhances 
IFNGR1 signaling (further detailed in Chapter 6). Taken together, the data show that CHIC2 
is required for the regulation of additional plasma membrane proteins, particularly those within 
the immune receptor family, though this may reflect the cell type used. I went on to confirm 
some of these cell surface changes by flow cytometry.   
 
4.2.2 IL-13αR1 and IL-6Rα as additional targets of CHIC2 and STUB1 
The CHIC2 and STUB1 dependence of IL-13αR1 and IL-6Rα were confirmed by flow 
cytometry in THP-1 Cas9 C22 CHIC2 knockout and STUB1 knockout cells, as compared to 
the parental THP-1 Cas9 C22 cell line (Figure 4.4). There was a marked increase in cell surface 
IL-13Rα1 (3-fold in CHIC2 KO and 6.4-fold in STUB1 KO) (blue to red histogram, Figure 
4.4), and cell surface IL-6Rα (2.1-fold in CHIC2 KO and 3.2-fold in STUB1 KO) (blue to red 
histogram, Figure 4.4) for cells deficient in either CHIC2 or STUB1. Cell surface IFNGR1 
was stained alongside these samples as a positive control (data not shown). Of the other 
identified upregulated shared proteins, IL-21R and IL-10R did not validate (a likely 




Therefore, CHIC2 is indeed required for the regulation of other cell surface receptors – of 
which 43% are also regulated by STUB1 (Figure 4.3).  
Figure 4.4 Validations of the PMP proteomics experiment. Cytofluorometric analysis of the 
indicated upregulated cell surface receptors in THP-1 Cas9 C22 cells lacking CHIC2 or STUB1 as 
compared to parental THP-1 Cas9 C22. WT THP-1 (gray), Cas9 C22 parent (blue), Cas9 C22 + sgRNA 
indicated (red shaded). IFNGR1 was used as internal control (not shown).  
 
 
4.2.3 Additional cell surface receptors regulated by CHIC2   
Although IFNAR2 was identified as upregulated in both a CHIC2 knockout cell and STUB1 
knockout cell, I did not have an IFNAR2 antibody to validate this candidate protein. Because 
IFNAR2 and IFNAR1 are the two subunits of IFNAR and are required for signal transduction 
of type I IFN from the plasma membrane, I wanted to ascertain whether CHIC2 or STUB1 
played a significant role in the downregulation of IFNAR1. I used the GB8 antibody from 
Chapter 3, even though the cell surface staining of IFNAR1 was poor (Figure 3.2B) in 
comparison to the other cell surface antibodies I used in this chapter. Cell surface IFNAR1 
expression was increased in both THP-1 Cas9 C22 CHIC2 knockout C17 (1.6-fold) and 
STUB1 knockout C13 (1.4-fold) as compared to the parental THP-1 Cas9 C22 cell line (Figure 
4.5). Cell surface IFNGR1 was stained alongside these samples as a positive control (1.7-fold 





Figure 4.5 CHIC2 and STUB1 also regulate IFNAR1. Cytofluorometric analysis of the indicated 
upregulated cell surface receptors in THP-1 Cas9 C22 cells lacking CHIC2 or STUB1 as compared to 
parental THP-1 Cas9 cells. THP-1 Cas9 C22 (gray), Cas9 parent + secondary only stained (light blue), 
Cas9 parent (blue) and Cas9 + sgRNA indicated (red shaded). IFNGR1 used as internal control. 
 
STUB1 is known to mediate plasma membrane quality control of additional cell surface 
receptors such as CFTR (Okiyoneda et al. 2010; Fukuda and Okiyoneda 2018), GHR (Slotman 
et al. 2012), IL-4R (Wei et al. 2014), Met receptor (Jang et al. 2011) and EGFR (Chung et al. 
2016) (Table 1.1). Only one of these candidate receptors, IL-4Rα, was identified in the STUB1 
knockout dataset (addressed in the discussion), possibly due to the fact that these studies were 
carried out in different cell types.  
STUB1 also regulates the Insulin Receptor (INSR) and is essential for longevity in C. elegans 
(Tawo et al. 2017) and in M. musculus (Qian et al. 2006). However, although INSR was 
detected in the STUB1 knockout PMP dataset, it was not upregulated. A likely reason for this 
could be greater expression of various receptors in certain cell types. Tawo and colleagues use 
293T in their studies, and cell surface staining of INSR in 293T Cas9 cells provided a large 
window (Figure 4.6A). Given that my PMP data demonstrated that CHIC2 and STUB1 
regulate some of the same cell surface receptors (Figure 4.3, Table 4.1), I wondered if CHIC2 
might also regulate the INSR, and by extrapolation be involved in longevity in C. elegans?  
Stably expressing Cas9 293T cells were made by lentiviral transduction and Cas9 activity 
confirmed by a sgRNA to 2m showing a decrease in cell surface MHC-I expression (Figure 




by transiently transfecting three separate INSR sgRNAs into 293T Cas9 cells, and cells were 
analyzed by flow cytometry four days post transfection (Figure 4.6B). I made genetic deletions 
of INSR, IFNGR1, CHIC2 and STUB1 (as before), and tested both cell surface INSR and 
IFNGR1 expression by flow cytometry six days post transfection (Figure 4.6C). Cell surface 
staining of INSR suggested that CHIC2 also regulates INSR, as the loss of CHIC2 increased 
cell surface INSR compared to 293T Cas9 cells (1.5-fold in CHIC2 KO), as did STUB1 
knockout cells (2.1-fold) (Figure 4.6C) - my positive control as previously reported (Tawo et 
al. 2017). 293T Cas9 CHIC2 knockout and STUB1 knockout cells produced the same cell 
surface increase in IFNGR1 (2-fold, Figure 4.6C), which I had not previously observed in 
other cell types stained for cell surface IFNGR1 (Figure 3.13). The loss of CHIC2 in 293T 
cells was confirmed via immunoblot in two separate knockout populations (lanes 4 and 5, 
Figure 4.6D), as was the increase in IFNGR1, compared to 293T control cells (lane 1, Figure 
4.6D). Residual CHIC2 is detected as the populations were not knockout clones (Figure 4.6D). 
The subtle difference in IFNGR1 expression in STUB1 KO compared to CHIC2 KO cells could 
suggest a greater dependency for CHIC2 in 293T cells. 
My data indicate that the absence of both CHIC2 and STUB1 increase cell surface expression 
of INSR and increase endogenous IFNGR1 expression in 293T Cas9 cells, likely due to 
impaired degradation. CHIC2 is therefore likely to be required for the regulation of a significant 
variety of plasma membrane receptors. As CHIC2 also regulates the INSR, I am in 
conversation with the Hoppe lab (CECAD, University of Cologne) to determine the phenotype 





Figure 4.6 CHIC2 regulates the Insulin Receptor in 293T cells. (A) 293T Cas9 cells were tested for 
Cas9 activity by flow cytometry. Cells were transduced with Cas9 lentiviral vector (chapter 3), 
blasticidin selected and stained for cell surface MHC-I with W6/32 mAb five days post-transduction. 
293T Cas9 unstained (gray), 293T Cas9 parent (blue), 293T Cas9 parent + sgβ2m (red). (B) Specificity 
of INSR antibody confirmed in 293T cells. 293T Cas9 cells were transiently transfected with control 
sgβ2m and three respective guides against INSR, puromycin selected starting at 24 h post transfection 
and stained for cell surface INSR four days post-transfection. 293T Cas9 unstained (gray), 293T Cas9 
+ sgβ2m (blue), 293T Cas9 parent + sgIndicated (red). (C) Increase of both INSR and IFNGR1 
confirmed in 293T Cas9 CHIC2 KO or STUB1 KO. Cells were transiently transfected as before to 
create genetic knockouts, stained and tested for cell surface INSR or IFNGR1 by flow cytometry six 
days post-transfection. 293T Cas9 unstained (gray), 293T Cas9 + sgβ2m (blue), 293T Cas9 parent + 
sgIndicated (red). (D) Immunoblot confirming loss of CHIC2 and increase of IFNGR1 in 293T Cas9 





4.3 Discussion  
A potential role for CHIC2 in the regulation of additional cell surface receptors was exciting. 
The loss of both CHIC2 and STUB1 was implicated in the upregulation of shared substrate 
receptors, and I want to highlight two plasma membrane proteins that I followed up. My PMP 
data show that CHIC2 plays a more generalized role in the regulated expression of other 
receptors including IL-13αR1 and IL-6Rα, which were subsequently validated by flow 
cytometry. PMP also identified IFNGR1 (positive control) as upregulated in cells lacking 
CHIC2 or STUB1. In comparing the fold-change significance (Table 4.1), IFNGR1 was 
identified as upregulated with a lower significance in comparison to IL-13αR1 and IL-6Rα 
(Table 4.1), which could be an explanation for why the window for IFNGR1 cell surface 
staining is smaller than for cell surface staining of IL-13αR1 and IL-6Rα (Figure 4.4).  
A consistent finding for each validated cell surface receptor in Figure 4.4 was that STUB1 
knockout cells had greater total cell surface increases in comparison to THP-1 Cas9 parent 
cells, whilst a smaller increase was usually present in CHIC2 knockout cells (Figure 4.4). In 
Chapter 3, I made the same observations in other cell types (Figure 3.13), indicating that the 
loss of the E3 ligase STUB1 usually has a more marked effect on cell surface expression of 
IFNGR1, than CHIC2. However, the only cell line that this did not seem to hold true for was 
293T cells (Figure 4.6C and 4.6D).  
STUB1 regulates other cell surface receptors like IL-4Rα (Wei et al. 2014) (Table 1.1). 
Reassuringly, my PMP dataset comparing THP-1 Cas9 C22 versus THP-1 Cas9 C22 STUB1 
knockout cells also showed increased IL-4Rα expression in STUB1 knockout cells. Ligands 
IL-4 and IL-13 share the IL-4Rα subunit for signal transduction and the second receptor subunit 
can either be γc (type 1 receptor) or IL-13Rα1 (type 2 receptor), the latter of which was 




Wei and colleagues report threefold higher cell surface IL-4Rα expression in STUB1−/− MEF 
cells than in wild-type MEF cells by flow cytometry (Wei et al. 2014). Although I cannot make 
a direct comparison to the first receptor subunit, IL-4Rα, I validated the IL-13Rα and report a 
6.4-fold increase in cell surface IL-13Rα in THP-1 STUB1 knockout cells as compared to THP-
1 Cas9 cells by flow cytometry. STUB1 regulates IL-4Rα and this confirms Wei’s hypothesis 
that in the IL-4R signaling pathway, STUB1 specifically targets the degradation of IL-4Rα, but 
not IL-13Rα1 and γc (Wei et al. 2014). However, in contrast to their findings, I find that the 
depletion of STUB1 also strongly upregulates IL-13Rα1, suggesting that STUB1 may be 
responsible for degradation of both subunits of the IL-13R. However, I did not validate the 
interaction between STUB1 and either of these two subunits, nor the mechanism by which IL-
4Rα is degraded. Finally, IL-4Rα was not identified in CHIC2-deficient cells, thereby alluding 
to the fact that CHIC2 does not ubiquitously regulate all subunits of immune cell surface 
receptors, and is only specific to certain subunits. Recruitment of CHIC2 may be restricted to 
certain receptor subunits or mediated by a specific motif, or another adaptor protein may recruit 
CHIC2 to its substrate.   
Advantages and Disadvantages of PMP 
PMP specifically identifies plasma membrane (PM) proteins and provides a greater enrichment 
of PM proteins in comparison to analysis of the whole cell proteome (WCP). In terms of 
biological relevance, PMP can identify proteins that have differences in trafficking (relevant to 
my area of study), whereas I may not have seen these differences in the WCP. For example, if 
a protein traffics to a different organelle within the cell, but has not changed in total abundance, 
then it might not be picked up as easily in the WCP as opposed to PMP.  Since PMP quantifies 
the abundance of PM proteins, it does not provide information about potential downstream 
effects or signaling consequences mediated by these genetic deletions. Furthermore, in 




4.4 Summary  
In this chapter, I utilized PMP to obtain an in depth understanding of cell surface receptors 
whose expression is dependent on CHIC2, and on STUB1. I identified receptors, in addition to 
IFNGR1, that are regulated by CHIC2. The results indicate that CHIC2 is responsible for the 
regulation of multiple immune cell surface receptors, thereby providing a good rationale for 









Chapter 5: CHIC2 is a novel regulator of 
cell surface IFNGR1 
 
 
5.1 Introduction  
CHIC2, previously known as brx-like translocated in leukemia (BTL), is a small membrane-
associated protein with a predicted molecular weight (MWT) of 19-kD. CHIC2 is predicted to 
contain a coiled-coil region, 12 lysine residues, and a 23 amino acid long cysteine-rich 
hydrophobic (CHIC) motif including eight cysteine residues (amino acids 88-106, Figure 5.1). 
The CHIC motif is reported to be palmitoylated and this post-translational modification (PTM) 
anchors CHIC2 to a membrane (Cools et al. 2001).   
 
Figure 5.1 Schematic showing relative positions of different CHIC2 domains. CHIC2 consists of 
165 amino acids. Coiled-coil (aa 1-26, green), CHIC-motif (hydrophobic, 23 aa stretch between aa 88-
106, blue) wherein six out of eight cysteine residues are palmitoylated (at the Golgi). Palmitoylation is 
used as a membrane anchor. Three out of 12 lysines (K76, K77, K117) are highlighted as potential sites 
of monoubiquitination. aa, amino acids.  
 
What little is known about CHIC2 comes from a few reports mainly from authors Cools, 
Fink, Pardanani and Ketterling, relating to CHIC2’s involvement in hematological cancers, 
and a literature report by Cools characterizes CHIC2’s features (palmitoylation) and 




interested in further studying CHIC2 because the STUB1 E3 ligase and CHMP5 (ESCRT-III), 
which like CHIC2, were identified in the CRISPR IFNGR1high screen, and are involved in the 
regulation of receptors from the plasma membrane, and in onward subsequent targeting for 
lysosomal degradation. However, no prior studies have analyzed CHIC2’s function.   
A single paper characterized CHIC2 as a highly conserved protein (Cools et al. 2001), with a 
single chic gene found in C. elegans and D. melanogaster (but absent from S. cerevisiae). D. 
rerio, M. musculus and H. sapiens each contain two genes, CHIC1 and CHIC2. Despite some 
differences at the N-terminus, the overall similarity between these two genes is high. A 
nucleotide Basic Local Alignment Search Tool (BLAST) (NIH) analysis revealed that human 
CHIC1 and CHIC2 contain 83% homology at the amino acid level but encode different 
proteins. 
This same group report that CHIC2 localizes to the plasma membrane, a Golgi-like vesicular 
compartment, and scattered vesicles. Cools’ observation suggests that endogenous CHIC2 
could be more localized to one of these organelles (e.g. plasma membrane, vesicles, or Golgi), 
but is present within each of these sites (Cools et al. 2001). They additionally report that CHIC2 
is palmitoylated and as a result, membrane associated (Cools et al. 2001). Palmitoylation is a 
reversible post-translational modification that involves the addition of long-chain fatty acids 
(typically, a 16-carbon saturated fatty acid) to one or more cysteine residues via thioester 
linkages. This PTM is important in the trafficking of proteins to specific cellular membranes 
(Resh 1999), and is not solely a membrane anchor.  
Cools and colleagues detect two MWT bands for CHIC2 via immunoblot, and utilize 
membrane fractionations to ascertain the differences between these two bands by treating 
membrane fractions with Tris (as a control) or hydroxylamine (NH2OH). NH2OH breaks the 




MWT. Using this approach, they report that membrane-bound palmitoylated CHIC2-myc runs 
at 27-kD, whilst an unpalmitoylated cytosolic CHIC2-myc runs at 23-kD; the reason for this 
sizeable jump in MWT is likely due to multiple palmitoylation PTMs with the multiple cysteine 
residues in the CHIC motif. CHIC2’s palmitoylation was further confirmed by 
immunoprecipitating radiolabeled palmitic acid and observing the same differences in MWT 
(Cools et al. 2001). Lastly, Cools and colleagues investigate whether the CHIC motif is a 
variant of the cysteine string domain. They suggest that CHIC2 has structural similarity to 
cysteine string proteins (CSP), which are palmitoylated proteins present on vesicular 
membranes and involved in calcium (Ca2+) regulated exocytosis (Mastrogiacomo et al. 1994; 
Chamberlain and Burgoyne 2000; Greaves and Chamberlain 2006). CSPs may therefore 
represent a new family involved in vesicular transport.  
CHIC2’s functional role is even less well defined. Interestingly, a chromosomal translocation 
involving CHIC2 (amino terminal 110 amino acids, exons 1-3) with ETV6/TEL 
(carboxyterminal 441 amino acids, exons 2-8), a transcription factor containing a helix-loop-
helix (HLH) oligomerization domain and an ETS binding domain, has been implicated in some 
cases of acute myeloid leukemia (AML) (Cools et al. 1999; Kuchenbauer et al. 2005). Due to 
this rearrangement in the fusion protein, the HLH domain of ETV6 activates the kinase 
domain of PDGFRB (Golub et al. 1994), ABL (Papadopoulos et al. 1995), and JAK2 
(Peeters et al. 1996). Other studies on CHIC2’s role in disease examined cells from patients 
with systemic mastocytosis. These patients have a fusion rearrangement of the Fip1-like 1 
(FIP1L1)-platelet-derived growth factor receptor α (PDGFRα) (FIP1L1-PDGFRα), 
containing an 800 base pair deletion (and CHIC2 is deleted within this region) (Pardanani 
et al. 2003; Fink et al. 2008). FIP1L1-PDGFRα is a constitutively active tyrosine kinase that 
transforms hematopoietic cells, phosphorylates itself and STAT5, but is associated with 




PDGFRα (Cools et al. 2003; Fink et al. 2008). The fusion protein is highly sensitive to the 
kinase inhibitor Imatinib (Gleevac) and treatment with this drug results in rapid complete 
remission for FIP1L1–PDGFRα positive patients (Jovanovic et al. 2007; Bempt et al. 2016). 
As a novel protein, with no ascribed function, CHIC2 became the major focus of my subsequent 
experiments. In this chapter, I determine which domains of CHIC2 are functionally important, 
identify the cellular localization of CHIC2 using an epitope-tagged CHIC2, confirm CHIC2’s 
palmitoylation and determine whether the loss of palmitoylation abolishes membrane 
interaction. I investigate the role of ubiquitin, another PTM on CHIC2, as a recruitment factor 
for STUB1, or as an internalization signal for IFNGR1. I examine if CHIC2 associates with 
STUB1, and if STUB1 interacts with CHIC2, to determine if the two proteins act in the same 
pathway and show that the loss of STUB1 affects CHIC2’s function and subcellular 
localization. Finally, as CHIC2 has not previously been implicated in IFNGR1’s regulation, I 
performed functional studies on CHIC2’s regulation of IFNGR1.  
 
5.2 Results  
5.2.1 Loss of CHIC2 causes an increase in IFNGR1 cell surface expression  
Both the CRISPR/Cas9 IFNGR1high genetic screen and PMP identified CHIC2 as essential for 
the regulation of IFNGR1. PMP also identified a number of other immune cell surface receptors 
regulated by CHIC2, indicating that the loss of CHIC2 is responsible for regulating multiple 
immune receptors (Figure 4.2).   
 
The observation that the loss of CHIC2 was responsible for an increase in cell surface IFNGR1 
(Figure 5.2A), demonstrated that CHIC2 is important for cell surface regulation of IFNGR1. 




revealed a total loss of endogenous CHIC2 in THP-1 cells (Figure 5.2B). CHIC2 was detected 
as two bands (Figure 5.2B), a 25-kD band initially interpreted as ‘palmitoylated’ CHIC2, and 
a 20-kD band, interpreted as ‘unpalmitoylated’ CHIC2 (these differences will be addressed 
later). Immunoblot analysis of CHIC2 knockout, or STUB1 knockout cells, revealed an 
increase in total IFNGR1 expression as compared to THP-1 Cas9 control cells (Figure 5.2C), 
thereby indicating that the changes in expression observed at the cell surface by flow cytometry 
are reflected in a total increase in cellular IFNGR1.   
Prior to carrying out further studies, CHIC2 knockout clones were isolated and screened for an 
increase in cell surface IFNGR1 from a CHIC2 knockout parent population by flow cytometry 
(Figure 5.2D). CHIC2sg2 knockout (KO) clone 17 displayed a 2.5-fold increase from the 
control population, CHIC2sg3 KO C10 displayed a 2.2-fold increase, and CHIC2sg4 KO clone 
7 displayed a 2.3-fold increase (Figure 5.2D). Immunoblot analysis revealed a loss of both the 
CHIC2 bands in the three KO clones screened by flow cytometry (highlighted in red, Figure 
5.2E); a longer exposure with DURA did not reveal any additional bands for these clones (data 
not shown). Of the clones no longer expressing CHIC2, the CHIC2sg2 knockout clone 17 





Figure 5.2 CHIC2 is required for cell surface expression of IFNGR1 in THP-1 cells. (A) THP-1 
Cas9 Clone 22 (C22) was transduced with a guide targeting CHIC2 or control sgRNA (β2m). 
Transduced cells were selected with puromycin. IFNGR1 expression was measured by flow cytometry 
10 days post-transduction. (B) Immunoblot confirming loss of CHIC2 in (A) using three respective 
guides as compared to control. Two bands are detected for CHIC2 (25 and 20-kD). (C) Immunoblot 
confirming increase in total IFNGR1 in a CHIC2 knockout (KO) and STUB1 KO as compared to THP-
1 Cas9 cells. (D-E) Isolation of THP-1 Cas9 C22 CHIC2 KO clones. Single-cell cloning of the selected 
CHIC2 population identified three separate KO clones with increased cell surface IFNGR1 (confirmed 
by flow cytometry) that did not express CHIC2 by immunoblot (in red). WT THP-1 unstained (gray), 
THP-1 Cas9 C22 parent (blue), Cas9 CHIC2 KO population (red), Cas9 CHIC2 KO clone (green). KO, 
knockout. WT, wild-type.  
 
 
5.2.2 A CHIC2 knockout clone has increased cell surface IFNGR1 expression, which is 
lost upon complementation with full-length CHIC2 cDNA 
Upon successful validation of the CHIC2 genetic knockout by immunoblot, I wanted to 
confirm a role for CHIC2 in the internalization of IFNGR1, so I sought to restore homeostatic 
regulation in THP-1 Cas9 C22 CHIC2 KO C17 by genetic complementation. Codon-
optimized full-length CHIC2 cDNA was cloned by PCR from a gBlock (IDT, 498 bp) into a 




(palmitoylation mutant) and CHIC2-ΔC) were cloned by PCR using template DNA from the 
CHIC2 wild-type construct (Figure 5.3B). The ΔN-CHIC2 mutant has an N-terminal 
truncation of the coiled-coil region. Palmitoylation mutant, CHIC2-C6S (herein, C6S), 
contains full-length CHIC2 with six of the eight cysteines in the CHIC motif mutated to six 
serines (as modelled off the Cools et al. paper). The CHIC2-ΔC mutant contains a C-terminal 
truncation of the last 13 amino acids.  
 
Figure 5.3 Cloning of CHIC2 mutants. (A) A schematic of the lentiviral construct encoding CHIC2, 
in place of a multiple cloning site. CHIC2 expression is driven by the powerful spleen focus-forming 
virus (SFFV) promoter. Construct encodes a resistance gene for hygromycin (HygroR) driven by the 
phosphoglycerate kinase (PGK) promoter. (LTR, long-terminal repeat; WPRE, Woodchuck hepatitis 
virus posttranscriptional regulatory element). (B) CHIC2 mutants cloned by PCR from wt-CHIC2 
template DNA. wt-CHIC2 (aa 1-165), ΔN-CHIC2 (aa 27-165), CHIC2-C6S (aa 1-165, CHIC motif 
with six cysteines mutated to six serines (6C6S), and CHIC2-ΔC (aa 1-152). wt, wild-type; aa, amino 
acids. 
 
To formally demonstrate that the loss of CHIC2 was responsible for an increase in IFNGR1, I 
used this synthesized lentivirus to exogenously re-express wt-CHIC2 or mutant-CHIC2 in 




wild-type IFNGR1 cell surface expression, as did ΔN-CHIC2 cells (red to green shaded, 
Figure 5.4A). However, both CHIC2-ΔC cells and CHIC-C6S (non-palmitoylated CHIC2) 
cells were unable to restore wild-type cell surface IFNGR1 (compare the green and red 
histograms, Figure 5.4A), indicating that both the C-terminus and C6S (site of palmitoylation, 
located within the CHIC motif) regions are functionally important and required for the 
regulation of IFNGR1 in THP-1 cells. The cell surface phenotype was also validated for two 
other CHIC2 sgRNAs, ensuring that this finding was not guide specific (data not shown). 
 
Figure 5.4 Re-expression of CHIC2 restores IFNGR1 downregulation as measured by flow 
cytometry and immunoblot. (A) Rescue of CHIC2 function by exogenous re-expression of CHIC2. 
CHIC2 KO and mutant-CHIC2 are unable to downregulate IFNGR1 from the cell surface, whilst re-
expression of CHIC2 restores this downregulation. WT THP-1 unstained (gray), Cas9 C22 parent 
(blue), Cas9 C22 CHIC2 KO C17 (red), KO C17 + CHIC2 cDNA (green). (B) Immunoblot confirming 
re-expression of CHIC2 in THP-1 as compared to CHIC2 mutants. (*, unspecific background band). 
(C) Immunoblot confirming that CHIC2 is required for the downregulation of IFNGR1 in THP-1 cells.  
 
Immunoblot analysis of this experiment revealed that KO C17 + wt-CHIC2 cells (lane 4 




previously seen in Figure 5.2B and E. However, there is an unspecific background band 
directly beneath the 20-kD band indicated by an * that appears in lanes 2, 3 and 6 (Figure 
5.4B). ΔN-CHIC2 cells also express two CHIC2 bands that are at lower MWT bands as 
predicted, due to the deletion of the first 26 amino acids (lane 5, Figure 5.4B). In both CHIC2-
ΔC cells (lane 6, Figure 5.4B) and CHIC2-C6S cells (lane 7, Figure 5.4B), CHIC2 is expressed 
as a single, non-palmitoylated band, and is non-functional as the cell surface IFNGR1 
phenotype suggested (Figure 5.4A). Expression of the two C-terminal mutants is also less than 
wt-CHIC2 and ΔN-CHIC2 expression (Figure 5.4B). These results indicate that CHIC2’s 
coiled-coil domain is non-essential for protein function, whereas the palmitoylated CHIC motif 
and C-terminus are indispensable for its function. 
Immunoblot analysis of a subsequent experiment revealed that KO C17 + wt-CHIC2 cells 
restored wild-type IFNGR1 expression (lane 3 compared to lane 1), as did KO C17 + ΔN-
CHIC2 cells (lane 4, Figure 5.4C). KO C17 + CHIC2-ΔC and KO C17 + CHIC2-C6S cells 
expressed greater total levels of IFNGR1 (lanes 5 and 6, Figure 5.4C), in line with the cell 
surface data that these two mutants are unable to restore wild-type IFNGR1, confirming the 
importance of these domains in the regulation of IFNGR1.    
 
5.2.3 Epitope-tagging allows for visualization of CHIC2’s cellular localization by 
immunofluorescence     
Although I was able to detect endogenous CHIC2 in THP-1 lysates, it is important to determine 
where an epitope tagged protein will localize, so I explored how an epitope-tagged CHIC2 
affected the IFNGR1 cell surface readout and CHIC2 immunoblot expression. I opted for either 
a N-or C-terminal 3x-HA tag and generated stable cell lines in CHIC2 KO C17 by lentiviral 




was restored to steady-state levels (red to green, Figure 5.5A), as it was for untagged wt-
CHIC2 cells, whereas the C17 KO + CHIC2-3xHA cells were unable to restore cell surface 
IFNGR1 (apparent from the green and red histograms, Figure 5.5A). This finding implies that 
the N-terminal tagged protein functions like wt-CHIC2, whereas the C-terminal 3xHA tag 
interferes with CHIC2’s function. Immunoblot analysis revealed that 3xHA-CHIC2 cells 
express three HA bands (addressed later), whereas CHIC2-3xHA cells only express one HA 
band (Figure 5.5B), showing that CHIC2 is expressed but non-functional, as it does not include 
the slow-migrating, top band (~33-kD).  
To visualize CHIC2 by confocal microscopy, I exogenously expressed 3xHA-CHIC2 in WT 
HeLa cells by lentiviral transduction. 3xHA-CHIC2 was seen in unidentified vesicular 
structures, however, 3xHA-CHIC2 expression was extremely faint (Figure 5.5C). Since an N-
terminal tag did not perturb CHIC2’s function, I opted for the brighter mScarlet-CHIC2 for 
follow-up immunofluorescence (IF) experiments. Confocal images confirmed that expression 
of mScarlet-CHIC2 in a WT HeLa cell was more readily detectable and CHIC2 appeared to 
localize to vesicular structures of unknown origin (Figure 5.5E). I confirmed the cell surface 
phenotype in THP-1 cells by showing that CHIC2 KO C17 + mScarlet-CHIC2 cells rescue 
IFNGR1 to steady-state levels (red to green, Figure 5.5D), but CHIC2 KO C17 + mScarlet-






Figure 5.5 N-terminal tagged CHIC2 is fully functional and assumes a vesicular localization, but 
C-terminal tag renders CHIC2 nonfunctional. (A, D) Rescue of CHIC2 function by exogenous re-
expression of 3xHA-CHIC2 and mScarlet-CHIC2. CHIC2-3xHA is non-functional. WT THP-1 
unstained (gray), THP-1 Cas9 C22 control (blue), CHIC2 KO C17 (red), KO C17 + epitope-tagged 
CHIC2 (green). (B) Immunoblot analysis confirming re-expression of 3xHA-CHIC2 in CHIC2 KO C17 
+ 3xHA-CHIC2 cells (3 bands), whereas KO C17 + CHIC2-3xHA is non-functional (1 band). (C, E) 
Wild-type HeLa cells were transduced with a lentiviral construct encoding epitope-tagged CHIC2 and 
selected with hygromycin. Cells were (C) fixed and immunostained with a rat antibody against HA 
(CHIC2) together with α-rat secondary conjugated to Alexa Fluor-546, or (E) fixed. Scale bar, 10µM. 
 
5.2.4 CHIC2 is a membrane-associated, palmitoylated protein   
I hypothesized that CHIC2 may be acting at the plasma membrane to regulate its substrate, 
IFNGR1, so I performed IF to see if I could detect CHIC2 at the plasma membrane (as 
previously reported in the literature by Cools et al.). mScarlet-CHIC2 or palmitoylation mutant, 




transduction. For these experiments, mScarlet-CHIC2 expression was enhanced with an α-RFP 
antibody. Colocalization of mScarlet-CHIC2 with plasma membrane marker, MHC-I, and with 
the trans-Golgi (TGN) marker, TGN-46, suggested that CHIC2 is distributed in the plasma 
membrane, Golgi, and an unidentified vesicular organelle (Figure 5.6A). In a palmitoylation 
mutant, mScarlet-CHIC2-C6S was localized to the cytosol and lost its membrane association 
(Figure 5.6A). This confirms that wt-CHIC2 is a membrane-associated protein and that 
palmitoylation is essential for CHIC2’s function and membrane association, thereby mirroring 
the report that CHIC2 is present at an internal membrane, in the Golgi and at the plasma 
membrane, and that palmitoylation is required for membrane association (Cools et al. 2001).   
 
Figure 5.6 CHIC2’s membrane localization is essential for its function. (A) HeLa Cas9 CHIC2 KO 
cells + mScarlet-CHIC2 or mScarlet-CHIC2-C6S cells were fixed and immunostained for RFP 
(mScarlet-CHIC2), w6/32 (MHC-1) and TGN-46 (Golgi) to mark vesicular structures, the plasma 
membrane and Golgi as assessed by immunofluorescence. RFP (mScarlet-CHIC2, red), MHC-I (w6/32) 
(green), TGN-46 (blue), DAPI (gray). RFP was stained using a rat antibody together with an α-rat 
secondary antibody conjugated to Alexa Fluor-546. MHC-I was stained using a mouse antibody 
together with an α-mouse secondary antibody conjugated to Alexa Fluor-488. TGN46 was stained using 
a sheep antibody together with an α-sheep secondary antibody conjugated to Alexa Fluor-647. Scale 
bar, 10µM. (B) Immunoblot confirming re-expression of 3xHA-CHIC2 in THP-1 Cas9 C22 CHIC2 KO 
C17 + 3xHA-CHIC2 cells (two palmitoylated bands and one, non-palmitoylated band, lane 1) and 




After making this observation, I compared the different MWT bands in THP-1 Cas9 C22 
CHIC2 KO C17 cells complemented with 3xHA-CHIC2 or 3xHA-CHIC2-C6S (Figure 5.6B). 
The C6S mutant lost its membrane association and was weakly expressed compared to wt-
CHIC2 (Figure 5.6A). Therefore, the single CHIC2 band detected in 3xHA-CHIC2-C6S cells 
is non-palmitoylated CHIC2 (lane 2, Figure 5.6B), which is subsequently used as a reference 
point. The top two bands in 3xHA-CHIC2 cells (lane 1, Figure 5.6B) are likely palmitoylated, 
membrane associated forms of CHIC2 (post-translational modifications, PTMs).  
Taken together, these results indicate that CHIC2 is a palmitoylated membrane-resident 
protein, and this palmitoylation is essential for CHIC2’s function, since a cytosolic, 
palmitoylation-deficient mutant (C6S) loses its membrane localization.   
5.2.5 Identifying CHIC2 interaction partners by mass spectrometry  
Since IF demonstrated that CHIC2 was present at the membrane, I sought to identify CHIC2 
binding partners by performing an immunoprecipitation (IP) on HA-CHIC2 followed by mass 
spectrometry (MS) analysis, kindly performed by Dr. James Williamson. Stably expressed 
3xHA-CHIC2 cells in THP-1 Cas9 C22 CHIC2 KO C17 were used alongside the CHIC2 KO 
clone (C17) that did not express 3xHA-CHIC2 to control for non-specific binding to α-HA 
antibody. Previous immunoblot analysis demonstrated that the expression level of 3xHA-
CHIC2 was similar to endogenous CHIC2 (Figure 5.5B). Therefore, it is unlikely that the 
interaction partners identified in Table 5.1 are artefacts of protein over-expression. Proteins 
identified from the HA-CHIC2 IP are listed in Table 5.1 (full list of identified proteins is in 
Appendix 2). 
The MS identified 1036 total proteins, and the top 126 proteins were candidate CHIC2 
interactors (>1.5-fold, 99% confidence) of which 12 proteins had more than three enriched 




previous observation that CHIC2 is membrane associated (Table 5.1). Proteins that have a high 
number of peptides (higher abundance) which are absent in the CHIC2 KO (control) are likely 
to be strong interactors with the bait (e.g. 3xHA-CHIC2).  
Accessio
n 
Gene Name Gene ID Peptide
s 
Q9UNE7 E3 ubiquitin-protein ligase CHIP STUB1 17 
Q9UKJ5 Cysteine-rich hydrophobic domain-containing protein 2 CHIC2 8 
P11166 Solute carrier family 2, facilitated glucose transporter member 1 SLC2A1 8 
P05023 Sodium/potassium-transporting ATPase subunit alpha-1 ATP1A1 7 
Q99808 Equilibrative nucleoside transporter 1 SLC29A1 6 
Q9H7F4 Transmembrane protein 185B TMEM185B 4 
Q8NFB2 Transmembrane protein 185A TMEM185
A 
3 
P63104 14-3-3 protein zeta/delta YWHAZ 3 
Q96FN4 Copine-2 CPNE2 3 
A8K2U0 Alpha-2-macroglobulin-like protein 1 A2ML1 3 
Q9UBG3 Cornulin CRNN 3 
Q96RR1 Twinkle protein, mitochondrial PEO1 3 
 
Table 5.1 Interaction partners of CHIC2 identified with three or 
more unique peptides. Immunoprecipitation performed in THP-1 Cas9 C22 CHIC2 KO 17 stably 
expressing 3xHA-CHIC2 rescue cells. CHIC2 KO 17 was used as a negative control. Hits were 
excluded from the samples if they were detected in the negative control. 1.0x108 cells from each 
condition were lysed and HA-CHIC2 was immunoprecipitated with α-HA 
antibody. Immunoprecipitates were analyzed by mass spectrometry. Proteins identified in 3xHA-
CHIC2 rescue cells. Number of unique peptides shown. See Appendix 2 for the complete set 
of identified proteins.  
 
Reassuringly, STUB1 was identified as the top interactor with 17 enriched peptides. Since 
STUB1 is reported to regulate many cell surface receptors (Table 1.1, Wei et al. 2014; 
Okiyoneda et al. 2010), I hypothesized that CHIC2 interacted with this cytosolic E3 ligase at 
the plasma membrane, thereby regulating the internalization of IFNGR1. No other E3 ligases 
were identified in the MS analysis within the criteria I set.  
Other hits include SLC2A1, which is a glucose transporter and membrane associated protein 




glycoprotein that localizes to the plasma membrane and mitochondrial membranes. ATP1A1 
is a cation transport ATPase. 
Also listed in Table 5.1 are TMEM185B (with four unique peptides) and TMEM185A with 
(three unique peptides) – both uncharacterized seven-transmembrane proteins. These two 
proteins could be involved in regulating IFNGR1, along with CHIC2, so I used CRISPR-
mediated gene disruption to test whether their loss also upregulated IFNGR1. Single knockouts 
did not cause an increase in cell surface IFNGR1 (data not shown), and a pooled attempt of 
guides targeting both TMEM185B and TMEM185A only slightly increased cell surface 
IFNGR1 as assessed by flow cytometry (Figure 5.7). Hence, these proteins were not pursued 
for further characterization.  
Figure 5.7 Combinatorial knockout of TMEM185B and TMEM185A does not affect cell surface 
IFNGR1. THP-1 Cas9 Clone 22 (C22) was transduced with pooled guides targeting TMEM185B/A or 
control sgRNA (β2m). Transduced cells were selected with puromycin. IFNGR1 expression was 
measured by flow cytometry 10 days post-transduction. WT THP-1 unstained (gray), THP-1 Cas9 C22 
+ sgβ2m (blue), Cas9 C22 + pooled sgTMEM185B/A combination (red).   
 
The data in Table 5.1 showed that CHIC2 interacts with STUB1. CHIC2 is therefore a 
membrane protein that interacts with STUB1 and other cell surface receptors (and perhaps 




(Appendix 5) showed the reverse interaction – e.g. wt-STUB1 interacted with CHIC2, as well 
as TMEM185B and TMEM185A. These additional proteins could be members of a complex 
that help mediate the recruitment of CHIC2, although STUB1 binding is dependent on a Hsp70 
binding motif.  
 
5.2.6 CHIC2 interacts with STUB1   
Having found that CHIC2 interacts with STUB1 (Table 5.1) and the reverse (i.e. STUB1 
interacts with CHIC2) (Appendix 5) by mass spectrometry analysis, I sought to first confirm 
these findings by immunoprecipitation and subsequent immunoblot, and I went on to determine 
which regions were responsible for mediating the interactions between CHIC2 and STUB1. 
In trying to identify suitable cell lysis reagents for a HA-CHIC2 immunoprecipitation (IP), I 
found that NP-40 detergent did not allow me to visualize the interaction between CHIC2 and 
STUB1 (data not shown). An initial HA-CHIC2 IP in 1% digitonin comparing CHIC2 KO C17 
and CHIC2 KO C17 + 3xHA-CHIC2 cells showed that STUB1 binds CHIC2 (data not shown). 
Prior to carrying out the IP in Figure 5.8B, cells which stably expressed wild-type and mutant 
3xHA-CHIC2 were analyzed for the expression of cell surface IFNGR1 by flow cytometry 
(Figure 5.8A). In the resulting 3xHA-CHIC2 cells, CHIC2 KO C17 + 3xHA-CHIC2 restored 
wild-type IFNGR1 cell surface expression, as did 3xHA-ΔN-CHIC2 cells (red to green shaded 
histogram, Figure 5.8A). However, neither 3xHA-CHIC2-ΔC cells nor 3xHA-CHIC2-C6S 
(non-palmitoylated CHIC2) cells were able to restore wild-type cell surface IFNGR1 (compare 
the green and red histograms, Figure 5.8A), as seen in the untagged complemented cells in 
section 5.2.2.  
Endogenous STUB1 was detected by immunoblot following immunoprecipitation of HA-
CHIC2 in digitonin lysates, confirming that STUB1 does indeed interact with 3xHA-CHIC2 




CHIC2-C6S nor 3xHA-CHIC2-ΔC cells bound to STUB1 (lanes 3 and 5, Figure 5.8B). 
Therefore, CHIC2’s palmitoylation motif and C-terminus are likely to be required for 
membrane association and are essential for the CHIC2-STUB1 interaction. 
Figure 5.8 STUB1 is readily detected in association with CHIC2. (A) THP-1 Cas9 C22 CHIC2 
KO C17 cells were transduced with 3xHA-wild-type or-mutant CHIC2, hygromycin selected and 
analyzed by flow cytometry. WT THP-1 unstained (gray), Cas9 C22 parent (blue), Cas9 C22 CHIC2 
KO C17 (red), CHIC2 KO C17 + 3xHA-CHIC2 (green). (B) Schematic diagram of CHIC2 showing 
important binding domains. Immunoprecipitation (IP) of HA-CHIC2 from digitonin lysates of THP-
1 Cas9 cells. Analysis by immunoblot. Lysate, 5% of input.  
 
5.2.7 STUB1 interacts with CHIC2 and IFNGR1  
Stably expressing FLAG-tagged wild-type and mutant STUB1 cell lines were generated in 
STUB1 KO C13 background by lentiviral transduction (Figure 3.16A). Since STUB1-receptor 
interactions were visualized by other groups (Table 1.1, Wei et al. 2014; Tawo et al. 2017; 




STUB1 (from my data in Table 5.1 and Figure 5.8B). I predicted that the TPR domain would 
be essential for the STUB1-IFNGR1 interaction since chaperone intermediates mediate 
interactions between STUB1 and various known substrate receptors. The loss of this domain 
was reported to abolish STUB1-cell surface receptor interactions (e.g. IL-4Rα, Met receptor). 
The U-box domain seemed unlikely to be essential for an IFNGR1 interaction, since STUB1’s 
E3 ligase activity is mediated by this domain, and instead, I predicted a stabilization of 
IFNGR1.  
Endogenous IFNGR1 and CHIC2 were detected by immunoblot following 
immunoprecipitation of FLAG-STUB1 in NP-40 lysates, validating that both CHIC2 and 
IFNGR1 do indeed physically interact with FLAG-STUB1 and FLAG-ΔU-box cells (herein, 
ΔU-box) (lanes 2 and 4, Figure 5.9), confirming that the U-box domain is not essential for 
either the STUB1-CHIC2 or STUB1-IFNGR1 interaction. The STUB1-IFNGR1 interaction in 
ΔU-box cells is stronger than in FLAG-STUB1 cells as expected. However, neither STUB1 
KO C13 (negative control) nor FLAG-STUB1-ΔTPR cells (herein, ΔTPR) cells bind CHIC2 
or IFNGR1 (lanes 1 and 3, Figure 5.9). Therefore, STUB1’s TPR domain is essential for a 
STUB1-CHIC2 and STUB1-IFNGR1 interaction. I cannot conclude that this interaction was 
dependent on a chaperone intermediate (e.g. Hsp70), but since the TPR domain is essential, a 
role for Hsp70 would seem likely. In addition, equal FLAG expression was detected in the IP, 
excluding the fact that the loss of the interaction in ΔTPR cells was due to unequal loading or 
an unequal amount of FLAG-STUB1 being pulled down (i.e. in the off chance that a different 
amount of FLAG antibody was used for that sample) (Figure 5.9).  
Overall, these results indicate that STUB1 is associated with CHIC2 and IFNGR1 in THP-1 






Figure 5.9 CHIC2 and IFNGR1 are readily detected in association with STUB1. THP-1 Cas9 
C22 STUB1 KO C13 cells were transduced with FLAG-wild-type and mutant-STUB1 and hygromycin 
selected. Immunoprecipitation (IP) of FLAG-STUB1 from NP-40 lysates of THP-1 Cas9 cells. 
Analysis by immunoblot. Lysate, 5% of input.  
 
Figures 5.8 and 5.9 show that I was able to clearly detect an interaction between CHIC2 and 
STUB1 in both directions, and that STUB1 interacts with IFNGR1 (see Appendix 6, Figure 
S1 for probable explanation of lower MWT band for IFNGR1 in Figure 5.9). However, I was 
unable to detect IFNGR1 in a HA-CHIC2 IP (data not shown). An endogenous IFNGR1 IP 
was performed in NP-40 THP-1 lysates to gauge whether I could see an interaction between 
IFNGR1 and CHIC2 and/or STUB1. The IP worked well, but neither CHIC2 nor STUB1 were 
detected by immunoblot following IP of IFNGR1 (Figure 5.10). To confirm specificity of the 
antibody used to IP IFNGR1, IFNGR1 KO C32 (Figure 3.14A) was used as an internal control 






Figure 5.10. Immunoprecipitation of endogenous IFNGR1. Immunoprecipitation (IP) of IFNGR1 
from NP-40 lysates of THP-1 Cas9 C22 cells. Analysis by immunoblot. Lysate, 5% of input.  
 
5.2.8 CHIC2 is not absolutely required for the interaction between STUB1 and IFNGR1 
Since CHIC2 and STUB1 interacted, I wanted to test whether the loss of STUB1 in a CHIC2 
KO would further affect the functional IFNGR1 cell surface phenotype. If there was an 
additional increase in cell surface IFNGR1, this would suggest that the two proteins are acting 
in the pathway. THP-1 Cas9 C22 cells and CHIC2 KO C17 -/+ sgSTUB1 were analyzed by 
flow cytometry, and the ‘double knockout’ increased cell surface IFNGR1 (red to green 
histogram, Figure 5.11A), validating my hypothesis. Despite my inability to detect an  
interaction between  CHIC2 and STUB1 in Figure 5.10, CHIC2 and STUB1 act in the same 
pathway, since a CHIC2 KO cell transduced with a sgRNA targeting STUB1 showed a further 
increase in cell surface IFNGR1 (Figure 5.11A).   
 To assess whether CHIC2 was essential for the interaction between STUB1 and IFNGR1, 
stably expressing STUB1 C13 KO + FLAG-STUB1 cells (from Figure 5.9) were transduced 
with a CHIC2 sgRNA and cells were analyzed for cell surface IFNGR1 (Figure 5.11B). There 
was a large increase in cell surface IFNGR1 in FLAG-STUB1 cells + CHIC2 KO (green to 
orange histogram, Figure 5.11B). Endogenous CHIC2 and IFNGR1 were detected by 




5.2.7). In the absence of CHIC2 the interaction between STUB1 and IFNGR1 (lane 2 compared 
to lane 3, Figure 5.11C) was more difficult to detect (and this finding was reproducible, n=2), 
suggesting that the interaction may be partially dependent on CHIC2. In addition, I found that 
re-expression of 3xHA-CHIC2 (lane 4), re-stabilized IFNGR1 as seen in lane 2 (Figure 
5.11C). Taken together, the interaction between STUB1 and IFNGR1 appears to be partially 
dependent on CHIC2.  
 
 
Figure 5.11 CHIC2 facilitates the interaction between STUB1 and IFNGR1. (A) THP-1 Cas9 
C22 STUB1 KO C13 + FLAG-STUB1 cells were transduced with sgCHIC2 and puromycin selected. 
WT THP-1 unstained (gray), THP-1 Cas9 C22 (blue), STUB1 KO is unable to downregulate IFNGR1 
from the cell surface (red), whilst re-expression of FLAG-STUB1 restores this downregulation (green). 
Further upregulation of IFNGR1 confirmed in STUB1 KO C13 + FLAG-STUB1 + sgCHIC2 (orange). 
(B) Immunoprecipitation (IP) of FLAG-STUB1 from NP-40 lysates of THP-1 Cas9 C22 cells. 
Analysis by immunoblot. Lysate, 5% of input. (C) CHIC2 and STUB1 act in the same pathway. WT 
THP-1 unstained (gray), THP-1 Cas9 C22 control (blue), CHIC2 KO C17 (red), CHIC2 C17 KO + 
sgSTUB1 (green). 
 
Confirming the interactions between these proteins was promising, and since STUB1 is an E3 




CHIC2 is regulated in a STUB1-dependent manner. How would the loss of STUB1 affect 
CHIC2’s subcellular localization?  
 
5.2.9 STUB1 post-translationally modifies CHIC2  
Confirmation of the CHIC2-STUB1 interaction and the reciprocal STUB1-CHIC2 interaction 
prompted me to examine how the loss of STUB1 affected endogenous CHIC2 expression. The 
finding in Figure 5.6B suggested that 3xHA-CHIC2 was post-translationally modified (as 
exhibited by the top two palmitoylated bands). Since STUB1 is an E3 ligase, and because I 
previously found a higher MWT band on CHIC2 (Figure 5.6B), I hypothesized that STUB1 
ubiquitinates CHIC2 (and could be an explanation for the higher MWT band observed).  
To validate a role for STUB1 in the ubiquitination of CHIC2, I treated WT THP-1 or STUB1 
KO C13 cells with the lysosomal inhibitor, Bafilomycin A1 (BafA1). As previously observed, 
endogenous CHIC2 expression in WT-THP1 cells was detected as two bands – 25- and 20-kD 
(lane 1, Figure 5.12). Upon treatment with BafA1, there was a marked stabilization of the more 
prominent 25-kD band in WT THP-1 cells suggesting that CHIC2 might be degraded in a 
vacuolar ATPase (v-ATPase) sensitive compartment – likely the lysosome (lane 2, Figure 
5.12). This prominent 25-kD band was not detected in a STUB1 KO, but in these cells, a 
dramatic increase in the 20-kD band was detected (lane 3, Figure 5.12). Upon treatment with 
BafA1, there was a further accumulation of the 20-kD band in STUB1 KO cells, and a re-
appearance of the 25-kD band (lane 4, Figure 5.12). These findings suggest that the 25-kD 
band in lanes 1 and 2 is STUB1-sensitive, since the loss of STUB1 diminishes this band (lane 
3, Figure 5.12), suggesting that this band could represent a ubiquitinated form of CHIC2. In 
lane 4, there was only a minor stabilization of the 25-kD band with BafA1 treatment, suggesting 
that this modified form of CHIC2 is predominantly STUB1-dependent. The WT ratios of 




with FLAG-STUB1 confirming the reproducibility of these findings (lanes 5 and 6, Figure 
5.12).  
I also noted that BafA1 treatment led to the accumulation of IFNGR1 in both WT THP-1 and, 
to a lesser extent in STUB1 KO cells (lanes 2, 4, and 6, Figure 5.12), implying that active 
degradation of IFNGR1 was not completely STUB1 dependent. An additional, unidentified E3 
ligase may therefore also be involved in IFNGR1 degradation (see Appendix 6, Figure S2). 
Taken together, the results in Figure 5.12 suggest that in the absence of STUB1, the ratios of 
CHIC2 changes, and CHIC2 may not get efficiently ubiquitinated and degraded.  
 
Figure 5.12 STUB1 mediated post-translational modification of CHIC2. Immunoblot analysis 
depicting differences of endogenous CHIC2 ratios in WT THP-1 and STUB1 KO 13 -/+ FLAG-STUB1 
cells untreated or treated with 25nM BafA1 for 16h. Immunoblot analysis of IFNGR1 suggests 
lysosomal degradation for IFNGR1.  
 
5.2.10 CHIC2 is mono-ubiquitinated by STUB1 
To support my hypothesis that CHIC2 was ubiquitinated, THP-1 Cas9 C22 CHIC2 KO C17 + 
3xHA-CHIC2 or 3xHA-CHIC2-C6S cells were treated with BafA1 for 16h and HA-
immunoprecipitated HA-CHIC2 was probed with an α-ubiquitin (Vu-1) antibody (LifeSensor 
Technologies). In 3xHA-CHIC2 cells, mono-ubiquitinated CHIC2 was readily detected by an 




at 37-kD and above (lane 1, Figure 5.13). In 3xHA-CHIC2-C6S cells (palmitoylation mutant), 
there was a complete loss of mono-ubiquitinated CHIC2 (lane 2, Figure 5.13), but very high 
MWT ubiquitin bands were detected. An HA immunoblot indicated that the lowest MWT band 
is non-ubiquitinated, non-palmitoylated CHIC2 (lane 2, Figure 5.13), and this band was 
previously observed in 3xHA-CHIC2-C6S cells (Figure 5.6B). In 3xHA-CHIC2 cells, this 25-
kD non-palmitoylated HA-CHIC2 band is still detected (running slightly faster), along with 
another group of bands starting at ~33-kD, equivalent to the mono-ubiquitinated CHIC2 bands 
seen in the ubiquitin blot (HA blot, lane 1, Figure 5.13). This result confirms that CHIC2 is 
ubiquitinated, with a very dominant monoubiquitinated form.  
 
Figure 5.13 CHIC2 is a monoubiquitinated protein. Immunoprecipitation (IP) of HA-CHIC2 from 
NP-40 lysates of THP-1 Cas9 C22 cells (5x107 cells each) treated with 25nM BafA1 for 16h. 
Analysis by immunoblot.  
 
Following this observation, I was interested to examine if CHIC2’s palmitoylation acts as a 
signal for CHIC2’s ubiquitination and subsequent degradation from the plasma membrane, and 
to understand the role of the mono-ubiquitin moiety on CHIC2. Could CHIC2’s mono-




5.2.11 Mono-ubiquitination on CHIC2 is mediated by STUB1 
Identification of the slower migrating band on CHIC2 as being monoubiquitinated (Figure 
5.13) helps explain the change in ratios of the two CHIC2 bands in the presence and absence 
of STUB1 (Figure 5.12). Since depletion of STUB1 led to the loss of the (now recognized, 
monoubiquitinated) band, this finding would imply that the monoubiquitination on CHIC2 is 
predominantly mediated by the STUB1 E3 ubiquitin ligase.  
To confirm this, I transduced THP-1 Cas9 C22 CHIC2 C17 KO + 3xHA-CHIC2 cells with a 
sgRNA targeting STUB1, and observed increased cell surface IFNGR1 by flow cytometry 
(green to purple histogram, Figure 5.14A). HA-immunoprecipitated HA-CHIC2 was probed 
with an α-ubiquitin (Vu-1) antibody (LifeSensor Technologies) (as in Figure 5.13). 
Comparison of 3xHA-CHIC2 cells -/+ STUB1 KO (lanes 1 and 3) showed a much decreased 
mono-ubiquitinated CHIC2 band and loss of higher MWT ubiquitin bands (as indicated by the 
loss of those bands on the ubiquitin blot at 33-kD and above) (Figure 5.14B). 3xHA-CHIC2-
C6S cells were used as a control (lane 2, Figure 5.14B).  
This finding strongly suggests that CHIC2 is a target of STUB1 mediated-ubiquitination. I 
cannot exclude the role of an additional E3 ligase contributing to CHIC2’s ubiquitination, since 
I did not see a complete loss of mono-ubiquitinated CHIC2. I expected a difference in HA 
expression of the HA immunoblot (lanes 1 and 3, Figure 5.14B) based on my finding in Figure 
5.12. However, the HA band at 33-kD looks the same, and slightly greater in lane 3, suggesting 






Figure 5.14 CHIC2 is monoubiquitinated by STUB1. (A) Cytofluorometric analysis confirming 
that THP-1 Cas9 C22 CHIC KO C17 + 3xHA-CHIC2 + STUB1 KO display upregulated cell surface 
IFNGR1. WT THP-1 unstained (gray), THP-1 Cas9 C22 (blue), CHIC2 KO C17 (red), CHIC2 KO C17 
+ 3xHA-CHIC2 (green), CHIC2 KO C17 + 3xHA-CHCI2 + sgSTUB1 (purple). (B) 
Immunoprecipitation (IP) of HA-CHIC2 from NP-40 lysates of THP-1 Cas9 C22 (5.0x107 cells each) 
treated with 25nM BafA1 for 16h. Analysis by immunoblot.  
 
 
After making the finding in Figure 5.14B, I considered whether STUB1 may also ubiquitinate 
IFNGR1 since other groups have shown STUB1-mediated ubiquitination of various receptor 
substrates (Table 1.1). Because ubiquitination is a sorting signal for onward degradation, I 
wanted to investigate if IFNGR1 was ubiquitinated by STUB1. Endogenous IFNGR1 was 
pulled down following treatment of THP-1 Cas9 C22, CHIC2 KO C17 and STUB1 KO C13 
with BafA1, and probed with an α-ubiquitin (Vu-1) antibody. However, the differences 
observed in the ubiquitination of IFNGR1 did not provide any evidence to suggest that STUB1 
ubiquitinates IFNGR1 (Figure 5.15), although IFNGR1 does appear to be polyubiquitinated. 
Indeed, another pathway is likely involved in the degradation of IFNGR1 since the absence of 
STUB1 in lane 3 showed more ubiquitination of IFNGR1. This may be occurring in the ER 






Figure 5.15 IFNGR1 is ubiquitinated. Immunoprecipitation (IP) of IFNGR1 from NP-40 lysates 
of THP-1 Cas9 C22 (2.5x107 cells each) treated with 25nM BafA1 for 16h. Analysis by immunoblot.  
 
 
5.2.12 CHIC2 is internalized from the plasma membrane in a STUB1-dependent manner  
Although the results regarding the potential ubiquitination of IFNGR1 were inconclusive, I was 
confident that STUB1 ubiquitinated CHIC2. I therefore examined if the loss of STUB1 affected 
CHIC2’s subcellular localization in HeLa Cas9 CHIC2 KO cells. In complemented mScarlet-
tagged CHIC2 cells, depletion of STUB1 (STUB1 KO) led to a relocalization of mScarlet-
CHIC2 from predominantly internal vesicular structures to both plasma membrane and 
vesicular structures (Figure 5.16), indicated by the co-localization of mScarlet-CHIC2 and 
MHC-I (yellow). There was also a lot more total mScarlet-CHIC2 in the absence of STUB1, 
and CHIC2’s re-localization to the plasma membrane suggests that in the absence of STUB1, 
CHIC2 is not efficiently ubiquitinated and internalized. Overall, this result suggests that the 
STUB1-mediated-mono-ubiquitination of CHIC2 is essential for CHIC2’s internalization from 






Figure 5.16 CHIC2 is internalized from the plasma membrane in a STUB1-dependent manner. 
HeLa Cas9 CHIC2 KO cells + mScarlet-CHIC2 -/+ STUB1 KO cells were fixed and immunostained 
for RFP (mScarlet-CHIC2, red), and w6/32 (MHC-1, green) to mark the plasma membrane as aassessed 
by immunofluorescence. RFP was stained using a rat antibody together with an α-rat secondary 
antibody conjugated to Alexa Fluor-546. MHC-I was stained using a mouse antibody together with an 
α-mouse secondary antibody conjugated to Alexa Fluor-488. Scale bar, 10µM. 
 
5.2.13 CHIC2 triple lysine mutant resembles CHIC2 localization in the absence of STUB1  
Since the absence of STUB1 decreased the mono-ubiquitinated form of CHIC2, and changed 
CHIC2’s localization from vesicular structures to the plasma membrane, I mutated critical 
lysine (K) residues to try to identify which specific lysine residue was ubiquitinated. I 
particularly wanted to explore if mutating these residues would have the same effect on 
CHIC2’s subcellular localization as a STUB1 KO in Figure 5.16.   
CHIC2 contains 12 lysine residues, and mass spectrometry results of the HA-CHIC2 IP 
(section 5.2.5, Table 5.1) indicated that K77 and K117 are ubiquitinated. PhosphoSite, a web-
based bioinformatics resource providing comprehensive information for protein PTMs (Cell 




117, and putative phosphorylation on threonine residue 159. In the absence of the preferred 
acceptor lysine residue, ubiquitin can attach to nearby acceptor lysine residues i.e. K76. 
Therefore, K76, K77 and K117 were mutated to arginine (R) residues individually or in a triple 
mutant by PCR from wt-CHIC2 (herein referred to as K76/77R, K117 and K76/77/117R). 
mScarlet-or 3xHA-tagged lysine mutants were re-expressed in HeLa Cas9 CHIC2 KO cells 
(for analysis by IF and flow cytometry, day 4), or in THP-1 Cas9 CHIC2 KO C17 (for analysis 
by immunoblot, day 7), respectively.  
In CHIC2 KO + mScarlet-CHIC2-K76/77/117R cells, mScarlet-CHIC2 re-localizes from 
internal vesicular structures to the plasma membrane (Figure 5.17A), whilst some mScarlet-
CHIC2 is still present in vesicular structures (Figure 5.17A). A similar distribution was 
observed in mScarlet-CHIC2 cells depleted of STUB1 (Figure 5.16), indicating that the 
absence of CHIC2’s lysine acceptor residues 76, 77 and 117, have a comparable effect on 
CHIC2’s localization as the absence of STUB1. However, despite the fact that mScarlet-
CHIC2 is clearly retained at the PM in K76/77/117R cells on day 4, the functional cell surface 
IFNGR1 phenotype did not match up for the triple mutant on this day (Figure 5.17B), since 
the triple mutant still corrected to wt-CHIC2 levels (red to purple/green histograms overlap, 
Figure 5.17B). The cell surface phenotype of mScarlet-tagged CHIC2 cells, depleted of 
STUB1 (STUB1 KO), is shown as a control (cells from Figure 5.16), which expressed 
increased cell surface IFNGR1 (Figure 5.17B).  
To further understand the unanticipated finding in Figure 5.17B, HA immunoblot analysis of 
THP-1 Cas9 C22 CHIC2 KO C17 + 3xHA-K76/77/117R cells reproducibly revealed a total 
loss of monoubiquitinated CHIC2 (lane 4, loss of the top HA band, Figure 5.17C), and a 
marked stabilization of non-palmitoylated CHIC2 (lane 4, bottom band, Figure 5.17C), 
indicating that CHIC2 is unable to be monoubiquitinated or degraded on day 7. However, and 




in culture for about 10+ days, suggesting that the cells may have adapted over time. Even 
though the 3xHA-K76/77/117R cells lost monoubiquitination on day 7, the functional cell 
surface IFNGR1 phenotype did not match up for the triple mutant on the same day (red to 
purple histogram, Figure 5.17D), since cell surface IFNGR1 also corrected to wt-CHIC2 
rescue levels (red to green histogram, day 7) (Figure 5.17D).  
 
 
Figure 5.17 Loss of mono-ubiquitinated CHIC2 mirrors a STUB1-dependent CHIC2 
localization.  (A) HeLa Cas9 CHIC2 KO cells + mScarlet-CHIC2-wt or K76/77/117R cells were fixed and 
immunostained for RFP (mScarlet-CHIC2, red) and w6/32 (MHC-1, green) to mark the plasma 
membrane as aassessed by immunofluorescence. RFP was stained using a rat antibody together with an 
α-rat secondary antibody conjugated to Alexa Fluor-546. MHC-I was stained using a mouse antibody 
together with an α-mouse secondary antibody conjugated to Alexa Fluor-488. Scale bar, 10µM. (B) 
CHIC2-K76/77/117R mutant rescues wild-type cell surface IFNGR1 (day 4 post-transduction). WT 
HeLa unstained (gray), HeLa Cas9 (blue), HeLa Cas9 CHIC2 KO (red), CHIC2 KO + mScarlet-CHIC2 
(green), CHIC2 KO + mScarlet-CHIC2K76/77/117R  or +sgSTUB1 (control) (purple). (C) Immunoblot 
analysis of THP-1 Cas9 C22 CHIC2 KO C17 + 3xHA-CHIC2 cells suggests 3xHA-CHIC2 triple 
mutant is not ubiquitinated. (D) CHIC2-K76/77/117R mutant restores wild-type cell surface IFNGR1 
(day 7 post-transduction). WT THP-1 unstained (gray), THP-1 Cas9 C22 (blue), CHIC2 KO C17 (red), 




A repeat experiment to create a lysine-less CHIC2 (CHIC2K0) in THP-1 cells also showed an 
initial loss of monoubiquitinated CHIC2 in 3xHA-CHIC2-K0 cells on day 4 (Figure 5.18A), 
but monoubiquitinated CHIC2 may have returned after cells had been in culture for 11 days. 
The cell surface IFNGR1 phenotype also corrected to wt-CHIC2 rescue levels (red to green 
histogram, Figure 5.18B), and I am in the process of confirming whether CHIC2 is still 
ubiquitinated.   
 
Figure 5.18 Loss of monoubiquitinated CHIC2 in a lysine-less CHIC2 mutant also corrects cell 
surface IFNGR1 phenotype to wt-CHIC2 rescue levels. (A) Immunoblot analysis of THP-1 Cas9 
C22 CHIC2 KO C17 + 3xHA-wild-type or lysine-less (K0)-CHIC2 suggests 3xHA-CHIC2-K0 is not 
ubiquitinated. (B) CHIC2-K0 mutant rescues wild-type cell surface IFNGR1 (day 4 post-transduction). 
WT THP-1 unstained (gray), THP-1 Cas9 C22 (blue), CHIC2 KO C17 (red), KO C17 + 3xHA-CHIC2 
or  3xHA-CHIC2-K0 (green).  
 
Overall, these findings imply that CHIC2’s monoubiquitination is essential for CHIC2’s 
internalization from the cell surface and subsequent lysosomal degradation. Stabilization of 
both IFNGR1 and CHIC2 was observed upon BafA1 treatment confirming that CHIC2 and/or 
IFNGR1 are lysosomally degraded (Figure 5.12). Thus, either CHIC2 or IFNGR1 or both are 
likely to be ubiquitinated by STUB1. I provide evidence that CHIC2 is ubiquitinated (Figure 




5.15). If IFNGR1 is not ubiquitinated, perhaps CHIC2’s monoubiquitination serves as an 
internalization signal for IFNGR1 internalization, but this could not be confirmed with my 
CHIC2 ubiquitination mutants.  
Further directions of this work include exploring the localization of a lysine-less CHIC2 by IF, 
and mutating CHIC2’s serine (of which there are 12) and threonine (of which there are six) 
residues, in the event that ubiquitin can be transferred to these residues, although that would 
likely greatly alter the expression and function of this small protein. In addition, a lysine-less 
IFNGR1 cytoplasmic tail could show if ubiquitination of IFNGR1 is essential for 
internalization, or if just CHIC2’s ubiquitination alone is required for the internalization of the 
IFNGR1.  
 
5.3 Discussion   
Prior to these studies, little was known about CHIC2’s function. The limited CHIC2 literature 
has focused mainly on the role of CHIC2 in hematological malignancies. This chapter 
demonstrates that CHIC2 regulates cell surface receptors such as IFNGR1. In this chapter, I 
further characterized the role of CHIC2 in THP-1 cells and determined which domains of 
CHIC2 are of functional importance. Both untagged and N-terminal epitope-tagged wt-CHIC2 
cells completely restored cell surface wild-type IFNGR1 in CHIC2 KO cells, whereas the 
palmitoylation mutant, CHIC2-C6S, was unable to restore wild-type IFNGR1. In HeLa cells, 
mScarlet-tagged exogenous CHIC2 localizes to the plasma membrane, Golgi, and vesicular 
structures of unspecified origin. I confirmed a critical role for palmitoylation in CHIC2 
function, and showed that the loss of palmitoylation in the CHIC2-C6S mutant abolished 
CHIC2’s membrane interaction, and CHIC2’s interaction with STUB1. Both mass 
spectrometry analysis and immunoprecipitation studies identified STUB1 as co-




substrates, I found that TPR chaperone-binding domain of STUB1 is required for its association 
with both IFNGR1 and CHIC2.  
Subsequently, I found that CHIC2 is monoubiquitinated by STUB1. The loss of STUB1, or a 
CHIC2 lysine mutant, both reduced CHIC2 ubiquitination and altered CHIC2’s subcellular 
localization. However, a CHIC2-lysine mutant did not have an obvious effect on IFNGR 
expression – in fact the CHIC2-lysine mutant rescued a CHIC2 KO cell as efficiently as wild-
type CHIC2, a somewhat disappointing result. Overall, these results suggest that STUB1-
mediated-CHIC2 ubiquitination, is a pre-degradation event, essential for the internalization and 
subsequent degradation of CHIC2. In addition, the enhancement of CHIC2 and IFNGR1 
expression following BafA1 treatment, indicates that CHIC2, and IFNGR1, are lysosomally 
degraded, despite the suggestion that IFNGR1 is degraded – by the proteasome (Londino et al. 
2017).  
Taken together, a combination of events could determine the fate of CHIC2 and IFNGR1 at 
the cell surface: monoubiquitinated CHIC2 can be internalized, de-ubiquitinated and recycled 
back to the cell surface, and polyubiquitinated CHIC2 can be rapidly degraded, likely along 
with the IFNGR1. Alternatively, ubiquitinated CHIC2 could serve as an internalization signal 
for IFNGR1 (without being ubiquitinated at the cell surface), and IFNGR1 could be 
subsequently polyubiquitinated in endosomes, for onward lysosomal degradation. Finally, the 
IFNGR1 could also be ubiquitinated at the plasma membrane (by STUB1 or another E3 ligase) 
and IFNGR1 recycling can follow the same routes (i.e. either IFNGR1 could be internalized 
and recycled back to the cell surface, or some IFNGR1 could be misfolded, ubiquitinated and 
degraded), as a recent report by Okiyoneda suggests for CFTR (Mou 2018). 
The Lehner and Nathan laboratories created a unique ubiquitome library as a powerful more-




involved in HMGCR regulation (Menzies et al. 2018). Future directions of this project include 
performing a targeted ubiquitome CRISPR screen aimed at identifying the E2’s and E3’s 
further implicated in the regulation of IFNGR1 and perhaps in the regulation of CHIC2 (if done 
in a STUB1 KO background cell). 
 
5.4 Summary  
In this chapter, I have defined an essential role for CHIC2 in the regulation of cell surface 
receptor IFNGR1. I show that CHIC2 is a membrane-resident, palmitoylated protein. CHIC2 
interacts with STUB1, and is mono-ubiquitinated in a STUB1-dependent fashion, at the plasma 
membrane. I show that without STUB1, CHIC2 partially loses its vesicular localization. More 
importantly, I have discovered that ubiquitinated CHIC2 plays a role in CHIC2’s 
internalization and subsequent degradation. Future work will need to determine whether this 
ubiquitination affects IFNGR1 internalization. The next chapter explores the functional 




Chapter 6: Regulation of cell surface 




CHIC2, together with STUB1, is responsible for the internalization of IFNGR1 and other 
immune receptors, including signaling receptors. While it is of interest to the field to identify 
and characterize the route of IFNGR1 internalization (discussed briefly in this section), it is of 
critical importance to determine if the internalization of IFNGR1 has functional consequences, 
particularly for important signaling receptors such as IFNGR1.   
Cell surface receptors are internalized via clathrin-mediated endocytosis (CME) and clathrin-
independent endocytosis (CIE), and can be recycled back to the cell surface or ubiquitinated 
and processed for onward degradation as discussed in section 1.4. IFN receptor (IFNR) 
downregulation limits further IFN responses, but IFNAR and IFNGR have distinct modes of 
activation and the regulatory mechanisms for IFNGR turnover remain elusive. Upon ligand 
binding of a type I IFN, IFNAR1 is internalized via CME, polyubiquitinated by the substrate-
recognizing F-box protein E3 ligase -Trcp, and degraded by the lysosome (Kumar et al. 2003; 
Kumar et al. 2007). However, little is known about the role of ubiquitin-mediated mechanisms 
in the downregulation of IFNGR. Li and coworkers reported that K3 and K5, KSHV viral 
proteins, stimulated ubiquitination, endocytosis and degradation of IFNGR1, leading to the 
attenuation of cellular responses to IFN-γ (Li et al. 2007). More recently, the Mallampalli group 
claim that IFNGR1 is degraded by the proteasome (Londino et al. 2017b), but in Chapter 5, I 
showed that STUB1, potentially along with another unidentified E3 ligase, is involved in the 




Like IFNR, Interleukin (IL) receptors undergo both CME and CIE. Studies have shown that 
the common gamma chain (γc) (Figure 1.1) undergoes constitutive internalization followed by 
lysosomal degradation (Morelon and Dautry-Varsat 1998). IL-2R, which contains a γc chain, 
has been characterized in greatest detail of all the γc containing receptors, and is internalized 
and degraded in a constitutive manner (Duprez and Dautry-Varsat 1986; Lamaze et al. 2001). 
IL-4Rα is also internalized by CIE (Kurgonaite et al. 2015), and IL-4Rα signaling plays an 
important role in the pathogenesis of airway inflammation, RA, diabetes and cancer. Wei and 
colleagues report that STUB1 regulates IL-4Rα by targeting it for proteasomal degradation 
(Wei et al. 2014). The same group showed sustained IL-4Rα-STAT6 signaling in response to 
cytokine stimulation in STUB1 KO cells, which is relevant to a finding I make in this chapter 
(Figure 6.5).  
Furthermore, IL-6R – an IL receptor sharing the common gp130 chain (Figure 1.1) – 
undergoes ligand-independent constitutive internalization, which did not require activation of 
the JAK-STAT pathway (Thiel et al. 1998). In addition to the IL-6R undergoing CIE, IL-6 
stimulated STAT3 phosphorylation on early endosomes (German, Sauer, and Howe 2011), 
suggesting that STAT3 can allow for signal propagation as long as JAK-bound cytoplasmic 
tails are exposed, which is terminated upon sequestration into ILVs (Cendrowski et al. 2016).  
The signaling pathway of IFNGR1, previously described in Figure 1.2, demonstrates that after 
engagement of IFN-γ, JAK1 and JAK2 are activated to regulate downstream phosphorylation 
of IFNGR1 at tyrosine (Y) residue Y440. Recruitment and phosphorylation of STAT1α 
(pSTAT1) takes place at Y701. This results in the formation of STAT1-STAT1 homodimers 
that translocate to the nucleus and bind γ-interferon-activated sites (GAS) to initiate 
transcription of interferon-stimulated genes (ISGs) (Decker, Kovarik, and Meinke 1997; 
Platanias 2005). Gene transcription occurs rapidly – within 15-30 min of IFN-γ treatment (Kerr 




factors themselves (e.g. interferon regulatory factor-1 (IRF1)) and are able to drive regulation 
of the next wave of transcription (Schroder et al. 2004). Other IFN-γ regulated genes include 
MHC-I, ICAM-1, B7.2 and vascular cell adhesion molecule-1 (VCAM-1) (Schroder 2004).  
The rapid increase of pSTAT1 upon IFN-γ stimulation provokes a reversible and dynamic 
response to rapidly restore homeostasis (Green et al. 2017), and must therefore be tightly 
regulated. In the absence of STAT1, IFN-γ can also activate STAT3 and STAT5, thereby 
diversifying the cellular response to IFN-γ stimulation, and activating MAPKs (Hu et al. 2001) 
and GSK3β (Grimes and Jope 2001), resulting in the activation of different transcription 
factors. Aberrant cytokine signaling has been implicated in many diseases such as lupus and 
leukemia. Moreover, excessive or sustained signaling of pro-inflammatory cytokines, e.g. 
tumor necrosis factor (TNF), interleukin-1 (IL-1) and IL-6, leads to severe diseases including 
rheumatoid arthritis (RA), inflammatory bowel diseases (e.g. Crohn’s disease and ulcerative 
colitis), periodic fevers and cancer (Hermanns et al. 2016). For inflammatory disorders, the 
overall effects of IFN-γ signaling are activated sequentially from a combinatorial balance of 
STAT1-dependent and STAT1-independent mechanisms (Green et al. 2017). Hence, 
investigating the signaling of IFNGR1 is of major importance.   
In this introduction, I briefly introduced accounts of signaling receptors that are well-studied. 
In this chapter, I wanted to identify how the internalization of IFNGR1 differs from other well-
studied cytokine receptors. I set out to a) assess if there was a difference in the internalization 
of IFNGR1 in cells lacking CHIC2 or STUB1 by internalization assays, and b) to determine 
whether an increase in cell surface IFNGR1 in CHIC2 KO cells has functional consequences 
in terms of the IFNGR1 signaling pathway. In the next chapter, I propose a model of how 




6.2 Results  
6.2.1 IFNGR1 is constitutively internalized  
I sought to understand the mechanism by which IFNGR1 is internalized from the cell surface 
using internalization assays. Briefly, cell surface IFNGR1 was labelled with α-IFNGR1 
antibody for 20 min on ice, washed twice to remove unbound antibody, incubated at 37°C for 
the indicated time periods and kept on ice to prevent further endocytosis. Remaining surface-
bound IFNGR1 was stained with a secondary antibody.  
An initial internalization assay was performed in WT THP-1 cells over 2 h to gauge the half-
life of IFNGR1 (data not shown). A repeat internalization assay in untreated versus IFN-γ 
treated WT THP-1 cells showed a negligible difference in the rate of internalization after 40 
min at 37°C (red to green histogram, Figure 6.1A). Subsequent internalization assays were 
performed for 40 min because I repeatedly found that 50% of surface bound IFNGR1 was 
internalized within approximately 20 min, and roughly 80% of IFNGR1 was internalized 
within 40 min (Figure 6.1A). Thus, IFNGR1 internalization was confirmed to be constitutive, 
and IFNGR1 is likely degraeded by the lysosome as illustrated in Appendix 6, Figure S2. All 
subsequent internalization assays in this chapter were carried out without IFN-γ stimulation.  
The half-life of IFNGR1 calculated from this obtained experimental data was plotted in Figure 
6.1B. WT THP-1 cells lost approximately 50% of cell surface IFNGR1 within 18 min (Figure 
6.1B). To ensure that this effect was not cell-type specific, a follow-up experiment was 
performed in the WM-852 melanoma cell line, which exhibited the same pattern for 





Figure 6.1 Constitutive internalization of IFNGR1 as illustrated in the absence of IFN-γ. (A) WT 
THP-1 cells were labelled with α-IFNGR1 antibody, washed, incubated at 37°C in the absence or 
presence of 200U/mL IFN-γ, washed again, and labelled with a secondary antibody conjugated to Alexa 
Fluor-647. WT THP-1 unstained (gray), WT THP-1 stained and kept at 4°C for the duration of the 
experiment (blue), WT THP-1 ‘baseline’ stained with α-IFNGR1 antibody, washed, and sample taken 
immediately upon incubation at 37°C (red), and WT THP-1 cells incubated at 37°C for 40 minutes. (B) 
Half-life of IFNGR1 in untreated WT THP-1 cells from (A). 50% of cell surface IFNGR1 is internalized 






6.2.2. CHIC2 and STUB1 are required for the internalization of IFNGR1  
I found that both a CHIC2 knockout (KO) cell and a STUB1 knockout (KO) cell increased cell 
surface IFNGR1, suggesting that these knockout populations internalized IFNGR1 more 
slowly than WT THP-1. Prior to carrying out the next set of experiments, the half-life of 
IFNGR1 in Figure 6.1B was compared against a follow-up internalization assay in WT THP-
1 cells (data not shown). Reproducibility across these assays was variable, making reliable 
quantitation difficult (e.g. the time required for 50% of cell surface IFNGR1 to be internalized 
ranged from 18-20 min in WT THP-1). Therefore, to control for factors that could lead to 
inconsistencies, I set up the assay so that different cells (e.g. WT versus STUB1 KO cells) 
could be compared within the same tube (one-tube assay) to minimize variability in subsequent 
experiments (Figure 6.2).   
CRISPR-mediated gene disruption was previously used to create knockout populations of 
CHIC2, STUB1 and CHMP5 in THP-1 Cas9 C22 cells (Figure 3.11). sgRNA expression in 
these cells was fused to BFP so KO cells were BFP+ (Figure 3.1B). The distinction in cellular 
fluorescence enabled me to compare the internalization of IFNGR1 in WT THP-1 (no 
color/grey) to either CHIC2 KO (BFP+), STUB1 KO (BFP+) or CHMP5 KO cells (BFP+), 
respectively (Figure 6.2A). In a follow-up experiment (section 6.2.3), I used an enhanced 
gating strategy with three cell populations in one tube, including grey, blue and red cells – e.g. 
WT THP-1 (grey), CHIC2 KO (BFP+) and either CHIC2 KO + mScarlet-CHIC2 cells 
(mScarlet+) or  CHIC2 KO + mScarlet-CHIC2-C6S cells (mScarlet+) (Figure 6.2B). The gating 
strategy used for these experiments, and the cell surface IFNGR1 expression for ‘un-





Figure 6.2 Internalization assay workflow and gating strategy. (A-B) Schematic of internalization 
assay workflow. Cells were labelled with α-IFNGR1 antibody, washed, incubated at 37°C to internalize 
IFNGR1, washed again, and labelled with a secondary antibody conjugated to Alexa Fluor-647. (A) 
WT THP-1 (grey) versus either CHIC2 knockout (KO), STUB1 KO or CHMP5 KO cells (all KOs are 
BFP+), or (B) WT THP-1 (grey) versus CHIC2 KO (BFP+) versus CHIC2 KO + mScarlet-wt-CHIC2 
or CHIC2-C6S cells (mScarlet+). (C) FACS gating strategy used for (A) grey and BFP+, and for (B) 
grey, BFP+ and mScarlet+. sgRNA (x-axis), mScarlet (y-axis). Histogram showing expression of cell 
surface IFNGR1. WT THP-1 unstained (grey shaded), WT THP-1 stained (grey), CHIC2 KO (blue), 
mScarlet-CHIC2 (red).  
 
 
The internalization assays in Figure 6.3 were performed as described in section 2.6.4 and cells 




reduction in cell surface IFNGR1 was observed after about 30 minutes in CHIC2 KO cells, as 
compared to 20 minutes in WT THP-1 cells, averaging 10 minutes less (Figure 6.3A), 
indicating that CHIC2 is involved in the constitutive internalization of IFNGR1. Individual 
CHIC2 KO internalization assays showed a reproducible delay of about 8-10 min, however, 
the delay in internalization looks greater in Figure 6.3A, most likely because the normalized 
values varied across the different datasets (as indicated by the greater standard deviations in 
Figure 6.3A). A 50% reduction in cell surface IFNGR1 was observed after 40 minutes in 
STUB1 KO cells, as compared to 20 minutes in WT THP-1 cells (Figure 6.3B), indicating that 
the rate of internalization is two times slower in STUB1 KO cells, and that STUB1 is also 
required for the constitutive internalization of IFNGR1. The greater delay in the internalization 
of cell surface IFNGR1 in STUB1 KO cells than CHIC2 KO cells could be attributed to the 
fact that STUB1 is an E3 ligase. In addition, there was a greater increase in cell surface IFNGR1 
in STUB1 KO versus CHIC2 KO cells as compared to WT THP-1 cells in Chapter 3. CHMP5 
KO cells served as an important control. Although CHMP5 KO cells, like CHIC2 KO cells, 
showed increased cell surface IFNGR1 staining, internalization of IFNGR1 in CHMP5 KO 
cells was equivalent to wild-type IFNGR1 (averaging 20 minutes) (Figure 6.3C). Since 
CHMP5 is an ESCRT-III component, this protein acts much later in the degradation pathway, 
so I would not expect a change in the rate of IFNGR1 internalization from the cell surface. 
Hence, CHMP5 KO cells were used as the positive control for these experiments. Although the 
internalization rates fluctuated slightly for WT THP-1 cells in individual experiments (within 
a 18-20 min range), the average time of internalization for WT THP-1 cells was 20 min, as 
illustrated in Figure 6.3.  
These experiments show a difference in the internalization of IFNGR1 in the absence of both 
CHIC2 and STUB1, indicating that both of these proteins are responsible for the regulation and 






Figure 6.3 Decreased rates of cell surface IFNGR1 internalization in CHIC2 knockout and 
STUB1 knockout cells as compared to WT THP-1 cells. WT THP-1 versus (A) CHIC2 KO cells 
(n=2), (B) STUB1 KO cells (n=3), or (C) CHMP5 KO cells (n=2). ‘WT’ THP-1 refers to THP-1 Cas9 
C22 cells. Cells were labelled with α-IFNGR1 antibody, washed, incubated at 37°C to internalize 




6.2.3 CHIC2 mutant displays greater delay in cell surface IFNGR1 internalization than 
CHIC2 KO cells 
To rescue the rate of ‘wild-type’ cell surface internalization in a CHIC2 KO, I exogenously re-
expressed mScarlet-CHIC2 or mScarlet-CHIC2-C6S in CHIC2 KO cells as before (section 
5.2.3) and previously confirmed the cell surface phenotype (Figure 5.5D). I predicted that 
CHIC2 KO + mScarlet-CHIC2wildtype cells (herein mScarlet-CHIC2wildtype) would display 
comparable rates of IFNGR1 internalization to WT THP-1 cells, since they were able to restore 
‘wild-type’ levels of cell surface IFNGR1. On the contrary, CHIC2 KO + mScarlet-CHIC2-
C6S (herein mScarlet-CHIC2-C6S) cells would have the same defect in internalizing cell 
surface IFNGR1 as CHIC2 KO cells, since they had nearly identical cell surface IFNGR1 
expression as CHIC2 KO cells (Figure 5.5D).   
A similar delay in internalization was observed in CHIC2 KO cells (28 min compared to 19 
min in WT THP-1) (Figure 6.4A). Indeed, a 50% reduction in cell surface IFNGR1 was 
observed after 25 minutes in mScarlet-CHIC2wildtype cells compared to WT THP-1 control cells 
(Figure 6.4B). Although the time taken to internalize 50% of IFNGR1 in Figure 6.4B was 
slightly longer than usual (by 5 min, which could be attributed to assay conditions), both of the 
cell populations internalized IFNGR1 at the same rate. However, a 50% reduction in cell 
surface IFNGR1 was observed after 32 min in mScarlet-CHIC2-C6S cells compared to 20 min 
for WT THP-1 cells (Figure 6.4C), and this was similar to the cell surface IFNGR1 
internalization time of 28 min in CHIC2 KO cells (Figure 6.4A), implying that the loss of 







Figure 6.4 Mutant CHIC2 exhibits delayed internalization of cell surface IFNGR1 as compared 
to WT THP-1 cells.  WT THP-1 versus (A) CHIC2 KO, or (B) CHIC2 KO + mScarlet-CHIC2wild-type 
cells, or versus (C) CHIC2 KO + mScarlet-CHIC2-C6S cells. ‘WT’ THP-1 refers to THP-1 Cas9 C22 
cells. Cells were labelled with α-IFNGR1 antibody, washed, incubated at 37°C to internalize IFNGR1, 
washed again, and labelled with a secondary antibody conjugated to Alexa Fluor-647. 
 
Collectively, I was able to restore a ‘wild-type’ cell surface internalization in CHIC2 KO + 
mScarlet-CHIC2wildtype cells, whilst mScarlet-CHIC2-C6S cells and CHIC2 KO cells 
internalized cell surface IFNGR1 more slowly than a WT THP-1 cell. This result confirms the 
finding in Chapter 5 that the C6S mutant-expressing cells show greater cell surface IFNGR1 
expression by flow cytometry, as does a CHIC2 KO, indicating that CHIC2 has an important 









6.2.4 Loss of CHIC2 enhances IFNGR1-pSTAT1 signaling and increases IRF-1 
expression  
Once I confirmed that CHIC2 helps mediate the internalization of IFNGR1, I wanted to 
determine the downstream consequences of CHIC2 on IFNGR1 signaling. All experiments in 
this section were performed in the presence of IFN-γ, and IFN-γ-initiated signal transduction 
was first examined in WT THP-1 cells. IFN-γ induced pSTAT1 expression after 15 minutes in 
WT THP-1 cells (and was stabilized by 30 min) (Figure 6.5A), as previously reported (Bach 
et al. 1997; Londino et al. 2017). Thus, cells were stimulated with IFN-γ for a maximum time 
of 30 min in Figure 6.5B.  
Since CHIC2 KO cells expressed more cell surface IFNGR1, I investigated the functional 
consequence of upregulated cell surface IFNGR1 expression in CHIC2 KO cells via pSTAT1 
induction (as discussed in section 6.1). Immunoblot analysis revealed a dramatic increase of 
pSTAT1 in CHIC2 KO cells after just 5 min of IFN-γ treatment, as compared to the very slight 
appearance of pSTAT1 after 5 min in WT THP-1 cells (Figure 6.5B). The marked difference 
in pSTAT1 expression between CHIC2 KO and WT THP-1 cells after 5 min, and at 30 min, 
suggested that CHIC2 plays an essential role in the homeostatic regulation of IFNGR1-
pSTAT1 signaling. This experiment was promising and I was able to restore ‘wild-type’ 
signaling in a CHIC2 KO cell reconstituted with 3xHA-CHIC2 cDNA, and examine IRF-1 







Figure 6.5 CHIC2 is required for cell surface IFNGR1 signaling. (A) Immunoblot analysis of 
pSTAT1 in WT THP-1 cells either untreated (0) or treated with IFN-γ (4-120 min). (B) Immunoblot 
analysis of pSTAT1 in WT THP-1 versus CHIC2 KO cells, either untreated (0) or treated with IFN-γ 
for 5 or 30 min. (C) Immunoblot analysis of pSTAT1 and IRF1 in WT THP-1 versus CHIC2 KO cells 
-/+3xHA-CHIC2, either untreated (0) or treated with IFN-γ for 60 or 120 min. (D) Real-time qRT-
PCR analysis of IRF-1 mRNA abundance in THP-1 Cas9 C22 cells versus CHIC2 KO cells. 
Values were generated using the ΔΔCT method relative to GAPDH abundance and normalized 
to the control condition. n=4. Statistical analysis is shown (*p<0.05). p-value=0.04. Marked with an 
*. Analysis by paired T-test. (Cells treated with 200U/ml IFN-γ where indicated).  
 
In Figure 6.5C, I examined IFN-γ-stimulated pSTAT1 expression at 60 or 120 min. I used 
these later time points since transcription of IRF-1 is induced later in the signaling pathway. 
Immunoblot analysis of CHIC2 KO cells revealed a slight increase in pSTAT1 expression in 
both of these later time points, as compared to WT THP-1 (Figure 6.5C). The effect of IFN-γ 
stimulation at 60 and 120 min was more modest in comparison to the effect at the earlier time 




expression is stabilized after 30 min, as I demonstrated in Figure 6.5A, and hence, I saw a 
more modest increase in CHIC2 KO cells. To complement these findings, immunoblot analysis 
of stably expressing 3xHA-CHIC2 cells revealed a rescue of ‘wild-type’ pSTAT1 expression 
in 3xHA-CHIC2 cells after stimulation at these same two time points (last three lanes, Figure 
6.5C), as compared to WT THP-1 cells (first three lanes, Figure 6.5C). Cell surface IFNGR1 
expression in THP-1 Cas9 C22 CHIC2 KO + 3xHA-CHIC2 cells (herein 3xHA-CHIC2 cells) 
was previously shown and confirmed in this experiment (Figure 5.5A). 
Finally, I investigated the effect of increased pSTAT1 on downstream IRF1 expression by 
immunoblot and qRT-PCR. Immunoblot analysis confirmed increased IRF1 expression in 
CHIC2 KO after 60 and 120 min of IFN-γ stimulation, as compared to WT THP-1 (Figure 
6.5C). This difference in IRF-1 expression was rescued to ‘wild-type’ levels in 3xHA-CHIC2 
cells for both time points (Figure 6.5C). To validate that increased pSTAT1 affected 
transcription of IRF-1, I utilized qRT-PCR to quantify IRF-1 mRNA expression in CHIC2 KO 
cells (red) as compared to WT THP-1 cells (blue) (Figure 6.5D). There was a significant 
increase in transcription of IRF-1 after 120 min in a CHIC2 KO cell (Figure 6.5D), as was 
illustrated by the small increase of IRF-1 by immunoblot Figure 6.5C. Although increased 
IRF-1 expression was also observed by immunoblot after 60 min in Figure 6.5C, the qPCR 
difference only became significant at 120 min post IFN-γ stimulation.  
Taken together, increased cell surface IFNGR1 in CHIC2 KO cells augments pSTAT1 directly 
after ligand binding, although this effect is less prominent at later time points. IRF-1 expression 
is marginally greater at later time points in comparison to WT THP-1 cells. The increased 
pSTAT1 and increased transcription of ISGs like IRF-1 could help explain the disease 




6.3 Discussion   
The first aim of this chapter was to determine if there was a difference in the rate of 
internalization of IFNGR1 in the absence of CHIC2 and STUB1. The results in Figure 6.3 
demonstrate that CHIC2 and STUB1 are essential for the constitutive internalization of cell 
surface IFNGR1; their absence delays cell surface IFNGR1 internalization. I consistently found 
that IFNGR1 has a short half-life (50% reduction in cell surface IFNGR1 within about 20 
minutes) in both WT THP-1 and WM-852 cells. In Figure 6.3B, the STUB1 KO cells 
internalized 50% of IFNGR1 at half the wild-type rate i.e. in unstimulated, steady–state 
conditions, STUB1’s ubiquitination activity is required for the rapid internalization of 
IFNGR1.  
Another aspect of this project that merits further investigation is the effect of a CHIC2 lysine 
mutant on the internalization of IFNGR1 in unstimulated cells. Initial evidence presented in 
Chapter 5 showed that these cells corrected to wild-type IFNGR1 levels. It would be 
interesting to determine if the loss of ubiquitin acceptor sites perturbed internalization of 
IFNGR1. Another unexplored area is whether the IFNGR1 substrate needs to be ubiquitinated 
to be internalized (i.e. would a lysine-less cytoplasmic-tail of IFNGR1 deter, or completely 
abolish, internalization of this signaling receptor)?   
In relation to other receptors, IL-6R was identified as a candidate receptor in the PMP (Figure 
4.2). Since IL-6R undergoes CIE (Cendrowski et al. 2016), the effect of a CHIC2 KO may be 
studied on the internalization of IL-6R, or a more well-known receptor like EGFR. Therefore, 
constitutive internalization plays a crucial role in the stoichiometric availability of cell surface 
IFNGR1, and later, for signal transduction.  
The second aim of this chapter was to examine the functional consequences of increased cell 




The results in Figure 6.5 showed that the loss of CHIC2 led to sustained STAT1 signaling and 
increased transcription of IRF-1. STAT1 is an essential mediator for IFN-related intracellular 
signaling and is considered a tumor suppressor protein related to the IFNs (Schindler et al. 
1992). The role of STAT1 in the IFN-signaling pathway, in the context of its antiviral activity 
has been extensively studied (Khodarev et al. 2012), and nearly two-thirds of ISGs are STAT1-
dependent (Haverkamp et al. 2006). Therefore, additional contributions to this particular area 
of signaling are important. Future directions could explore if CHIC2 is implicated in the 
regulation of other ISGs, downstream of pSTAT1. Since I found CHIC2 to regulate other 
receptors (Figure 4.3), it would be helpful to know fhow CHIC2 affects other signaling 
pathways associated with other STAT proteins.  
The broader implications of CHIC2 on signaling have been studied in leukemia. The FIP1L1-
PDGFRα fusion protein contains a CHIC2 deletion and is a constitutively active tyrosine 
kinase that transforms hematopoietic cells, phosphorylates itself and STAT5. Imatinib is 
widely used to treat some types of leukemia, is a specific inhibitor of PDGFR TKs, and induces 
dramatic clinical and molecular responses in Chronic Eosinophilic Leukemia (CEL) patients 
with PDGFRα fusions (Klion et al. 2003). The importance of understanding these downstream 








6.4 Summary  
This chapter highlights the importance of studying the molecular mechanisms underlying 
IFNGR1 internalization as initiated by CHIC2 and STUB1. I demonstrate the need to 
understand the functional consequences beyond cell surface expression and the importance of 
signaling termination. Future work exploring the role of CHIC2 on other signaling receptors 
that utilize the JAK-STAT pathway would be of interest. In the next chapter, I propose a model 









Chapter 7: General Discussion  
 
 
7.1 Summary and model for IFNGR1 regulation   
IFN-γ plays an essential role in the innate and adaptive immune response, and is of critical 
importance for anti-viral defense. Dysregulation of cell surface IFNGR1 and IFNGR1 
signaling is implicated in immunodeficiency (Newport et al. 1996) and leukemia (Kulling et 
al. 2018), and downregulation of IFNGR has been proposed as a mechanism for evading tumor 
surveillance (Kooy et al. 1998). Although the internalization of IFNRs has been characterized, 
the regulation of cell surface IFNGR1 remains poorly understood and was the main topic of 
my thesis.  
In this thesis, I investigated the ligand-independent turnover of cell surface IFNGR1. Unlike 
the IFNAR, IFNGR is constitutively internalized (Figure 6.1) and degraded in the absence of 
IFN-γ (Londino et al. 2017). I show that cell surface IFNGR1 is rapidly turned over (with a 
cell surface half-life of about 20 minutes) (Figure 6.1) and degraded (Figure 5.12). How much 
of this represents receptor ‘unfolding’ versus internalization for other reasons is unclear. To 
interrogate which proteins are involved in regulating cell surface IFNGR, I used 
a CRISPR/Cas9 genome-wide forward genetic screen to identify a role for the poorly 
characterized CHIC2 protein, together with the STUB1 E3 ligase as essential for regulation of 
IFNGR (Figure 3.10B). This was coupled with a systematic quantitative proteomic approach 
‘plasma membrane proteome profiling (PMP),’ which showed that CHIC2, and STUB1, 
regulate additional cell surface receptors (Figure 4.2). Since CHIC2’s endogenous function 
remains poorly understood, I chose to biochemically characterize the role of this protein, along 
with STUB1, on the regulation of IFNGR cell surface expression and internalization (discussed 




internalized from the cell surface. In the absence of CHIC2, the increased cell surface 
expression of IFNGR1 potentiated receptor-mediated IFN-γ signaling.  
In my proposed model (Figure 7.1), membrane-resident palmitoylated CHIC2 regulates 
IFNGR1 by binding to STUB1 and facilitates the STUB1-IFNGR1 interaction. STUB1 
deposits ubiquitin on CHIC2 via its U-box domain, leading to the subsequent internalization 
and degradation of CHIC2, potentially along with IFNGR1. However, another E3 ligase may 
contribute to CHIC2 ubiquitination, since I did not observe complete loss of monoubiquitinated 
CHIC2 in STUB1 knockout cells (Figure 5.14). Adaptor proteins could be recruited to 
facilitate the internalization of ubiquitinated CHIC2 and may mediate the internalization of 
IFNGR1. How this occurs remains to be determined. 
 
 
Figure 7.1 CHIC2 and STUB1 mediate the cell surface turnover of IFNGR1. Palmitoylated CHIC2 
resides at the plasma membrane and is responsible for facilitating the interaction between STUB1 and 
the IFNGR1. STUB1 interacts with CHIC2 and IFNGR1 via its TPR domain, possibly through an 
interaction with Hsp70. STUB1-mediated-monoubiquition of CHIC2 acts as an internalization signal 
for CHIC2, and possibly IFNGR1, sending them for subsequent lysosomal degradation. TPR, 




Recruitment of the STUB1 E3 ligase to substrates is thought to be mediated by Hsp70 
chaperones that bind misfolded proteins, or exposed hydrophobic regions. My observation that 
the TPR domain is essential for STUB1’s interaction with IFNGR1 (Figure 5.9) suggests 
involvement of Hsp70. Hsp70 may bind to an exposed hydrophobic region on IFNGR1 and 
subsequently recruit STUB1 (Figure 7.1). Interestingly, the TPR domain is also essential for 
STUB1 to bind CHIC2 (Figure 5.9). Whether this interaction is Hsp70 dependent remains 
unclear.  
Some caveats to this model include an inability to detect a direct interaction between IFNGR1 
and CHIC2. This could be due to technical limitations or a hand-off model whereby STUB1 is 
transferred from CHIC2 to IFNGR1 without forming a trimeric complex. Indeed, STUB1 
interacts with both the IFNGR1 and CHIC2 through its TPR domain (Figure 5.9). The 
interaction between IFNGR1 and STUB1 was less readily detected in the absence of CHIC2 
(Figure 5.11B), implying that CHIC2 may facilitate the interaction between STUB1 and 
IFNGR1. STUB1 might thereby ubiquitinate both CHIC2 and the IFNGR1. However, in the 
absence of STUB1, I failed to see a decrease in IFNGR1 ubiquitination (Figure 5.15). Whether 
the ubiquitination of both CHIC2 and IFNGR1 is required for IFNGR1 internalization remains 
unclear. A CHIC2 lysine-mutant showed a loss of monoubiquitination and block in CHIC2 
internalization but rescued wildtype levels of cell surface IFNGR1 to CHIC2 KO cells (Figure 
5.17). Thus, the effect of CHIC2 ubiquitination on IFNGR1 internalization remains 
inconclusive.  
The Hoppe laboratory suggest a role for STUB1 in the monoubiquitination of the INSR, in the 
absence of a chaperone-dependent mechanism responsible for the processing of misfolded 
proteins (Tawo et al. 2017). By extrapolation to my model, and from my data showing that 
STUB1 regulates IFNGR1, STUB1 may directly bind IFNGR1 via its TPR domain, without a 




overexpressed poly-glutamine (polyQ) repeats (derived from the N-terminus of huntingtin 
(htt)) resulting in the sequestration of cytosolic STUB1 to intracellular inclusion bodies. This 
prevented STUB1-mediated INSR downregulation, resulting in increased INSR expression 
(Tawo et al. 2017). Their finding suggests that palmitoylated CHIC2 may help recruit STUB1 
to the plasma membrane, a function which may be of particular importance when the 
multifunctional STUB1 ligase is being sequestered in the cytosol e.g. by unfolded proteins like 
mutant htt. Future work will test this effect in my system, and determine whether expression 
of polyQ makes recruitment of STUB1 to IFNGR1 more CHIC2 dependent.  
The majority of reports suggest that IFNGR1 and IFNGR2 are not pre-associated and only 
associate at the PM upon ligand binding. One group suggests that a pre-assembled heterodimer 
does exist (Krause et al. 2002, 2006). My studies indicate that IFNGR1 and IFNGR2 are not 
associated and that IFNGR1 is rapidly internalized. Moreover, cell surface staining of IFNGR1 
was not affected by the absence of IFNGR2 (IFNGR2 KO) suggesting that the two receptors 
are not pre-associated. A future area of research could explore the oligomeric state of the two 
receptor subunits, and determine whether the ubiquitination of either IFNGR1, IFNGR2, or 
both subunits is required for their internalization.  
In this thesis, I have shown that CHIC2 and STUB1 facilitate cell surface turnover of IFNGR1, 
as well as other cytokine receptors. CHIC2 itself is monoubiquitinated by STUB1, and this 
ubiquitination mediates the internalization and subsequent lysosomal degradation of CHIC2. 
How CHIC2 ubiquitination links to IFNGR1 internalization requires further investigation. 
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Appendix 1: Plasma Membrane Proteome 
Profiling 
 
The list of identified plasma membrane proteins from the PMP dataset (>1,400 plasma 






Appendix 2: 3xHA-CHIC2 
Immunoprecipitation 
 
Gene ID Gene Name  # peptides 
STUB1 E3 ubiquitin-protein ligase CHIP 17 
CHIC2 Cysteine-rich hydrophobic domain-containing protein 2 8 
SLC2A1 Solute carrier family 2, facilitated glucose transporter member 1 8 
ATP1A1 Sodium/potassium-transporting ATPase subunit alpha-1 7 
SLC29A1 Equilibrative nucleoside transporter 1 6 
TMEM185B Transmembrane protein 185B 4 
TMEM185A Transmembrane protein 185A 3 
YWHAZ 14-3-3 protein zeta/delta 3 
CPNE2 Copine-2 3 
A2ML1 Alpha-2-macroglobulin-like protein 1 3 
CRNN Cornulin 3 
PEO1 Twinkle protein, mitochondrial 3 
CD81 CD81 antigen 2 
SPRR3 Small proline-rich protein 3 2 
GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 2 
SRSF5 Serine/arginine-rich splicing factor 5 2 
SPN Leukosialin 2 
UBAP2 Ubiquitin-associated protein 2 2 
DDX39B Spliceosome RNA helicase DDX39B 2 
ZG16B Zymogen granule protein 16 homolog B 2 
ANXA1 Annexin A1 2 
SREBF1 Sterol regulatory element-binding protein 1 2 
ITGB1 Integrin beta-1 2 
ALOX12B Arachidonate 12-lipoxygenase, 12R-type 2 
ITGA4 Integrin alpha-4 2 
MAST3 Microtubule-associated serine/threonine-protein kinase 3 2 
TXNIP Thioredoxin-interacting protein 2 
SYNPO2 Synaptopodin-2 2 
DNAJC5 DnaJ homolog subfamily C member 5 2 
KNTC1 Kinetochore-associated protein 1 2 
RRBP1 Ribosome-binding protein 1 2 
ABCD3 ATP-binding cassette sub-family D member 3 1 
ACOT7 Cytosolic acyl coenzyme A thioester hydrolase 1 
ALKBH5 RNA demethylase ALKBH5 1 
AMBRA1 Activating molecule in BECN1-regulated autophagy protein 1 1 
APOBEC3B DNA dC->dU-editing enzyme APOBEC-3B 1 
ARHGAP33 Rho GTPase-activating protein 33 1 
ATHL1 Acid trehalase-like protein 1 1 




BRI3BP BRI3-binding protein 1 
BSG Basigin 1 
C19orf68 Uncharacterized protein C19orf68 1 
CABIN1 Calcineurin-binding protein cabin-1 1 
CBX4 E3 SUMO-protein ligase CBX4 1 
CDC20 Cell division cycle protein 20 homolog 1 
CDC37 Hsp90 co-chaperone Cdc37 1 
CDCA7L Cell division cycle-associated 7-like protein 1 
CDK13 Cyclin-dependent kinase 13 1 
CLIP1 CAP-Gly domain-containing linker protein 1 1 
CLIP1 Isoform 3 of CAP-Gly domain-containing linker protein 1 1 
CMTM3 CKLF-like MARVEL transmembrane domain-containing protein 3 1 
CNBP Cellular nucleic acid-binding protein 1 
COIL Coilin 1 
COPA Coatomer subunit alpha 1 
CSTB Cystatin-B 1 
CXorf56 UPF0428 protein CXorf56 1 
DDX27 Probable ATP-dependent RNA helicase DDX27 1 
DLAT Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase 
complex, mitochondrial 
1 
DMBT1 Deleted in malignant brain tumors 1 protein 1 
DR1 Protein Dr1 1 
DRAP1 Dr1-associated corepressor 1 
DYNLL1 Dynein light chain 1, cytoplasmic 1 
EEF1G Elongation factor 1-gamma 1 
F11R Junctional adhesion molecule A 1 
FABP5 Fatty acid-binding protein, epidermal 1 
FHAD1 Forkhead-associated domain-containing protein 1 1 
GNAI2 Guanine nucleotide-binding protein G(i) subunit alpha-2 1 
GNAI3 Guanine nucleotide-binding protein G(k) subunit alpha 1 
GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 1 
GUCD1 Isoform 3 of Protein GUCD1 1 
GUCD1 Protein GUCD1 1 
HADH Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial 1 
HIST1H2B
A 
Histone H2B type 1-A 1 
HLA-A HLA class I histocompatibility antigen, A-68 alpha chain 1 
IDE Insulin-degrading enzyme 1 
IGHV1-45 Immunoglobulin heavy variable 1-45 1 
KIF5C Kinesin heavy chain isoform 5C 1 
KLHL12 Kelch-like protein 12 1 
LGALS7 Galectin-7 1 
LOR Loricrin 1 
M6PR Cation-dependent mannose-6-phosphate receptor 1 
MRPL15 39S ribosomal protein L15, mitochondrial 1 




MYCBP C-Myc-binding protein 1 
NCSTN Nicastrin 1 
NFATC1 Nuclear factor of activated T-cells, cytoplasmic 1 1 
NFKBIL1 NF-kappa-B inhibitor-like protein 1 1 
NHLRC2 NHL repeat-containing protein 2 1 
NOP2 Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferase 1 
NUS1 Dehydrodolichyl diphosphate synthase complex subunit NUS1 1 
OR1N2 Olfactory receptor 1N2 1 
OTX1 Homeobox protein OTX1 1 
PAPD7 Non-canonical poly(A) RNA polymerase PAPD7 1 
PLRG1 Pleiotropic regulator 1 1 
PPP2R3A Serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit alpha 1 
PRDM10 PR domain zinc finger protein 10 1 
RBM17 Splicing factor 45 1 
RECQL4 ATP-dependent DNA helicase Q4 (Fragment) 1 
REEP4 Receptor expression-enhancing protein 4 1 
RICTOR Rapamycin-insensitive companion of mTOR 1 
RP2 Protein XRP2 1 
S100A14 Protein S100-A14 1 
SCAMP3 Secretory carrier-associated membrane protein 3 1 
SLC16A1 Monocarboxylate transporter 1 1 
SLC2A5 Solute carrier family 2, facilitated glucose transporter member 5 1 
SLC39A14 Zinc transporter ZIP14 1 
SLC3A2 4F2 cell-surface antigen heavy chain 1 
SLC4A7 Sodium bicarbonate cotransporter 3 1 
SLC7A4 Cationic amino acid transporter 4 1 
SNAP23 Synaptosomal-associated protein 23 1 
SPRR1B Cornifin-B 1 
SRRM1 Serine/arginine repetitive matrix protein 1 1 
STK3 Serine/threonine-protein kinase 3 1 
SUPT5H Transcription elongation factor SPT5 1 
TAF5L TAF5-like RNA polymerase II p300/CBP-associated factor-associated factor 65 kDa subunit 
5L 
1 
TBR1 T-box brain protein 1 1 
TET2 Methylcytosine dioxygenase TET2 1 
TMEM60 Transmembrane protein 60 1 
TMTC3 Transmembrane and TPR repeat-containing protein 3 1 
TPM3 Tropomyosin alpha-3 chain 1 
TRRAP Transformation/transcription domain-associated protein 1 
TUBA1A Tubulin alpha-1A chain 1 
UBN2 Ubinuclein-2 1 
UGGT1 UDP-glucose:glycoprotein glucosyltransferase 1 1 
UPF3B Regulator of nonsense transcripts 3B 1 





Appendix 3: gRNA sequences 
 
Target gene   gRNA sequence  
Control (β2M)   GGCCGAGATGTCTCGCTCCG 
IFNRA1 #1  GGATAATTGGATAAAATTGTC  
IFNRA1 #2   GGACAACTTTATCCTGAGG  
IFNRA1 #3  GGAGTGAAGAAAAGTTGCATT   
IFNRA1 #4  GCGGCTGCGGACAACACCCA 
TYK2 #1  GCACTGGTGGCATCCAGTGG    
TYK2 #2  GACTCACTGAAAGTGACCCA    
TYK2 #3  GGTGCAGAAAGGCCATGCCC    
TYK2 #4  GGAAGGCGCAGCCGGGTCA  
SEC61β #1  GCGCTCTCCCAGCAAAGCAG 
SEC61β #2  GAGTGCAGGCCGCACAACCT 
SEC61β #3   AAGACTTACACTTTGAGCCC 
SEC61β #4  GACCCCCAGTGGCACTAACG   
SEC62 #1  GCAAAGGCCAAGAAAGGAG   
SEC62 #2  AACGCAGGAGACACAAGAAG    
SEC62 #3  GGTGTTTATTACCTCAGTGT   
SEC62 #4  GGGCCACCCTCTTCCCCCTT  
MBNL1 #1  AGTATGTAGAGAGTTCCAGA 
MBNL1 #2  ACTCACCATGGCAGCTGCGG 
MBNL1 #3  GGGTTGTAATGGGGCACC 
IFNGR1 #1   GAACCCTATCGTATATT  
IFNGR1 #2  GGTAACATTAGTTGGTGT  
IFNGR1 #3  GATGAGAAATATTGATGC 
IFNGR1 #4  GGAGTACCAGATCATGCCAC      
SRP72 #1  TGTCTTCTGATAATGAACGG   
SRP72 #2  GGAGACATACTATCTGACGA   
SRP72 #3  GGTCGCCGTTCTGGCCATAC  
SRP68 #1  GGGCTCACCAAGGATGGCTG   
SRP68 #2  GGCAGATGAGATTGAGGTC  
SRP68 #3  GGCTTCACGGCTTTGCGT 
STUB1 #1  GAAGTTCAGCCGCTGCTCCT    
STUB1 #2  GACTGCCCGTCCAGCTCC   
STUB1 #3  CGTGGGCCGAAAGTACCCGG 
STUB1 #4  GGAGATGGAGAGCTATGATG   
CHIC2 #2   GTACGTTGGCTACTTTG   
CHIC2 #3  CAAGTACTCGCCGGACCCGG    
CHIC2 #4   ACCTTCCTGTTAATGTACGT   
CHMP5 #1  GTTTCGCTTTCCCGAAGAGT   
CHMP5 #2  GTTATGGCACCCCAGAAC   
CHMP5 #3  GCCTTACACGGTGACGTGAC   
AHR #1  GGTCCGGATTTCAAGTA  
AHR #2  GGCTGCTCTACAGTTATCC  
AHR #3  CCTACGCCAGTCGCAAGCGG   
AHR #4  TCCCCTACTGAAAGAAACGG   
INSR #1  GGAATTCATCGTGTACCCGG  
INSR #2  GGTCGTTGGACCTCAGGGG   
INSR #3  GAATGTGACGGAGTTCGA  
 
Appendix 3. gRNA target sequences cloned into lentiviral pKLV vector.  




Appendix 4: Oligonucleotides for screen 
preparation 
 
Bassik library   Sequence 5'-3'  
sgRNA_outer_F  AGGCTTGGATTTCTATAACTTCGTATAGCATACATTATAC  






Illumina sequencing primer AGACTATAAGTATCCCTTGGAGAACCACCTTGTTGG 
 
Appendix 4. Primer and adapter sequences used to prepare samples from forward genetic screens for 





Appendix 5: FLAG-STUB1 
Immunoprecipitation  
 
Gene ID Gene Name  #WT #_dTPR #_dU-box 
STUB1 E3 ubiquitin-protein ligase CHIP 47 40 35 
HSPH1 Heat shock protein 105 kDa 38 2 40 
HSPA4L Heat shock 70 kDa protein 4L 29   26 
NADSYN1 Glutamine-dependent NAD(+) synthetase 19   25 
USP19 Ubiquitin carboxyl-terminal hydrolase 19 19   17 
ERP44 Endoplasmic reticulum resident protein 44 14   16 
BAG5 BAG family molecular chaperone regulator 5 13   9 
C3orf38 Uncharacterized protein C3orf38 10   6 
CHIC2 Cysteine-rich hydrophobic domain-containing 
protein 2 
8     
AARS Alanine--tRNA ligase, cytoplasmic 8 1 1 
MLF2 Myeloid leukemia factor 2 7   8 
BAG1 BAG family molecular chaperone regulator 1 7   8 
HSPBP1 Hsp70-binding protein 1 7   2 
BAG3 BAG family molecular chaperone regulator 3 7   7 
TXLNG Gamma-taxilin 7     
SDCBP Syntenin-1 6   1 
VPS13C Vacuolar protein sorting-associated protein 13C 6   19 
FAM96A MIP18 family protein FAM96A 5   5 
ANKRD13A Ankyrin repeat domain-containing protein 13A 5 2   
CLINT1 Clathrin interactor 1 5   4 
MMS19 MMS19 nucleotide excision repair protein 
homolog 
4   19 
HSPE1 10 kDa heat shock protein, mitochondrial 4     
ERAP1 Endoplasmic reticulum aminopeptidase 1 4   6 
ESYT1 Extended synaptotagmin-1 4 4 10 
XPO1 Exportin-1 4 2 15 
GNAI2 Guanine nucleotide-binding protein G(i) subunit 
alpha-2 
3     
BAG4 BAG family molecular chaperone regulator 4 3   4 
ATP23 Mitochondrial inner membrane protease ATP23 
homolog 
3     
TAX1BP1 Tax1-binding protein 1 3     
PFAS Phosphoribosylformylglycinamidine synthase 3   11 
RALYL RNA-binding Raly-like protein 3     
SCCPDH Saccharopine dehydrogenase-like 
oxidoreductase 
3 1 2 
GEMIN4 Gem-associated protein 4 3   14 
GCAT 2-amino-3-ketobutyrate coenzyme A ligase, 
mitochondrial 
3 1 7 
SF1 Splicing factor 1 3   1 
PRMT3 Protein arginine N-methyltransferase 3 3 3 5 




ZC3H3 Zinc finger CCCH domain-containing protein 3 2     
SPTLC1 Serine palmitoyltransferase 1 2   8 
HLTF Helicase-like transcription factor 2 1 3 
H2AFZ Histone H2A.Z 2     
H3F3A Histone H3.3 2     
TMEM185B Transmembrane protein 185B 2   2 
HSPA2 Heat shock-related 70 kDa protein 2 2   3 
UBE2N Ubiquitin-conjugating enzyme E2 N 2 7   
DNAJB1 DnaJ homolog subfamily B member 1 2   2 
TMEM185A Transmembrane protein 185A 2   3 
ZHX1 Zinc fingers and homeoboxes protein 1 2     
MLC1 Membrane protein MLC1 2 1 3 
ERLIN2 Erlin-2 2   6 
PTPN6 Tyrosine-protein phosphatase non-receptor type 
6 
2 3 1 
POLR1C DNA-directed RNA polymerases I and III 
subunit RPAC1 
2 1 6 
GNB2 Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-2 
2   3 
GARS Glycine--tRNA ligase 2   7 
PDXK Pyridoxal kinase 2   1 
SUCLG1 Succinate--CoA ligase [ADP/GDP-forming] 
subunit alpha, mitochondrial 
2 1 8 
MCCC1 Methylcrotonoyl-CoA carboxylase subunit 
alpha, mitochondrial 
2   11 
DNAJB14 DnaJ homolog subfamily B member 14 2   4 
S100A9 Protein S100-A9 2 5   
COX7B Cytochrome c oxidase subunit 7B, 
mitochondrial 
2   2 
AHNAK Neuroblast differentiation-associated protein 
AHNAK 
2 1 6 
TUT1 Speckle targeted PIP5K1A-regulated poly(A) 
polymerase 
2 1 2 
UNC45A Protein unc-45 homolog A 2   15 
ATP6V1B2 V-type proton ATPase subunit B, brain isoform 2   1 
TRMT1L TRMT1-like protein 2 3 3 
RAF1 RAF proto-oncogene serine/threonine-protein 
kinase 
2 1 15 
DPF2 Zinc finger protein ubi-d4 2     
EIF2B5 Translation initiation factor eIF-2B subunit 
epsilon 
2   5 
ARMC5 Armadillo repeat-containing protein 5 2 2 5 
MYO9B Unconventional myosin-IXb 2 3 29 
PDCD6IP Programmed cell death 6-interacting protein 2     
MCCC2 Methylcrotonoyl-CoA carboxylase beta chain, 
mitochondrial 
2   9 
KCNK5 Potassium channel subfamily K member 5 2     
TIA1 Nucleolysin TIA-1 isoform p40 1     
HMHA1 Minor histocompatibility protein HA-1 1   2 
KCMF1 E3 ubiquitin-protein ligase KCMF1 1 1 2 
SPATA5L1 Spermatogenesis-associated protein 5-like 
protein 1 




OTUD6B OTU domain-containing protein 6B 1     
HSPA6 Heat shock 70 kDa protein 6 1   1 
MYADM Myeloid-associated differentiation marker 1   2 
HAT1 Histone acetyltransferase type B catalytic 
subunit 
1   1 
PPIF Peptidyl-prolyl cis-trans isomerase F, 
mitochondrial 
1     
GOLPH3 Golgi phosphoprotein 3 1   1 
MICAL1 Protein-methionine sulfoxide oxidase MICAL1 1   13 
MTPN Myotrophin 1 1   
EEF1A2 Elongation factor 1-alpha 2 1     
SHC1 SHC-transforming protein 1 1   2 
CHRNA7 Neuronal acetylcholine receptor subunit alpha-7 1     
PIF1 ATP-dependent DNA helicase PIF1 1 1   
MLF1 Myeloid leukemia factor 1 1     
COA6 Cytochrome c oxidase assembly factor 6 
homolog 
1 1   
PRR35 Proline-rich protein 35 1     
DNTTIP1 Deoxynucleotidyltransferase terminal-
interacting protein 1 
1     
AQR Intron-binding protein aquarius 1     
DYNC1I2 Cytoplasmic dynein 1 intermediate chain 2 1     
ATP5F1 ATP synthase F(0) complex subunit B1, 
mitochondrial 
1   5 
S100A8 Protein S100-A8 1 1   
CLASP2 CLIP-associating protein 2 1   1 
RNF20 E3 ubiquitin-protein ligase BRE1A 1     
RPTOR Regulatory-associated protein of mTOR 1   6 
SETD9 SET domain-containing protein 9 1 1   
IKBKG NF-kappa-B essential modulator 1   4 
MBOAT7 Lysophospholipid acyltransferase 7 1   1 
USF1 Upstream stimulatory factor 1 1 1 1 
RFC5 Replication factor C subunit 5 1   6 
PYGB Glycogen phosphorylase, brain form 1   6 
MFN2 Mitofusin-2 1   7 
WWP1 NEDD4-like E3 ubiquitin-protein ligase WWP1 1     
SLC1A4 Neutral amino acid transporter A 1   2 
UBE2D3 Ubiquitin-conjugating enzyme E2 D3 1     
C2CD2L C2 domain-containing protein 2-like 1 1   
TOPORS E3 ubiquitin-protein ligase Topors 1 2   
AUP1 Ancient ubiquitous protein 1 1   6 
MAD2L1 Mitotic spindle assembly checkpoint protein 
MAD2A 
1   1 
HAX1 HCLS1-associated protein X-1 1   2 
IRF2BP2 Interferon regulatory factor 2-binding protein 2 1   5 
DDX60L Probable ATP-dependent RNA helicase 
DDX60-like 
1   10 
KCNAB3 Voltage-gated potassium channel subunit beta-3 1     




RALA Ras-related protein Ral-A 1 1   
PHF6 PHD finger protein 6 1     
APLP2 Amyloid-like protein 2 1 1   
C6orf47 Uncharacterized protein C6orf47 1 1   
TUBA1A Tubulin alpha-1A chain 1   1 
KCNAB2 Isoform 3 of Voltage-gated potassium channel 
subunit beta-2 
1     
KRT4 Keratin, type II cytoskeletal 4 1     
AZU1 Azurocidin 1     
NUDC Nuclear migration protein nudC 1   2 
OGDH 2-oxoglutarate dehydrogenase, mitochondrial 1   1 
GSG2 Serine/threonine-protein kinase haspin 1 1 2 
KIF13A Kinesin-like protein KIF13A 1     
TIMM23B Putative mitochondrial import inner membrane 
translocase subunit Tim23B 
1 1   
TMEM165 Transmembrane protein 165 1   5 
MON1B Vacuolar fusion protein MON1 homolog B 1     
USMG5 Up-regulated during skeletal muscle growth 
protein 5 
1 1 2 
HSPA1L Heat shock 70 kDa protein 1-like 1   1 
FAM105A Inactive ubiquitin thioesterase FAM105A 1 1 3 
DUT Deoxyuridine 5'-triphosphate 
nucleotidohydrolase, mitochondrial 
1 1   
PHB2 Prohibitin-2 1 1 3 
PTPN7 Tyrosine-protein phosphatase non-receptor type 
7 
1   3 
LANCL2 LanC-like protein 2 1 2 8 
DRG1 Developmentally-regulated GTP-binding 
protein 1 
1 2 1 
2 SV=1 Ras-related protein Rap-1b-like protein 1 1 1 
RAB10 Ras-related protein Rab-10 1 1   
RPAIN RPA-interacting protein 1 1 2 
BRD9 Bromodomain-containing protein 9 1   1 
CALM1 Calmodulin 1   4 
EIF2B3 Translation initiation factor eIF-2B subunit 
gamma 
1   6 
TBRG4 Protein TBRG4 1   6 
TAF12 Transcription initiation factor TFIID subunit 12 1     
SEL1L Protein sel-1 homolog 1 1   1 
PRDX3 Thioredoxin-dependent peroxide reductase, 
mitochondrial 
1     
RARS2 Probable arginine--tRNA ligase, mitochondrial 1   9 
PDDC1 Parkinson disease 7 domain-containing protein 
1 
1   1 
RING1 E3 ubiquitin-protein ligase RING1 1   3 
STXBP2 Syntaxin-binding protein 2 1   3 
EPB41L5 Band 4.1-like protein 5 1     
TSSC4 Protein TSSC4 1     
CCP110 Centriolar coiled-coil protein of 110 kDa 1   1 
RPRD1B Regulation of nuclear pre-mRNA domain-
containing protein 1B 




UQCC1 Ubiquinol-cytochrome-c reductase complex 
assembly factor 1 
1     
RHOC Rho-related GTP-binding protein RhoC 1   1 
UTRN Utrophin 1   6 
LONP1 Lon protease homolog, mitochondrial 1   8 
THOC3 THO complex subunit 3 1   2 
WDR18 WD repeat-containing protein 18 1   2 
RET Proto-oncogene tyrosine-protein kinase receptor 
Ret 
1   1 
MRPL28 39S ribosomal protein L28, mitochondrial 1     
CHUK Inhibitor of nuclear factor kappa-B kinase 
subunit alpha 
1   16 
ATP6V0D1 V-type proton ATPase subunit d 1 1   2 
JAK2 Tyrosine-protein kinase JAK2 1   1 
C3orf33 Protein C3orf33 1     
MTO1 Protein MTO1 homolog, mitochondrial 1   16 
PAFAH1B1 Platelet-activating factor acetylhydrolase IB 
subunit alpha 
1   1 
TXNIP Thioredoxin-interacting protein 1   2 
GCN1 eIF-2-alpha kinase activator GCN1 1   18 
VPS13A Vacuolar protein sorting-associated protein 13A 1   4 
EIF3M Eukaryotic translation initiation factor 3 subunit 
M 
1 1 1 
TTC37 Tetratricopeptide repeat protein 37 1   7 
SLC27A2 Very long-chain acyl-CoA synthetase 1   1 
TMSB4X Thymosin beta-4 1     
DAGLB Sn1-specific diacylglycerol lipase beta 1     
MAP2K2 Dual specificity mitogen-activated protein 
kinase kinase 2 
1   3 
DTX3L E3 ubiquitin-protein ligase DTX3L 1   3 
TOMM70 Mitochondrial import receptor subunit TOM70 1 1 2 
SZT2 Protein SZT2 1   12 
TRAM1 Translocating chain-associated membrane 
protein 1 
1 1 2 
TELO2 Telomere length regulation protein TEL2 
homolog 
1   7 
TRIM23 E3 ubiquitin-protein ligase TRIM23 1     
DCPS m7GpppX diphosphatase 1     
ALKBH5 RNA demethylase ALKBH5 1     
STX8 Syntaxin-8 1     
NUP155 Nuclear pore complex protein Nup155 1   12 
YTHDF2 YTH domain-containing family protein 2 1   7 
MED14 Mediator of RNA polymerase II transcription 
subunit 14 
1   1 
CAPN15 Calpain-15 1   1 
FXR1 Fragile X mental retardation syndrome-related 
protein 1 
1 1 1 
KAT7 Histone acetyltransferase KAT7 1   2 
TAGLN2 Transgelin-2 1     
NFXL1 NF-X1-type zinc finger protein NFXL1 1 1 2 








Figure S1. FLAG-STUB1-ΔU-box complementation demonstrates specificity of IFNGR1 detected 
below 50-kDa in a FLAG-STUB1 immunoprecipitation as illustrated by the loss of this band in 
an IFNGR1 KO cell. Exogenous re-expression of FLAG-STUB1-ΔU-box in THP-1 Cas9 C22 STUB1 
KO C13 or IFNGR1 KO C32. FLAG-STUB1-ΔU-box stabilized IFNGR1 in a STUB1 KO C13 
background cell. (A) Cell surface IFNGR1 expression was measured by flow cytometry. WT THP-1 
unstained (gray), Cas9 C22 (blue), C22 + sgIndicated knockout clone (red), C22 + sgIndicated knockout 
clone + FLAG-STUB1-ΔU-box (green shaded). (B) Immunoprecipitation (IP) of FLAG-STUB1 from 
NP-40 lysates of THP-1 Cas9 C22 cells (2.5x107 cells each). IP was performed for 3 h. Endogenous 









Figure S2. IFNGR1 is stabilized upon treatment with lysosomal inhibitors. Immunoblot analysis 
of IFNGR1 in THP-1 Cas9 C22 versus THP-1 Cas9 C22 STUB1 KO C13 cells without (w/o) treatment, 
or treated with lysosomal inhibitors Bafilomycin A1 (BafA1) (25nM), Leupeptin (Leup) (10nM), or 
proteasomal inhibitor Lactacystin (Lact) (10nM) for 16 h. Inhibition of the lysosome by either BafA1 
or Leupeptin led to an accumulation of IFNGR1 (90-kD and ~45-kD bands) (lanes 2, 4, 6, 8), whilst 
inhibition of the proteasome by Lactacytsin did not lead to an accumulation of IFNGR1. Stabilization 
of IFNGR1 in a STUB1 KO implied that degradation of the IFNGR1 was still taking place, so another 
E3 ligase must be involved in the degradation of IFNGR1.  
 
